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Heparan sulfate variant with high FGF-2 binding 
affinity isolated with FGF-2-HBD Baird peptide 
HS8C
+ve 
Heparan sulfate variant with high FGF-2 binding 
affinity isolated with FGF-2-HBD Cardin peptide 
HS8G
+ve
  Heparan sulfate variant with high FGF-2 binding 
affinity isolated with FGF-2-HBD Gandhi peptide 
HS8
-ve
    Heparan sulfate variant with low FGF-2 binding affinity 
HSPG    Heparan sulfate proteoglycan 
HSpm    Heparan sulfate from porcine intestinal mucosa 
IDO   indoleamine 2, 3-dioxygenase 
IdoA    α-L-iduronic acid 
IdoA (2S)    α-L-iduronic acid-2-O-sulfate 
IgM   Immunoglobulin M 
IgM   Immunoglobulin M 
IL1   Interleukin 1 
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IL-4   Interleukin 4 
IL-10    Interleukin 10 
IMBR1  affinity purified polyclonal rabbit IgG 
kDa    Kilodalton 
KGF    Keratinocyte growth factor 
Ki67   Antigen KI-67 
KS    Keratan sulfate 
 LPS    Lipopolysaccharide 
M    Molarity 
M   Molarity 
MACS   magnetic-activated cell sorting 
mAU    milli-absorbance unit 
mg/ml    milligram per milliliter 
 
Mg
2+   
Magnesium  
min    Minute (s) 
 
ml    Millilitre 
 
MLD    Multilineage differentiation  
Mrna   messenger ribonucleic acid 
MSCs   Mesenchymal stem cells  
Na2HPO4  Disodium hydrogen phosphate  
NaAc    Sodium acetate 
 
NaCl    Sodium chloride 
NaOH   Sodium Hydroxide 
NH2   amidogen 
nm  nanometer 
NMR   Nuclear magnetic resonance 
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NO    nitric oxide  
NOD-SCID  Non-obese diabetes- severe combined  
                                    immunodeficiency  
P   Passage 
PBMC   peripheral blood mononuclear cell  
PBS    Phosphate buffered saline 
PBS   Phosphate buffered saline 
PDGF-BB  platelet-derived growth factor-BB 
PE   Phycoerythrin  
PFA   paraformaldehyde  
pH   decimal cologarithm of hydrogen 
PNPP   p-nitrophenyl phosphate 
rpm   Rounds per minute 
RS    Rapidly self-renewing  
SAB   standard assay buffer  
SH2   Src Homology 2 
SSEA-4   Stage-specific embryonic antigen-4  
STRO-1 Stromal precursor antigen-1  
t1/2   Half-life 
TBST   Tris-Buffered Saline and Tween 20 
TFA Trifluoroacetic acid  
TGFβ3   Transforming growth factor beta 3 
Tm   Temperature 
TMB   3,3′,5,5′-Tetramethylbenzidine 
TNFRI   Tumor necrosis factor alpha receptor type 1 
TNF-α   Tumor necrosis factor alpha 
TNFα   Tumor necrosis factor alpha 
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U   Unit 
UA   Uronic acid 
V   Volts 
v/v   Volume per volume 
VEGF   Vascular endothelial growth factor 
Wnt3a   wingless-type MMTV integration site family, member 
3A 
α-MEM  α-modified Eagle’s medium  
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ABSTRACT 
 
Human  mesenchymal stem cells (hMSCs) hold immense therapeutic 
potential in the field of tissue regeneration. The major factor delaying the 
wider exploitation of such cell-based therapies is the difficulty in generating 
sufficient cell numbers to meet the clinical demand. The low proportions of 
hMSCs within bone marrow are clearly hindering their widespread clinical 
adoption. Collectively, these issues negatively impact on the therapeutic 
potential of hMSC for regenerative medicine. Current ex vivo expansion 
strategies attempt to mimic the bone marrow microenvironment by utilizing 
extracellular matrix (ECM) substrates and exogenous applications of growth 
factors, but diminishing stemness under these conditions is a major deterrent. 
Notably, autocrine fibroblast growth factor 2 (FGF-2) has been shown to 
increase the multipotentiality of hMSCs. Therefore, enhancing the activity of 
FGF-2 produced endogenously by MSCs in culture presents as a worthy 
strategy.  
 As with many extracellular growth factors, the powerful stem cell 
mitogen FGF-2 depends for its activity on a heparan sulfate (HS) 
glycosaminoglycan sugar, that specifically cross-binds it to FGFR1. Our group 
has previously demonstrated that murine-derived HS variants from either 
embryonic neural progenitor cells or adult liver tissue are able to accelerate the 
growth of hMSCs without a significant loss of multipotentiality. However, to 
be of use for regenerative medicine, there is a need to scale-up the production 
of this HS, and prove it retains the properties of the original embryonic sugar.  
Therefore this study was developed to address this major limitation. 
The strategy adopted was to isolate a bioactive HS sub-fraction by peptide-
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affinity chromatography from a commercial source of HS. The rationale being 
that, this affinity-selected HS would mediate the activity of endogenous FGF-
2 thereby acting to sustain the growth of hMSC without adversely affecting 
their multipotentiality.  
To affinity isolate FGF-2-binding HS, ten customized peptides 
mimicking the heparan-binding domain of FGF-2 were trialed as a 
chromatographic substrate.  Screening assays of FGF-2 binding affinity 
highlighted a particular HS variant (termed HS8
+ve
) that could be isolated at 





 dose-dependently increased hMSC proliferation whilst 
maintaining the tri-lineage potential of the expanded cells. Application of 
HS8
+ve
 also resulted in a higher efficiency of CFU-F formation. Compositional 
analysis by capillary electrophoresis revealed that HS8
+ve 
contained an 
enrichment of trisulfated disaccharides with di-sulfated disaccharides (6O and 
NS) and a depletion of mono- and un-sulfated disaccharides compared with 
the starting HS
pm
 pool. This appeared critical for formation of the FGF-2-HS-
FGFR1 ternary complex and downstream signal transduction, which required 
the HS to contain 2O-, 6O- and N-sulfation. In addition HS8
+ve
 was devoid of 
anticoagulation activity and increased FGF-2 stability in culture. Moreover, 
hMSC growth induced by exogenous FGF-2 was further enhanced by addition 
of HS8
+ve
, with FGF inhibition studies highlighting that HS8
+ve
 actively 
promotes FGF-2-FGFR1 signaling.    
 This thesis describes the development a robust, highly scalable, simple 
and cost-effective affinity chromatography platform isolate a heparan sulfate 
variant (HS8
+ve
) that can bind to endogenously produced FGF-2 and thereby 
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mediate hMSC proliferation. Further development of this particular HS 
strategy may yield benefits to the expansion and clinical use of hMSCs in 
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1.1. Extra cellular matrix (ECM) 
 Generally, the ECM can be considered to consist of all the secreted 
molecules that are present outside the cells. In fact the ECM is a dynamic and 
complex environment with different physical and biochemical properties 
which gives architectural support for the tissues (Gattazzo et al., 2014; 
Maquart and Monboisse, 2014). During development, the embryo undergoes 
complex cell-cell and cell to-matrix interactions (Hynes, 2009; Zagris, 2000). 
It is these direct or indirect interactions with the surrounding extracellular 
matrix (ECM) that helps governs these cell-fate decisions (Hynes, 2009). The 
ECM, modulate the production, degradation, and remodelling of its 
components namely proteins, glycoproteins, collagens, glycosaminoglycans, 
proteoglycans and other macromolecules and thereby is involved in diverse 
functions such as the migration of cells, adhesion, proliferation and 
differentiation (Adams and Watt, 1993; Aumailley and Gayraud, 1998; Dutta 
and Dutta, 2010; Gattazzo et al., 2014; Hay, 1991; Lu et al., 2011; Page-
McCaw et al., 2007; Timpl and Brown, 1994; Zagris, 2000). In addition, cells 
grown in tissue culture plates also depend on ECM components for their 
attachment, proliferation and differentiation (Evseenko et al., 2009; Hakala et 
al., 2009; Santiago et al., 2009).   
Stem cells have an extensive ability to self-renew and to produce 
daughter cells and irrespective of their existence in adult tissue or in a culture 
dish, their stem cell fate is regulated by a combination of intrinsic and 
extrinsic mechanisms (Watt and Driskell, 2010; Watt and Huck, 2013). 
Transcription factors expressed by the cells govern the intrinsic mechanisms 
while the local microenvironment or the niche consisting of ECM, govern the 
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extrinsic mechanisms (Gattazzo et al., 2014; Watt and Huck, 2013). Two 
components distributed in the ECM which are important for embryonic and 
adult stem cell development (and an important conceptual part of this thesis) 
are the family of sulfated proteoglycans, and fibroblast growth factors (FGFs).  
The former comprise a large group of molecules which appear to modulate 
cell outgrowth in both positive and negative ways (Fernaud-Espinosa et al., 
1994; Gandhi and Mancera, 2008; Ori et al., 2008) (Fernaud-Espinosa et al. 
1994: Ori et al, 2008). The latter, the family of FGFs, are generically known 
as heparin-binding growth factors due to their affinity for heparin and heparan 
sulfate. In the embryonic mouse brain, a developmentally regulated, novel 
HSPG and FGF-2 have been colocalized (Ford et al. 1994) and are able to 
stimulate mitogenesis in neural precursor cells (Nurcombe et al. 1993). These 
discoveries helped stimulate the need for more information about the nature of 
the precise interaction between heparan sulfate proteoglycans, fibroblast 
growth factors, and the previously characterized high affinity transmembrane 
fibroblast growth factor receptors. The structure and function of these 
relationships underpin this thesis. 
 
1.2. Heparan sulfate proteoglycans (HSPG) 
1.2.1. Classification of Glycosaminoglycans (GAGs)   
 HSPGs are part of the major family of glycosaminoglycans (GAGs). 
They are linear, highly negatively charged, complex molecules with a wide 
range of  molecular weight (10–100 kDa) (Gandhi and Mancera, 2008). These 
GAGs in aqueous solution are surrounded by a covering of water molecules, 
result in massive hydrodynamic volume in solution. Furthermore, they are 
 Confidential  4 
 
made up of repeating disaccharide units consist of uronic acid (D-glucuronic 
acid or its epimer L-iduronic acid) and an amino sugar (D-galactosamine or D-
glucosamine). Therefore the GAGs differ depending on the sugar and the 
geometry of the glycosidic linkage between these units. They are categorized 
into two main types; sulfated and unsulfated. Notably hyaluronic acid (HA) is 
un-sulfated, while chondroitin sulfate (CS), keratin sulfate (KS), dermatan 
sulfate (DS) and heparan sulfate (HS) are the sulfated GAGs (Gandhi and 
Mancera, 2008; Ori et al., 2008). The non-sulfated HA which is synthesized 
without a core protein and is digested by enzymes at the cell surface directly 
into the extracellular space. It is often bound to HA-binding proteins and other 
proteoglycans (Delpech and Halavent, 1981; Delpech et al., 1991). In 
addition, HA is the major component in the synovial fluid lubricant within 
body joints (Itano, 2008). Furthermore it has been extensive used for wound 
healing, mostly being an excellent lubricant (Price et al., 2005; Weigel et al., 
1986). 
 In contrast, sulfated GAGs secreted covalently attached to a core 
protein on the cell surface to yield the various species of proteoglycans as 
described above. The CS and DS contain galactosamine and called as 
galactosaminoglycans. The CS has a molecular mass of 5-50 kDa, and found 
particularly in cartilage, tendon, ligament and aorta (Clegg et al., 2006; 
Cummings and Etzler, 2009; Varki et al., 1998). On the other hand, DS is 
having a molecular weight of 15-40 kDa and is most common in skin and 
blood vessels (Trowbridge and Gallo, 2002; Varki et al., 1998). The KS can 
be found in cartilage and cornea with a molecular weight of 4-19 kDa 
(Cummings and Etzler, 2009; Varki et al., 1998). The other sulfated GAGs, 
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HSPGs consist of highly sulfated heparin and heparan sulfate (Ori et al., 
2008).  
 
1.2.2. Heparin and heparan sulfate 
 Heparin was identified in 1916 as a material extracted from dog liver 
which inhibit clotting of plasma ex vivo (Jorpes, 1959; McLean, 1916) while 
HS was discovered by Jorpes and Gardell in 1948 (Jorpes and Gardell, 1948). 
Whilst heparin is produced and stored in mast cells, HS is found in almost all 
animal tissues (Gandhi and Mancera, 2008; Ori et al., 2008).  They are 
synthesized as covalent complexes with the GAG chains attached to core 
proteins to form HSPGs. Three families of HSPGs are named according to the 
type of proteins attached and include the transmembrane syndecans, the 
membrane bound glypicans and the ECM bound prelecan.  
 The biosynthetic pathway leading to HS and heparin formation has 
been reviewed by several groups (Bienkowski and Conrad, 1984; Kreuger and 
Kjellén, 2012; Lamanna et al., 2007; Lindahl et al., 1986; Ori et al., 2008). 
The steps in the biosynthesis of heparin and heparan sulfate are probably the 
same so at least in principle, all sequences found in heparin, which is highly 
substituted with sulfates, can be found in HS. In the case of DNA the 
biological information is coded as linear sequences in the molecules. In 
contrast, scientists are faced with a challenge in decoding the sulfation pattern 
and  the dynamic nature of HS generation because of the non-template driven 
process (Lamanna et al., 2007). This process of HS occurs in Golgi, where 
multiple biosynthetic enzymes acts on the growing saccharide polymer, 
introducing modifications to the sugar backbone which do not go to 
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completion (Ori et al., 2008). There are 3 phases of HS synthesis that have 
been identified namely, chain initiation, polymerization and polymer 
modification. A linker tetrasaccharide attached to specific serine residues of 
newly translated core proteins in chain initiation step followed by addition of 
D-galactose residues. After that the polymerization of the heparin/HS chain 
occurs through alternate attachment of hexuronate and glucosamine residues 
in a non-branching polymer fashion. These are then subjected to the 
maturation process where epimerization and sulfation occur by 
sulfotransferases and an epimerase (Kreuger and Kjellén, 2012; Lamanna et 
al., 2007; Ori et al., 2008). However, epimerization and N-and O-sulfation 
reactions do not occur at all of the disaccharide units which results in a highly 
heterogeneous final product and an almost endless possibility of final 
products. 
 Heparin (7-20 kDa) and HS (10-70 kDa) are linear polysaccharides 
consisting of repeating uronic acid-(14)-D-glucosamine disaccharide 
subunits (Gandhi and Mancera, 2008). Uronic acid can either be D-
glucouronic acid or L-iduronic acid. In addition, modifications at specific 
places give rise to different N-sulfated, O-sulfated and N-acetylated complex 
sequences (Ori et al., 2008). The most abundant disaccharide in heparin is 
IdoA(2S)-(1 4)-GlcNS(6S) therefore giving rise to a highly negative charge 
throughout the chain length, that affords heparin little to no selectivity in 
binding to proteins. Furthermore, heparin has a higher N-sulfation (> 80 %) as 
compared to HS (40-60 %) (Gandhi and Mancera, 2008). On the other hand, 
HS has the unsulfated GlcA-(14)-GlcNA disaccharide as the most common 
form giving rise to segregated blocks of unsulfated NA domains and blocks of 
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highly sulfated, heparin-like IdoA-(14)-GlcNS disaccharides (NS domain). 
The diversity of HS is due the different regions of sulfation along HS chains 
and different degree of sulfation on each of the disaccharide units (Ori et al., 
2008). This diversity is responsible for the wide range of biological functions. 
HSPGs affect metabolism, transport, information transfer, cell adhesion, cell 
growth and differentiation, and support in all organ systems (Bishop et al., 
2007; Gandhi and Mancera, 2008) by virtue of their attached HS-GAG chains. 
 
1.3. Fibroblast growth factors (FGFs) 
In 1939, the first experiments of FGF activity was described (Trowell 
and Willmer, 1939) and they derived their name because of the original assay 
used to identify the growth promoting activity on fibroblasts (Gospodarowicz, 
1974).  
 The fibroblast growth factor family is comprised of 22 members in 
vertebrates with a molecular mass range from 17 to 34 kDa (Beenken and 
Mohammadi, 2009; Ornitz and Itoh, 2001; Powers et al., 2000; Steiling and 
Werner, 2003). Due to their isoelectric points (pI) of 9.6 and 5.6 the first two 
members of this family were originally known as basic FGF and acidic FGF 
respectively. Since the discovery of many other growth factors in the same 
family, the nomenclature has changed, and they are now numbered 
sequentially as discovered.  
Their gene structure and core amino acid sequence of 120–130 amino 
acids are highly conserved in vertebrates (Beenken and Mohammadi, 2009; 
Ornitz and Itoh, 2001). They have numerous functions in developmental 
processes including brain patterning, branching morphogenesis and limb 
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development. In addition, they have mitogenic, cytoprotective and angiogenic 
properties in wound repair and even play a role in neuronal protection (Ornitz 
and Itoh, 2001; Powers et al., 2000; Steiling and Werner, 2003) (Beenken and 
Mohammadi, 2009).  
 Beenken and Mohammadi have shown that FGF consist of a core 
region organized in 12 anti-parallel β-strands (β1–β12), and on the either side 
are the amino and carboxyl terminals (Beenken and Mohammadi, 2009). The 
HS binding sites are contained in this β1–β2 loop as well as parts of regions 
located between β10 and β12. FGFs carry out their various functions through 
binding interactions that involve the four FGF receptors (FGFR 1-4). FGFRs 
are tyrosine kinase receptors with several notably isoforms (FGFR1b, FGFR1c, 
FGFR2b, FGFR2c, FGFR3b, FGFR3c and FGFR4). These receptors have 
temporal and tissue-specific expression patterns as well as specificity for FGF 
binding (Beenken and Mohammadi, 2009). FGF-1 and FGF-2 were the first 
two FGFs identified, with FGF-2 being the most relevant variant in relation to 
this thesis.  
 
1.3.1. Fibroblast growth factor -2 (FGF-2) 
 FGF-2 was first identified in pituitary and brain extracts due to its 
ability to stimulate 3T3 cell proliferation in culture (Gospodarowicz, 1974).  It 
is usually present in all organs, solid tissues, tumours and cultured cells 
(Baird, 1986; Gospodarowicz et al., 1987). It has been shown that most FGFs 
have amino terminal signal peptides and are readily secreted from cells 
(Miyamoto et al., 1993). On the other hand, FGF-2 along with FGF-1 and 
FGF-9 lack the secretory signal peptide (Miyamoto et al., 1993). Ornitz and 
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Itoh have mentioned that the methods of secretion of these FGFs are still not 
completely understood, however they can be found on the cell surface and in 
the ECM (Ornitz and Itoh, 2001). Steringer et al recently reviewed that FGF-2 
been secreted independent of N-terminal signal recognition particle and rather 
by “unconventional Protein secretion” (Steringer et al., 2014). They further 
mentioned that FGF-2 is secreted from cells by direct translocation across 
plasma membranes (Schäfer et al., 2004; Steringer et al., 2014).   
 A variety of different FGF-2 mRNA transcripts, antisense transcripts 
and protein products have been identified in different tissues. Most of the 
variation arises from multiple initiation sites on the FGF-2 gene.  For example, 
bovine pituitary FGF-2 is 146 amino acids long (Duchesne et al., 2012) 
whereas human placental FGF-2 consists of 157 amino acids (Sommer et al., 
1987) through the use of different initiation codons.  FGF-2 consist of a core 
region organized in 12 anti-parallel β-strands (β1–β12) and the HS binding 
sites are contained in this β1–β2 loop as well as parts of regions located 
between β10 and β12 (Beenken and Mohammadi, 2009). There are two classic 
heparin-binding domains (HBD) in FGF-2, corresponding to amino acid 
residues 18-22 and 107-110 (Esch et al., 1985) although other regions have 
also been postulated to interact with this sugar (Baird et al., 1988). In fact, Ori 
and colleague recently claimed the identification of the third HBD (Ori et al., 
2009). 
  FGF-2 carries out their various functions through binding interactions 
that involve the four FGF receptors (FGFR 1-4). Although, Dombrowski and 
colleagues have shown that FGFR1 signalling activity is rate limiting for self-
renewal of hMSCs and thereby stimulates proliferation of hMSCs 
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(Dombrowski et al., 2013). FGFRs are receptor tyrosine kinases and receptor 
dimerization is needed for downstream signaling through ERK cascade. This 
uses a combination of bivalent ligand binding, direct receptor-receptor 
contacts, and the involvement of an accessory molecule (heparin/HS) 
(Lemmon and Schlessinger, 2010; Schlessinger, 2000; Schlessinger et al., 
2000; Stauber et al., 2000). X-ray crystal structures of a 2:2:2 dimeric ternary 
complexes of FGF-2, fibroblast growth factor receptor-1 (FGFR1) and a 
heparin decasaccharide has been resolved and shown that each receptor 
molecule simultaneously contacts both FGF and heparin (Schlessinger et al., 
2000). A more physiological model was proposed by Pellegrini et al who 
reported a crystal structure with the stoichiometric ratio 2:2:1 of 
FGFR2:FGF1:heparin decasaccharide where heparin simultaneously contacts 
both ligands in the dimer and both receptor molecules (Pellegrini et al., 2000). 
  In vivo administration of exogenous FGF-2 induces a variety of 
responses.  The FGF-2 is well known for its angiogenic properties and the 
exogenous FGF-2 stimulates migration and proliferation of endothelial cells in 
vivo (Ware and Simons, 1997). In addition, it causes a rapid 
neovascularization in the cornea, kidney capsule, skin, and fibroplasia in the 
dermis (Davidson et al., 1985; Folkman and Klagsbrun, 1987; Hayek et al., 
1987; Shing et al., 1985). Furthermore,  FGF-2 plays a major role in 
controlling the growth of endothelial and smooth muscle cells (Lindner and 
Reidy, 1991). This further described the role of FGF-2 in inflammation; in 
response to asthma triggers FGF-2 enables airway smooth muscle cells to 
proliferate (Bossé and Rola-Pleszczynski, 2008).  
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 In particular, of most interest to my thesis, FGF-2 has been shown to 
enhance the growth of mesenchymal stem cells (Auletta et al., 2011; 
Dombrowski et al., 2009; Ling et al., 2006; Sotiropoulou et al., 2006). In 
addition, Ng and colleagues have shown that FGF-2, TGFβ and PDGF 
signaling pathways are essential in hMSC proliferation (Ng et al., 2008). 
They have shown that in the presence of FGF-2 with TGFβ1 and PDGF BB 
in serum-free medium maintained hMSCs for 5 passages while in absence 
hMSCs showed a more flattened morphology. Furthermore, Rodrigues and 
colleagues in their review paper also highlighted the importance of FGF-2 as 
a mitogenic factor for MSC (Rodrigues et al., 2010). Moreover, Gharibi and 
Hughes have used several growth factors including FGF-2, PDGF BB, 
Wnt3a, IL-6 and EGF as medium supplements on MSC self-renewal and 
differentiation potential (Gharibi and Hughes, 2012). They have shown that 
out of all supplements FGF-2 has given the highest increase in MSC 
proliferation.    
 Szlachcic et al have mentioned that there are different strategies to 
improve the stability and the half-life of the protein drug efficiency (Szlachcic 
et al., 2011).  These can be done by means of genetic and chemical 
modifications. Few studies have shown that introduction of single or multiple 
amino acid substitutions in the wild type FGF-1 sequence can affect its 
susceptibility to degradation and stability (Motomura et al., 2008; Szlachcic et 
al., 2011; Zakrzewska et al., 2005). Zakrzewska et al have shown that 
multiple mutants of FGF1 were able to significantly enhanced resistance to 
proteases and prolonged in vivo half-life, even up to ten-fold (Zakrzewska et 
al., 2005). Extensive manipulations of wild type sequence of FGF-1 can also 
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increase their half-life as described by Motomura et al (Motomura et al., 
2008). They have shown that the chimeric FGF1:FGF2 variant in which a 
segment of 43 residues from FGF2 was introduced into the FGF1 sequence, 
can be used as an agent to stimulate wound healing. In addition, Lee and 
Blaber also shown that functional half-life and mitogenic activity were greatly 
extended in FGF-1 after a single mutation of the Ala66 to Cys (Lee and 
Blaber, 2013). They further illustrate that this mutation recovered vestigial 
disulfide bond between absolutely conserved Cys residue of FGF family of 
proteins at position 83, and thereby will be useful in protein engineering 
strategy to improve the functional half-life of other FGF family members.  
 Besides amino acid sequence modifications, the covalent linkage of 
carbohydrate moieties or synthetic polymers also can increase the half-life of 
proteins. Beeken and Mohammadi have discussed the importance of 
administering growth factors for angiogenic stimulation; long‑term presence 
and slow release in the tissue is important for maintenance of new vasculature. 
But the problem lies with the mean half‑life of fibroblast growth factor 2 
(FGF2) which is only about 7.6 hours in the body (Beenken and Mohammadi, 
2009). This half‑life can be extended when FGF-2 is co-administered with 
heparin (Beenken and Mohammadi, 2009; Bush et al., 2001). In addition, 
Caldwell et al using an ELISA assay, assessed the concentration of FGF-2 in 
growth media and shown that at 37 °C, FGF-2 levels dropped by over 80 % 
within the first 24 h (Caldwell et al., 2004). They also described that with the 
addition of heparin, this decline is significantly attenuated and prolonged the 
half-life of FGF-2. Furthermore, Uniewicz et al have successfully shown by 
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the differential scanning fluorimetry measurements, FGF-2 upon binding to 
heparin prevented its thermal degradation (Uniewicz et al., 2010). 
 
1.4. HS-FGF interactions  
The HSs regulate more than 400 extracellular proteins (Xu et al., 
2012). HS as a key regulatory component in ECM, binds to FGF-2 and effects 
their pericellular matrix transport (Duchesne et al., 2012; Schmidt et al., 2006) 
which required for assembly and interaction with FGF receptors in signal 
transduction (Xu et al., 2012). Furthermore, Xu et al have mentioned key 
areas in the interaction specificity between HS and FGF-2 namely binding 
parameters, heparin binding domain (HBD) of FGFs, specific structures in the 
HSs and changes in secondary structure in FGFs upon HS binding (Xu et al., 
2012).  
Various studies have recognized common structural features in the 
heparin/HS binding sites of proteins (Gandhi and Mancera, 2008; Hileman et 
al., 1998; Ori et al., 2009). Cardin and Weintraub in 1989 made a first attempt 
to define heparin-binding domains (HBDs) after analyzing 21 heparin-binding 
proteins. They have looked at the sequences of basic regions of various 
heparin-binding proteins which were shown experimentally that bind to 
heparin. With respect to that heparin binding domains of Vitronectin, 
Apolipoproteins E and B -100 and Platelet Factor 4 were analysed and the 
organization of basic and non-basic residues were noted. Thereafter they have 
looked at the basic regions of other known heparin-binding proteins which 
were not experimentally shown to bind heparin. Afterwards the consensus 
sequences were determined and proposed that typical heparin-binding sites 
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have the sequence XBBXBX or XBBBXXBX, where B is a basic residue 
which is a positively charged amino acid (arginine, lysine and very 
occasionally histidine) and X is a non-basic residue (Cardin and Weintraub, 
1989).  
The next consensus sequence TXXBXXTBXXXTBB, was posited by 
Hileman et al. after comparing X-ray diffraction patterns and the NMR 
profiles of several proteins. In this sequence T defines a turn, B a basic amino 
acid (arginine or lysine) and X a non-basic residue (Hileman et al., 1998). In 
addition, Ori et al have described a method using the “protect and label” 
strategy with the basis of protecting against the chemical modification given 
by heparin/HS to the residues located in the heparin binding site (Ori et al., 
2009). Therefore the once protected FGF-2 HBS can be identified by protein 
digestion and identified by MALDI-QTOF mass spectrometry. The 
differential scanning fluorimetry assay published by Uniewicz et al identified 
the preferences in various FGFs to different structural features of GAGs 
(Uniewicz et al., 2010). 
Strong ionic interactions are obviously expected between GAGs and 
proteins, wherein the positively charged basic amino acids form ionic bonds 
with the abundant, negatively charged sulfate or carboxylate groups on the 
sugar chains. These bonds are particularly important in the NS domain regions 
of HS (Fromm et al., 1997a; Ori et al., 2009). In addition, there are other types 
of bonds contributing to such association, including van der Waals forces, 
hydrogen bonds and hydrophobic interactions. These bonds become more 
important for the interactions with more heterogeneous HS mixtures, where 
neutral amino acids are also required (Fromm et al., 1997a; Ori et al., 2009). 
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In considering FGF-2, glutamine and asparagine also play important roles by 
forming hydrogen bonds with the hydroxyl groups of the sugar (Thompson et 
al., 1994). 
The numerous published studies so far have suggested several different 
peptide sequences as being the “key” heparin binding-domain of FGF-2; these 
have been compiled in Table 2.1. Here I have adopted a numbering system 
taking into the account the 288 aa which constitute the mature, secreted FGF-2 
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Disaccharide analyses of heparin have been published by various 
groups (Ampofo et al., 1991; Desai et al., 1993; Jandik et al., 1994; 
Karamanos et al., 1996; Ruiz-Calero et al., 1998; Scapol et al., 1996). As 
described, the key disaccharides of porcine intestinal mucosal heparin were 
DHexUA,2S-GlcNS,6S and DHexUA-GlcNS,6S, which indicated that 
trisulfated disaccharides (2O-, 6O- and N-sulfated) and disulfated 
disaccharides (6O- and N-sulfated) are major components for the binding to 
growth factors such as FGF-2. Various studies have presented data supporting 
the idea that HS’s different capacity for proteins is due to differentially 
modified HS units. Lindahl’s group in Sweden have shown that 3O-sulfated 
glucosamine, at a specific position in the antithrombin-binding sequence of 
heparin is essential for its anticoagulation effects (Lindahl et al., 1980).  
 Similarly, specific disaccharide sequences within HS GAGs chains 
support the signaling of the FGF family. The FGF1-binding affinity of HS is 
reduced in the absence of 6O-sulfate groups, indicating their importance for 
this interaction (Fromm et al., 1997b; Ishihara, 1994). Similarly, FGF4 
requires both 2O- and 6O-sulfation for binding and signaling (Ashikari-Hada 
et al., 2009; Guimond et al., 1993; Ishihara, 1994). FGF-2 binding to HS 
requires 2O-sulfation (Faham et al., 1996a; Maccarana et al., 1993). 
Furthermore, in addition to the 2-O sulfation, 6-O-sulfation of N-sulfated 
glucosamine residues is required for the promotion of FGF-2 mitogenic 
activity (Pye et al., 1998). Lundin and colleagues have also supported this idea 
by showing that FGF-2 binding requires N and 2-O-sulfate groups, whereas 
stimulation of FGFR-1 and Erk2 kinases by FGF-2 also required the presence 
of 6O-sulfate groups (Lundin et al., 2000). Furthermore, they demonstrated 
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that 6O-desulfated heparin could inhibit FGF-2-induced angiogenesis in chick 
embryo chorioallantoic membranes. Thus, formation of the ternary complex of 
FGF-2-HS-FGFR1 critical for signal transduction requires 2O-, 6O- and N 
sulfation.  
 Furthermore, HS, in order to qualify as a coreceptor for the FGF/FGFR 
complex, must have sufficient length and the requisite disaccharide 
composition to couple both FGF-2 and FGFR1. The minimum oligosaccharide 
that can bind FGF-2 is a tetrasaccharide, as shown by optical NMR 
spectroscopy (Delehedde et al., 2002; Guglieri et al., 2008). In addition, an 
increasing gradient in affinity for FGF-2 was seen from tetrasaccharide to 
octasaccharide.  However, according to Delehedde et al., the oligosaccharides 
from tetrasaccharides to octasaccharides were less potent in their stimulation 
of the proliferation of rat mammary fibroblasts than deca- or longer -
saccharides (Delehedde et al., 2002). In addition, a dodecasaccharide sequence 
has been proposed as the minimal requirement to promote receptor signaling 
by FGF-2 (Guimond et al., 1993). Thus an HS variant with the ability of 
binding to both FGF2 and FGFR1 will be critical in FGF-2 signal 
transduction.  
 
1.5. Therapeutic uses of Mesenchymal stem cells (MSCs) 
MSCs are defined as plastic-adherent fibroblast-like progenitor cells 
that can be directed to differentiate in vitro down the osteogenic, chondrogenic 
and adipogenic lineages at a minimum, as well as myogenic, and other 
lineages under certain conditions. More recently the term “multipotent 
mesenchymal stromal cells” was also coined to the acronym MSCs by the 
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International Society for Cytotherapy (Zulma et al., 2011). MSCs were first 
isolated from bone marrow by Friedenstein et al and  reported as plastic 
adherent fibroblast cells (Friedenstein et al., 1976). Since then, MSCs have 
been discovered in various adult tissues (Ikehara, 2013; Si et al., 2011; Zulma 
et al., 2011), namely skeletal muscle (Williams et al., 1999), adipose tissue 
(Zuk et al., 2001), umbilical cord (Erices et al., 2000), synovium (De Bari et 
al., 2001), the circulatory system (Kuznetsov et al., 2001), dental pulp 
(Gronthos et al., 2000), amniotic fluid (Scherjon et al., 2003), fetal blood 
(Noort et al., 2002), lung (Fan et al., 2005) and liver (Campagnoli et al., 
2001).  
The therapeutic potential of MSCs has long been suspected, and they 
have been used for many clinical applications, including soft tissue and bone 
tissue regeneration. Caplan and Correa in a recent review paper discussed the 
now standard view of MSCs: their multipotentiality, their means of tissue 
homing and integration, as well as the evolving view of their role as “cellular 
modulators” (Caplan and Correa, 2011). Most memorably, they likened the 
known trophic and immunomodulatory activities of MSCs, to them 
constituting an “injury drugstore”. The MSCs have been widely used in tissue 
engineering pre-clinical models in various tissues such as bone, cartilage, 
tendon and connective tissue with promising results (Caplan, 2007). In 
addition, Humpreys and Bonventre, highlight the path to translating MSCs in-
to the clinic (Humphreys and Bonventre, 2008) while Uccelli et al have 
described the possibility of forging new therapeutic approaches for MSCs 
(Uccelli et al., 2008).  
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1.5.1. MSCs as accelerators of wound healing 
Wound healing is an intricate process that requires coordination 
between cells, growth factors and the ECM (Maxson et al., 2012). Maxson and 
colleagues posit that MSCs present at sites of injury coordinate healing by 
secreting growth factors and ECM substances and recruiting other cells to the 
trauma site. Non-healing chronic wounds have become a serious and 
increasing problem on a global scale (Jackson et al., 2012; Maxson et al., 
2012). In the United States alone, 5-7 million cases of failure to heal have 
been reported, with current treatment methods ineffective for up to 50 % of 
these wounds (Hanson et al., 2010; Maxson et al., 2012; Mustoe et al., 2006).   
Maxson et al propose that MSCs participate during the three phases of 
wound healing (Maxson et al., 2012). In the inflammatory phase MSCs 
regulate inflammation, produce IL-10 and IL-4 and suppress TNF production 
and T cell proliferation. By the proliferative phase, they produce growth 
factors like VEGF, PDGF, HGF and recruit keratinocytes, dermal fibroblasts 
and host stem cells. In the last remodeling stage, MSCs produce TGFβ3, KGF 
and regulate collagen deposition.  The recruitment of host cells was further 
supported by Shin et al who showed that MSCs enhanced both normal and 
impaired wound healing (Shin and Peterson, 2013).  Furthermore, Chen et al 
highlighted that paracrine factors secreted by MSCs recruit macrophages and 
endothelial cells to enhance wound healing (Chen et al., 2008). Moreover, 
following injury, MSCs are recruited to the injury site from their perivascular 
location and establish the regenerative microenvironment (Caplan, 2007; 
Caplan and Correa, 2011). Also, MSCs have been shown to alleviate 
bleomycin-induced tissue fibrosis and suppress inflammation while supporting 
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ECM remodeling (Wu et al., 2013). These collective properties highlight the 
increasing importance of MSCs for regenerative medicine, and underpins 
strategies to enhance their ex vivo growth prior to reimplantation. 
 
1.5.2. MSCs in bone tissue engineering 
 Bone fractures most commonly occur due to trauma, surgical resection 
procedures and congenital defects. In most cases, normal healing progresses 
and the injury repairs itself. Unfortunately there are ~ 1 million cases of 
skeletal injuries per year that fail to heal, usually resulting from a large defect 
size coupled with other undesirable healing conditions (Chatterjea et al., 2010; 
Salgado et al., 2004). In such cases, bone-grafting strategies involving either 
autologous or allogenic bone are standard-of-care. Though autologous bone 
grafts are safe and relatively easy to access, patients must undergo an 
additional surgery that can be detrimental to their health. MSCs are being 
extensively trialed as alternatives to bone grafting in both autologous and 
allogeneic settings (Bueno and Glowacki, 2009; Chatterjea et al., 2010). This 
cell based strategy is being trialed in the clinics for fracture nonunion, 
osteogenesis imperfecta and hypophospertasia (Undale et al., 2009), amongst 
others.  
 
1.5.3. Immunomodulatory properties of MSCs  
 In recent years the immunosuppressive and anti-inflammatory effects 
of MSCs have received much attention. MSCs possess only slight or weak 
levels of immunogenicity, both because they express only low levels of major 
histocompatibility complex-I molecules (MHC-1) on their cell surfaces, and 
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because they have the ability to suppress the activation and proliferation of 
both T and B lymphocytes, and so modify the microenvironment of injured 
tissues by protecting damaged cells blood  (Si et al., 2011; Zulma et al., 2011). 
This MSC-mediated immunosuppression, which has long been trialed for 
cases of severe graft-versus-host disease (GVHD) has a species variation in 
mechanism (Ren et al., 2009; Shi et al., 2010). MSCs in the cytokine-primed 
mouse model have their levels of activity mediated by nitric oxide (NO) 
whereas cytokine-primed human MSCs are controlled by indoleamine 2, 3-
dioxygenase (IDO).  
Haemopoietic-cell transplantation (HCT) is an intensive therapy used 
to treat haematological malignant diseases and its prevalence increases 
annually (Ferrara et al., 2009). The major complication of HCT is GvHD, an 
immunological disorder that affects mainly gastrointestinal tract, liver, skin, 
and lungs. According to Billingham, (1966, 1967), three conditions serve to 
trigger GvHD: 1) the graft must contain immunologically competent cells T 
lymphocytes, 2) the recipient must express tissue antigens that are not present 
in the transplant donor, and 3) the patient must be incapable of mounting an 
effective response to abolish the transplanted cells.  
GvHD pathophysiology starts when myeloablative conditioning 
regimes are used to remove the host’s defective bone marrow. The host’s 
antigen-presenting cells become activated because certain cytokines (TNFα, 
IL1, LPS) are produced by the damaged tissues. Once the allogeneic HCT is 
performed, donor T cells get activated, thereby stimulating the release of more 
cytokines, leading to the cellular and inflammatory reactions that characterize 
GvHD. Non-haemopoietic stem cells such as MSCs seem to reduce allogeneic 
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T-cell responses due to their potent immunosuppressive capabilities, and often 
ameliorate the disorder (Le Blanc et al., 2008; Meuleman et al., 2009; Toubai 
et al., 2009). 
 
1.5.4. Other clinical uses of hMSCs 
In addition to MSC use in wound healing, bone tissue engineering and 
GvHD, their application to other areas of clinical interest has been 
investigated. Ikehara et al described hMSCs from bone marrow in various 
organ repair scenarios (Ikehara, 2013), including interstitial lung disease, acute 
and chronic kidney injuries (Morigi et al., 2004), myocardial infarctions in 
heart (Shabbir et al., 2009), acute liver injury (Dong et al., 2010), diabetes and 
acute pancreatitis (Lazebnik et al., 2011; Tu et al., 2012), brain and spinal 
cord injuries (Boido et al., 2012), inflammatory bowel disease (Castelo-
Branco et al., 2012), bone repair (Chatterjea et al., 2010; Undale et al., 2009), 
arthritic diseases (Chen and Tuan, 2008) and limb ischaemia . 
 
1.6. Is hMSC expansion needed for therapeutic purposes? 
The potential of using cell and tissue based treatments for trauma and 
disease is immense, especially when conventional treatments fail (Rayment 
and Williams, 2010). Mesenchymal stem cells (MSCs) have been suggested to 
have significant therapeutic potential, and have already been trialed clinically 
for such purposes as tissue regeneration and to accelerate bone marrow 
transplant integration for some time. The major issue retarding the wider 
exploitation of human MSCs for cell-based therapies is the difficulty in 
generating sufficient cell numbers to meet the clinical demand. The low 
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proportions of hMSCs within bone marrow - they represent only 0.01 - 0.0001 
% of the marrow mononuclear cell population - are clearly hindering their 
more widespread adoption. It has been established that bone marrow obtained 
from different aged donors, once placed into culture flasks, give rise to very 
different numbers of colony forming units-fibroblastic (CFU-Fs) (Caplan, 
2009). Thus there is a relationship between donor age and hMSCs present in 
the nucleated marrow. A remarkable decrease in the proportion of hMSC-per-
nucleated-marrow-cell has been observed, with a 10-fold decrease from birth 
to teens, and another 10-fold decrease from teens to old age. In addition, 
Caplan has pointed out that this proportional decrease correlates with the 
fracture healing rates in the young and in adults (Caplan, 2009). In contrast, 
the titres of haematopoietic stem cells in bone marrow, roughly one per 10
4 
nucleated marrow cells, remain constant throughout the lifespan of an 
individual. Collectively, these issues negatively impact on the therapeutic 
potential of hMSC for regenerative medicine. In addition, most clinical trial 
needs hMSCs in very large quantities. Ringden et al have reported that 0.5-
5x10
6
/kg of MSCs needed for treatment of GvHD (Ringdén et al., 2006), 
while Phillipe et al  have noted, for GvHD 3-8 x 10
8
 per patient is required 
(Philippe et al., 2010). Therefore in order to obtain required quantities of 
hMSCs for clinical therapy we need ex vivo expansion. The product 
Prochymal, from Osiris Therapeutics which contains MSCs from healthy adult 
donors are now been used in phase III clinical trials with a dose of 2-8 x 
10
6
/kg for GvHD (Chen et al., 2013).   
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1.7. Current expansion methods of MSCs 
In order to address this major question of the supply of hMSC, it was 
rapidly realized that ex vivo expansion was required in the same way that 
HSCs are treated. Thus, better mimicking of the bone marrow 
microenvironment is now a major research direction. It can be achieved in two 
broad ways: either growing hMSCs on properly constituted ECM substrates, 
or exogenous growth factor supplementation. 
 
1.7.1. Expansion of MSCs with growth factors 
 Growth factors are known to influence cell proliferation. Ng and 
colleagues have shown that FGF-2, TGFβ and PDGF signaling pathways are 
essential in hMSC proliferation (Ng et al., 2008).  They have shown that in the 
presence of FGF-2, TGFβ1 and PDGF BB hMSCs for 5 passages while in 
their absence hMSCs showed a more flattened morphology. In addition, 
Rodrigues and colleagues in their review paper described that several growth 
factors including TGFβ, FGF-2, FGF-4, VEGFA, PDGF BB, HGF, EGF and 
Wnt3a increase MSC proliferation (Rodrigues et al., 2010). Furthermore, 
Gharibi and Hughes have used several growth factors including FGF-2, PDGF 
BB, Wnt3a, IL-6 and EGF as medium supplements for MSC self-renewal and 
differentiation (Gharibi and Hughes, 2012). They have shown that out of all 
supplements FGF-2 resulted in the highest increase in MSC proliferation over 
passage 3 to 10. Therefore hMSC proliferation with FGF-2 supplementation 
can be used as guide to assess the relative effects of other agents on hMSC 
proliferation in a traditional monolayer system. Notably, increases in hMSCs 
numbers following FGF-2 supplementation has been widely reported (Auletta 
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et al., 2011; Dombrowski et al., 2009; Ling et al., 2006; Sotiropoulou et al., 
2006).   
Plastic adherence is a well described property of hMSCs: if cells are 
maintained and expanded in normal culture conditions they should adhere to 
plastic surface, and form mesenchymal stem cell colonies when plated at low 
densities (Friedenstein et al., 1976; Pochampally, 2008). Sotiropoulou and 
colleagues have isolated hMSCs with media supplemented with FGF-2 
(Sotiropoulou et al., 2006). They also claimed that FGF-2 supplementation 
clearly affects isolation which resulted in vast numbers of cells, but the 
colony-forming ability of such cells does not differ significantly among the 
groups. Although, Martin and colleagues have reported that FGF-2 
supplementation in isolation of hMSCs from  BMMNCs significantly reduced 
the CFU-F efficiency compared to unsupplemented media (Martin et al., 
1997). In addition, Fresciline et al claimed that rat MSC isolation from 
BMMNCs with FGF-2 supplemented media had decreased amounts of CFU-F 
efficiencies (Frescaline et al., 2012).  
The MSCs grown with FGF-2 go on to generate greater and greater 
proportions of differentiated progenitors as compared to the unstimulated 
hMSCs in the control cultures (Gronthos et al., 1999; Walsh et al., 2000). The 
reduction in CD49, STRO-1, CD90, CD105 and HLA-DR in FGF-2 expanded 
cells as compared to controls were recently reported (Hagmann et al., 2013). 
In addition, Gharibi et al also supported the reduction in CD90 and CD105in 
FGF-2 expanded cells (Gharibi and Hughes, 2012).  
In relation to multilineage differentiation, few groups have also 
reported that FGF-2 expanded cells have increased chondrogenic potential 
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(Hagmann et al., 2013; Tsutsumi et al., 2001). On the other hand, FGF-2 
generated greater proportions of differentiated progenitors as compared to the 
unstimulated hMSCs in the control cultures (Gronthos et al., 1999; Walsh et 
al., 2000). In addition, Ling et al. have shown that the longer osteogenic cells 
are in contact with FGF-2, the less potential they have for osteogenic 
development (Ling et al., 2006). It needs to be kept in mind that others have 
claimed that MSCs grown with FGF-2 supplementation results in cells that do 
maintain their osteogenic development (Auletta et al., 2011; Gharibi and 
Hughes, 2012; Sotiropoulou et al., 2006). Supporting this,  autocrine FGF-2 
has also been shown to increases the multipotentiality of human adipose-
derived MSCs (Rider et al., 2008). Endogenous growth factor activity also 
seems to modulate hMSC behaviour  (Hudalla et al., 2011). As such, there 
remains a conflict in this area. In addition, FGF-2 grown hMSCs have shown 
to pocess potent immunosuppressive effect (Auletta et al., 2011; Sotiropoulou 
et al., 2006).  
The question then becomes: is there a way of presenting hMSCs with 
the FGF-2 they need for expansion without simultaneously losing their 
capacity to differentiate from their multilineage potential?  
 
1.7.2. Expansion of MSCs with ECM substrates 
 ECM substrates have been shown to increase both hMSC attachment 
and cumulative cell number (Grünert et al., 2007; Matsubara et al., 2004) but 
the resulting expanded cells appear to lose the requisite level of “stemness” for 
clinical usefulness (Cool and Nurcombe, 2005). On the other hand, Ang et al 
have mentioned that in vivo stem cell environment is physiologically crowded 
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as compared to in vitro culture practices (Ang et al., 2013). They have 
demonstrated that re-introducing macromolecular crowding (MMC) during 
chemically induced adipogenesis substantially enhanced the adipogenic 
differentiation potential of hMSCS (Ang et al., 2013). Furthermore they claim 
that the MMC significantly enhance the deposition of ECM. In addition, 
Dombrowski et al from our group has shown that embryonic HS can mediate 
the proliferation and differentiation of rat MSCs (Dombrowski et al., 2009). 
Therefore, to answer the question in the previous sub chapter 1.7.1, 
sustaining the endogenous FGF-2 already secreted by MSCs through targeted 
HS fractions; the justification appeared reasonable as HS clearly regulates 
FGF signaling by direct molecular trimeric association with both FGFRs and 
FGFs (Pellegrini et al., 2000). The original data of Nurcombe et al. (1993) 
demonstrated that the activity of particular FGF isoforms for murine neural 
precursor cells was tightly regulated by HS and that this interaction is a 
requirement for the binding of FGF-2 to their receptors (Nurcombe et al., 
1993). In addition, there was a significant difference in the binding of HS to 
FGFs such that at embryonic day 9, the HS produced within the 
neuroepithelium preferentially bound FGF-2, but by day 11, HS binding 
preference had shifted to FGF1. Furthermore, these unique HS forms mediated 
the binding of FGF-2 to specific receptors via an interaction with specific cell-
surface receptors on the neural precursor cells (Brickman et al., 1995). In 
1998, Brickman et al provided further structural support for these 
physiological findings by isolating and characterizing two separate HS pools 
from immortalized embryonic day 10 mouse neuroepithelial 2.3D cells, and 
proving they had quite distinct binding preferences (Brickman et al., 1998). 
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One pool was derived from cells in log growth phase, and showed an increase 
their ability to activate FGF-2, while the other pool, from the same cells but 
undergoing contact-inhibition and differentiation, had preference for the 
activation of FGF1. This led to the isolation and characterization of the 
embryonic HS preparation named HS2, which in turn was shown to be able to 
accelerate hMSC growth without significant loss of multipotentiality; cells 
grown in this mixture could in turn trigger increased bone formation in mice 
when they were transplanted in vivo (Helledie et al., 2011). As a direct 
development of this work, Murali et al looked into the liver in mice (Murali et 
al., 2011), an organ rich in stem cells. Liver is a highly regenerative tissue 
with high levels of FGF-2; I reasoned that it should contain high levels of 
activating HS. The HSs extracted from the livers of mice did indeed increase 
rates of hMSC expansion and osteogenic differentiation (Murali et al., 2011). 
These data suggested that the ECM component HS could selectively improve 
the growth of the hMSCs exposed to FGF-2 without adversely affecting their 
multipotentiality, notwithstanding that although liver is a better source of HS 
than embryonic mouse brain, the problem of scalability was not resolved. 
 
1.7.3. Other expansion methods of MSCs 
 In addition to the two broad areas, other ways were also been 
investigated. One such method for ex vivo expansion for hMSCs is the forced 
expression human telomerase reverse transcriptase (hTERT) (Simonsen et al., 
2002). But  the immortalized hMSCs evolve into different types of tumor due 
to accumulated mutations (Burns et al., 2005). Others have replaced FCS in 
their protocols in expansion of hMSCs in order to eliminate the potential 
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source of xenogenic pathogens (Gottipamula et al., 2013; Hudson et al., 2010; 
Lange et al., 2007). Replacing FCS with human platelet lysates have shown 
that it alters some MSC relevant markers and decreased immunosuppression 
activity on T lymphocytes and Natural killer cells (Abdelrazik et al., 2011). 
Furthermore the use of stirred microcarrier (MC) culture has been 
suggested as another method for supplying large volumes of hMSCs for 
clinics (Chen et al., 2013; Goh et al., 2013; Rafiq et al., 2013; Santos et al., 
2011). Goh et al. have shown that a 12- to 16-fold enhancement in expansion 
of fetal MSCs can be effected by three-dimensional (3D) scaffold culturing as 
compared to the 4- to 6-fold expansion with traditional monolayer (MNL) 
cultures (Goh et al., 2013). Similar to these finding Rafiq et al have shown 
that hMSCs cultured at the litre-scale on microcarriers in a stirred-tank of 5 l 
bioreactor had a 6-fold increase with traditional monolayer (MNL) cultures 
while cells retained their multipotentiality (Rafiq et al., 2013).  In addition, 
Santos et al. have shown 18-fold and 14-fold MSC expansion in bone marrow 
derived hMSCs and adipose derived hMSCs respectively in a microcarrier-
based culture system under xeno-free conditions (Santos et al., 2011).  
 
1.7.4. Adult stem cell therapy market.  
Patent landscaping or patent mapping is a process where companies are 
able to identify relevant technology in particular technology space. Thereby, 
companies can verify the characteristics of each patent and identify the 
relationships among them to prevent any infringements. Further to the patent 
landscape of the adult stem cells, Syed and Evans in their recent review 
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described that beyond bone marrow transplantation there is a high near term 
prospects for mesenchymal stem cell derived stem cell therapies (Syed and 
Evans, 2013). They further mentioned that there are osteogenic products 
(Osteocel, Trinity and LiquidGen) already in the market which readily use 
MSCs to increase osteogenesis and decrease inflammation. In addition, MSC 
products like prochymal have already been approved in South Korea and 
Canada. Furthermore, they have summarized MSC products and their 
indications from companies like Aastrom, Gamida cell, Osiris and Mesoblast 
with near term approval as market products. Knowing the potential of this 
expanding market our group has patented methods of proliferating stem cells 
where the invention relate to expansion of hMSCs with the use of embryonic 
heparan sulfate (HS2) (Cool and Nurcombe, 2009). As a direct continuation of 
previous patent with embryonic heparan sulfate (HS2), another patent has 
been published by our laboratory as methods of culturing mesenchymal stem 
cells (Cool and Nurcombe, 2012). Investment in this sector is rapidly 
increasing due to the fact that the potential stem cell therapy market is 
expected to be around 8 billion by 2016 (Syed and Evans, 2013).  
 
1.8 Affinity chromatography 
Urh et al have described affinity chromatography as a powerful 
method which utilizes interaction between two molecules in order to purify a 
molecule from a mixture (Urh et al., 2009). They further mentioned that a 
thorough understanding of the target, ligand and the purification procedure is 
essential for success. On the other hand, fishing requires not only a fishing 
pole, but bait. A hook must have an appropriate bait attached at the end of the 
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fishing line of the pole to attract and catch a fish (Ward and Myers, 2007). The 
bait usually influences what you catch, as different fish are attracted to 
different type of fish bait. Managing bait type would seem to constitute a 
simple tool to influence the amount and composition of the fish catch (Alós et 
al., 2009), notwithstanding baited hooks can be also be re-used for catching 
fish.  
Cain et al. have described an affinity purification and mass 
spectrometry method to analyze molecular interactions within elastic fibres 
which they termed “molecular fishing” (Cain et al., 2009). They confirmed the 
sensitivity and validity of their method by identifying known interactions with 
the bait proteins. They used “bait” proteins that were purified, tagged 
recombinant fragments, added them to cell cultures, and detected susceptible 
“prey” proteins.   
We, the Glycotherapeutics group (IMB, A*STAR) have pioneered 
over several years an analogous affinity method that was sufficiently novel to 
allow patenting (#2009292236). With this technique our Glycotherapeutics 
group has built up a library of patent-protected heparan sulfates targeted to 
different, clinically relevant growth factors.  Our platform resembles a 
relatively straightforward method of fishing (Fig. 1.1). Here we used an FGF-
2-HBD peptide as the “bait” and pulled down the “prey” HS. Incorporation of 
the linker Ahx in the peptide design helped its free movement as it engaged 
candidate sugar chains in the HS mixture. In addition, the biotin’s strong 
interaction with streptavidin maintained peptide fidelity, which enables 
continual usage of the peptide bound column in pull down assays of affinity 
chromatography.    
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Figure 1.1. Molecular Fishing. An artistic rendering of our affinity chromatography 
technique platform that reinforces the concept of fishing. The FGF-2-HBD peptide as the 
“bait” protein pulls down the “prey” heparan sulfate, here termed as HS8+ve.  
 
1.9. Thesis outline 
1.9.1. Motivation 
We are now faced with an aging human population that is increasingly 
burdened by degenerative diseases. These illnesses are largely treated by 
surgery and drugs designed to mitigate symptoms. Given their role in 
maintaining and replenishing tissues, stem cells represent a potential means of 
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restoring tissue function and thereby treating the root cause of degenerative 
disease. The potential for hMSC therapy as an adult stem cell to contribute to 
this growing market are substantial.  
The major drawback retarding the wider exploitation of hMSCs for 
cell-based therapies is the difficulty in generating sufficient cell numbers to 
meet the clinical demand, both real and potential. The low proportions of 
hMSCs within bone marrow - they represent only 0.01 - 0.0001% of the 
marrow mononuclear cell population - are clearly hindering their more 
widespread adoption (Caplan, 2009). In order to address this major question of 
the supply of hMSC, mimicking of the bone marrow microenvironment with 
ECM substrates (Grünert et al., 2007; Matsubara et al., 2004) and exogenous 
FGF-2 (Dombrowski et al., 2009; Ling et al., 2006; Sotiropoulou et al., 2006) 
were promising but the resulting expanded cells “stemness” was unpredictable 
(Auletta et al., 2011; Cool and Nurcombe, 2005; Gronthos et al., 1999; 
Sotiropoulou et al., 2006; Walsh et al., 2000). Although, autocrine FGF-2 has 
also been shown to increase the multipotentiality of human adipose-derived 
MSCs (Rider et al., 2008). Therefore, enhancing the endogenous FGF-2 
already copiously secreted by MSCs through targeted HS fractions appeared 
reasonable as HS clearly regulates FGF signaling by direct molecular trimeric 
association with both FGFRs and FGFs (Pellegrini, 2001).  
Previous work in our group had demonstrated the apparently 
remarkable properties of a neuroepithelially-derived HSPG that, although 
retaining its core protein identity, was able to switch its growth factor-
potentiating abilities from FGF-2 to FGF-1 (Nurcombe et al., 1993). The 
group developed these findings by uncovering the structure compositions of 
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HS underpinning these (Brickman et al., 1995; Brickman et al., 1998):, 
showing they applied to bone (Jackson et al., 2002), and developing a rational 
platform for their scale-up (Murali et al., 2013) and showing they have 
therapeutic utility (Murali et al., 2013). In addition, this led to the isolation 
and characterization of the embryonic HS preparation named HS2, which in 
turn was shown to be able to accelerate hMSC growth without significant loss 
of multipotentiality; cells grown in this mixture could in turn trigger increased 
bone formation in mice when they were transplanted in vivo (Helledie et al., 
2011). As a direct development of this work, Murali et al extracted HSs from 
the livers of mice which indeed increase rates of hMSC expansion and 
osteogenic differentiation (Murali et al., 2011). These data suggested that the 
ECM component HS could selectively improve the growth of the hMSCs 
exposed to FGF-2 without adversely affecting their multipotentiality, 
notwithstanding that although liver is a better source of HS than embryonic 
mouse brain, the problem of scalability was not resolved. Therefore, this thesis 
is aimed at resolving this scalability issue. 
 
1.9.2. Specific Aims 
 As with many extracellular growth factors, maximum bioactivity of the 
powerful stem cell mitogen FGF-2 depends on the co-factor heparan sulfate 
glycosaminoglycan sugar. However, to fully realize the clinical potential of 
this important complexation event, sufficient HS GAG is required. Therefore 
the major aim of the thesis is to provide a scalable substance in the form of 
heparan sulfate that is capable of binding to FGF-2 without compromising its 
biological activity for scale up of naïve human mesenchymal stem cells within 
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a heterogeneous pool of adherent bone marrow cells.  In development of this 
strategy, consideration was given to the key factors of   simplicity, safety, 
scalability and efficacy. Thus the specific aims of this thesis are to: 
1. Identifying the heparin binding domain of FGF-2 and to use this 
knowledge to synthesize FGF-2-HBD peptides in order to develop an 
affinity substrate capable of binding to unmodified FGF-2 based on its 
affinity to glycosaminoglycans. 
2. Characterization of isolated heparan sulfate to determine its biological 
activity. 
3.  Evaluate the ability of isolated heparan sulfate to expand the hMSCs 





An HS sub-fraction that mediates the bioactivity of FGF-2 can be isolated 
from a crude HS preparation by peptide-based affinity chromatography. When 
used as a culture supplement during the culture expansion of adult human 
mesenchymal stem cells (hMSC), this HS sub-fraction will bind and 
activate endogenously produced FGF-2 resulting in a maintenance of a naïve 
hMSC phenotype whilst prolonging the long-term culture potential of these 
cells. 
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1.9.4. Thesis Organization 
This thesis is comprised of five chapters: 
 
Chapter 1 presents a review of literature focusing on areas of 
extracellular matrix, proteoglycans, glycosaminoglycans, fibroblast growth 
factors (FGFs),  FGF receptors (FGFRs), interactions of heparin/HS with 
FGF-2, mesenchymal stem cells (MSCs), the need to scale up of hMSC for 
therapeutic purposes, and current expansion methods for hMSCs. It will also 
describe the background, motivation, and objectives of this research. 
 
Chapter 2 identifies the HBD of FGF-2 and used this knowledge to 
synthesize FGF-2-HBD peptides. It also describes the potential use of these 
peptides by means of 
3
H heparin assay and GAG ELISA.  These peptides were 
then used as “bait” in affinity chromatography in order to isolate the “prey” 
heparan sulfate.  
Chapter 3 describes the characterization of isolated heparan sulfate to 
determine its capability of binding to unmodified FGF-2 without 
compromising its biological utility in expanding hMSCs. Various binding 
assays, including ELISA and heparin-sepharose competition were used to 
determine the binding affinity to full length FGF-2. Proliferation studies 
namely BrdU incorporation assay and GUAVA viacoiunt
®
 assay were used to 
examine the effect of the isolated HS on hMSC proliferation. In addition, the 
HS’s properties were further studied by anticoagulation assay and disaccharide 
analysis. Later in the chapter the effect of the HS variant on stability of FGF-2, 
 Confidential  38 
 
its synergistic activity with FGF-2, and inhibitor studies probe the mechanism 
involved.  
Chapter 4 describes the application of the isolated HS substrate in 
expanding hMSCs isolated from bone marrow, with a view to determining its 
direct clinical utility. 
Chapter 5 concludes with a summary of the findings of this study and 


































CHAPTER 2: ISOLATION 
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2.1. Introduction 
This initial study was developed to primarily address the issue of 
scalability; that is, to explore the possibility of isolating an HS variant not only 
with high binding affinity for FGF-2, but that potentiates the FGF-2-driven 
growth of hMSCs and which can ultimately be scaled with sufficient quality 
for future clinical use. This chapter describes such a strategy and further 
exemplifies the utility of a patent-protected (#2009292236) HS purification 
platform developed by the Glycotherapeutics group (IMB, A*STAR) (Murali 
et al., 2013). Importantly, the development of an affinity purified HS directed 
towards FGF-2 is a crucial extension of the exemplification of the platform 
first provided by the BMP-2 binding HS variant dubbed HS3 (Murali et al., 
2013). 
 
2.2. Materials and Methods 
2.2.1. Preparation of FGF-2-HBD peptides  
The first step was to identify a suitable FGF-2-HBD peptide that could 
be used to derivatize an affinity column. To achieve this, ten FGF-2-HBD 
peptides (12-20 mg, as depicted in Figure 2.1) were synthesized by GL 
Biochem (Shanghai) Ltd, Shanghai, China (peptides Sequence ID Nos. 1 and 
2) and NTU-SBS Peptide Core Facility, Nanyang Technological University, 
Singapore (peptides sequence ID Nos. 3 to 10). As shown in Figure 2.1, 
biotinylation was performed at both the N-terminal (*) and the C-terminal (**) 
of the FGF-2-HBD peptides in attempts to attach the biotin sufficiently far 
away from any of the clusters of positively-charged, heparin-binding amino 
acids. A hydrophobic spacer/linker, aminohexanoic acid (Ahx), was included 
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(Fig. 2.2) between the biotin and the FGF-2-HBD peptide in order to provide 
free movement of the peptide when it was bound to the streptavidin column 
prior to the affinity chromatographic step. To facilitate C-terminal 
biotinylation, an additional lysine was included between the biotin and the 
Ahx (Fig. 2.2). In order to improve the screening, all ten FGF-2-HBD peptides 
were synthesized with a purity of > 95%, as verified via HPLC by the 
manufacturer. Once synthesized, the peptides were stored at -20 °C until 




Figure 2.1. Illustration of overlapping peptides derived from the heparin-binding 
domain (HBD) of the FGF-2 sequence.  Ten peptides were synthesized (sequence ID Nos. 1 
to 10) with biotinylation at either at N-terminal (*) or at C-terminal (**).  
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Figure 2.2. Illustration of FGF-2-HBD peptide modifications. (A) N-terminal biotinylation 
of FGF-2-HBD peptide, and (B) C-terminal biotinylation of FGF-2-HBD peptide.  
 
2.2.2. Peptide binding assay with 
3
H-heparin 
To first confirm the binding ability of the synthesized FGF-2-HBD 
peptides for soluble heparin, before proceeding to subsequent experiments, a 
3
H-heparin binding assay was employed, essentially as described by Baird et 
al. (Baird et al., 1988). This assay was based on the immobilization of FGF-2-
HBD peptides onto nitrocellulose membranes, and the ability of 
3
H-heparin to 
bind to them.  
Biotinylated FGF-2-HBD peptides were serially diluted in 2.5 µl of 








 mol peptide) and 
individually spotted, in duplicate, onto uniform sheets of 0.2 μM nitrocellulose 
membranes (Biorad). The peptides were then air dried for 1 h at room 
temperature and heated to 80 °C with -10 psi in a vacuum oven (Thermo 
Fisher Scientific, USA) for 45 min. The membranes were then washed three 
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times with PBS. Thereafter 1 ml of 0.1 μCi of 3H-heparin (Perkin Elmer) in 4 
% BSA (Sigma Aldrich) was added to the membranes and incubated overnight 
(16 h) at room temperature with agitation (100 rpm). The next day, the 
membranes were washed four times with PBS and 1 ml of Ultima Gold 
scintillation cocktail (Perkin Elmer) added in a 5 ml scintillation vial (Perkin 
Elmer). The vial was analyzed in a liquid scintillation Tri-carb 2800TR 
counter (Perkin Elmer, Massachusetts, USA) for 2 min, twice. The counts-per-
minute readings were averaged and plotted. 
                 
2.2.3. GAG ELISA – bound heparin and HSpm and their ability to engage 
FGF-2-HBD peptides 
To further validate the binding affinities of the synthesized FGF-2-
HBD peptides for heparin, GAG ELISA (Glycosaminoglycan enzyme-linked 
immunosorbent Assay) was performed. A modified version this assay was 
used as described earlier by our group (Bramono et al., 2012; Murali et al., 
2011). The GAG binding plates are produced by cold plasma polymerization 
where microtitre plate surfaces are coated with allyl amine (Mahoney et al., 
2004; Marson et al., 2009). Heparin non-covalently immobilizes to these allyl 
amines by an electrostatic interaction without losing its ability to interact with 
proteins. The binding ability of each of the FGF-2-HBD peptides was then 
assessed via the biotinylated portion of the peptide, which yielded a 
colourimetric reaction as per the manufacturer’s instructions (Fig. 2.3).  
Wells were incubated overnight (16 h) at room temperature, protected 
from light, with 200 μl of a 5 μg/ml heparin solution in standard assay buffer 
(SAB:100 mM NaCl, 50 mM NaAc, (v/v) 0.2 % Tween 20, pH 7.2). Wells 
were then washed carefully with 250 μl of SAB three times, and blocked with 
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0.4 % (w/v) fish gelatin (Sigma Aldrich) in SAB (blocking buffer) for 1 h at 
37 °C protected from light. The initial experiments were designed to optimize 
the concentrations of FGF-2-HBD peptides best suited to bind with the 
immobilized heparin (5 μg/ml) on the GAG-binding 96-well plates. 
Optimization was carried out with the FGF-2-HBD Gandhi (G) peptide in a 
range from 0 - 3200 nM in serial two-fold dilutions. The wells were washed 
with SAB thrice and FGF-2-HBD in blocking buffer at different optimized 
concentrations (0, 50, 100, 200 nM) was added into triplicate wells (200 μl 
each) to be incubated at 37 °C for further 2 h. 
Wells were again washed thrice with SAB to remove unbound FGF-2-
HBD peptides. Next, ExtrAvidin (200 μl of 220 ng/ml) (Sigma Aldrich) was 
added and incubated for another 30 min at 37 °C. Wells were finally washed 
with SAB (3 times) and 200 μl of development reagent SIGMAFAST™ p-
Nitrophenyl phosphate (Sigma Aldrich) in DI water was added into the wells 
at room temperature for 40 min. Colourimetric absorbance was read at 405 nm 
with a Victor multiplate reader (Perkin Elmer, Massachusetts, USA). 
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Figure 2.3. Diagram illustrating arrangement of the elements within the GAG-ELISA 
assay of heparin and FGF-2-HBD peptide binding.       
 
The assay was repeated by replacing heparin in the initial step with 
porcine mucosal heparan sulfate (HS
pm
) (Celsus Laboratories); the wells were 
incubated overnight (16 h) at room temperature protected from light with 200 
μl of 5 μg/ml of HSpm in standard assay buffer (SAB). HSpm is a water-soluble, 
bulk-lyophilized fraction of crude heparin extracted from porcine mucosal 
tissue. This enabled a comparison between the binding affinities of the 




2.2.4. Affinity chromatography 
Once the FGF-2 HBD peptides were synthesized, I pursued an 
experimental path our Glycotherapeutics group (IMB, A*STAR) has 
pioneered over several years (Murali et al., 2013). FGF-2-binding HS 
fractions were isolated from a starting commercial source of porcine mucosal 
HS (HS
pm
) (Celsus Laboratories, USA). Biotinylated FGF-2-HBD peptide was 
used as the capture ligand, and so needed to be derivatised to streptavidin 
 Confidential  46 
 
columns. This forms a very strong interaction that would require strong 
denaturing conditions for elution. This affinity chromatography platform 
(AKTA Purifier Core 10, GE Healthcare), which is under patent protection 
(#2009292236), was clearly able to separate HBD peptide-binding HS from 
unbound HS when a mixture of HS (HS
pm
) was applied to the column (Fig. 
2.4). Biotinylated FGF-2-HBD peptides, dissolved in low salt buffer (20 mM 
phosphate buffer, 150 mM NaCl, pH 7.2), were coupled to a 1 ml HiTrap 
streptavidin HP column (GE Healthcare) as monitored by the detection of 
unbound peptide at 215 nm in the flow-through. The peptides were applied at 
a concentration of 1 mg/ml to a total of 3 mg. To ensure each peptide was 
firmly bound to the column, a 1.5 M high salt buffer (20 mM phosphate 
buffer, 1.5 M NaCl) wash was performed. When no traces at 215 nm were 
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Figure 2.4. Diagram illustrating the affinity chromatography platform.  Biotinylated 
FGF-2-HBD peptides were used as the capture ligand within streptavidin columns. This 
affinity platform was then able to separate FGF-2-HBD peptide-binding HS from unbound HS 
when a crude mixture of commercially available HS was applied.  
Porcine mucosal HS (HS
pm
) (Celsus Laboratories) was dissolved in 
low salt buffer (20 mM phosphate buffer, 150 mM NaCl, pH 7.2) at a 
concentration of 1 mg/ml. A total of either 100 mg or 400 mg HS
pm
 solution 
was loaded after a total of 40 or 160 separate injections, of 2.5 ml each, in 
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low-salt buffer at a flow rate of 0.2 ml/min, and the column washed with the 
same buffer until the baseline reached zero. The bound HS was eluted with a 
one-step gradient of 1.5 M high salt (20 mM phosphate buffer, 1.5 M NaCl), 
the bound and unbound variants collected (as monitored at A232 nm), and the 





) peak samples were collected separately, freeze-dried, and 
stored at -20 °C.  
 Desalting, size-exchange chromatography was next exploited to 





 variants away from the eluting NaCl. As 
shown in Figure 2.5, large molecular weight elements, such as HS, cannot 
enter the gel, and are so excluded from the gel bed, and thus elute before the 
small molecular weight ions (NaCl) which enter the pores freely, and thus take 
more time to elute. Both the HS8
+ve
 and the HS8
–ve
 variants were then 
separately dissolved in minimal amounts of HPLC grade water (Sigma 
Aldrich) until a clear solution was obtained, and the samples desalted once 
again on a HiPrep 26/10 desalting column (Amersham Biosciences) at a flow 
rate of 10 ml/min (AKTA Purifier, GE Healthcare). The HS variants were then 
collected, freeze-dried, and stored at – 20 °C.  




Figure 2.5. Diagram illustrating size exclusion chromatography platform.  Large 
molecular weight components such as HS cannot enter the gel, and are thus excluded from the 
gel, so eluting first compared to the small molecular weight components (NaCl) which enter 
the pores freely and thus take more time to elute. 
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2.3. Results 
2.3.1. Peptide binding assays with 
3
H-heparin 
Following the synthesis of the biotinylated FGF-2-HBD peptides (10 
in total), their ability to bind to heparin needed to be confirmed. For this, a 
3
H-
heparin radioactivity-binding assay was performed. It was adapted from an 
assay originally published by Baird et al. where overlapping peptides derived 
from the primary structure of FGF-2 were synthesized and purified by solid-
phase methodology, and gel permeation and ion exchange chromatography; 
they were then investigated as to their binding capacity for 
3
H-heparin (Baird 
et al., 1988). Three peptides namely, FGF-2-HBD Baird(B) : Biotin-Ahx-
YCKNGGFFLRIHPDGRVDGVREKSDPHIKL 
QLQEERGVVSIKGV (Sequence ID No.1, Figure 2.1),  FGF-2-HBD Cardin 
(C) - Biotin-Ahx-GSGAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVD 
(Sequence ID No.2, Fig. 2.1) and FGF-2-HBD Gandhi (G): 
GHFKDPKRLYCKNGGF-Ahx-(K)Biotin (Sequence ID No.3, Fig. 2.1) were 
able to bind to 
3
H-heparin in a concentration-dependent manner (Fig. 2.6). 
This suggested that these particular overlapping sequences of FGF-2, do 
indeed bind to heparin and were suitable for affinity chromatography. In 
addition, two other FGF-2-HBD peptides (Sequence ID Nos. 5 and 7, Fig. 
2.1), were also able to bind to 
3
H-heparin in a concentration-dependent 
manner (Fig. A1). These two peptides (Sequence ID Nos. 5 and 7, Fig. 2.1) 
however were not used for chromatography as they overlap the region that 
corresponds to the receptor-binding domain of FGF-2 (Plum et al., 2000), and 
would have been more likely to generate an artifact.   




Figure 2.6. Binding of FGF-2-HBD to 
3
H-heparin. FGF-2-HBD peptides (A) Gandhi-G, (B) 
Cardin-C and (C) Baird-B were spotted onto nitrocellulose membranes, air-dried and 
incubated with 3H-heparin. Bound 3H-heparin was determined by liquid scintillation as 
described. 
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2.3.2. GAG ELISA – FGF-2-HBD peptides  
 
Further assessments of the synthesized FGF-2-HBD peptides, via their 
binding capacities for heparin, were conducted by GAG ELISA. The initial 
experiments were designed to optimize the concentrations of FGF-2-HBD 
peptides best suited to bind with coated (5 μg/ml) and immobilized heparin on 
GAG-binding 96-well plates following the manufacturer’s recommendations 
(Iduron). Optimization was carried out with the FGF-2-HBD Gandhi (G) 
peptide in a range from 0 - 3200 nM in serial two-fold dilutions; from these 
experiments 0, 50, 100, and 200 nM concentrations were used for the rest of 
the study (Fig. 2.7).  
 
 
Figure 2.7. GAG ELISA – FGF-2 HBD peptide optimization. Optimization was carried out 
with the FGF-2-HBD Gandhi (G) peptide using a range from 0 - 3200 nM in serial two-fold 
dilutions. Thus 0, 50, 100, and 200 nM concentrations were used for the rest of the 
experiments. 
 
After determining these optimal concentrations, a saturating heparin 
concentration (5 μg/ml) was coated overnight and the resulting surface 
investigated for its binding capacity for the different FGF-2-HBD peptides 
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(Fig. 2.8).  The binding curves showed that, irrespective of FGF-2-HBD 
peptide, there was a dose-dependent increase in heparin binding with FGF-2-
HBD Gandhi (G) clearly showing the highest capacity for the sugar. The 
lowest affinity for FGF-2 was shown by the FGF-2-HBD Baird (B) peptide, 
interestingly the longest peptide tested, whereas the FGF-2-HBD Cardin (C) 
peptide displayed an intermediate capacity for binding FGF-2. In addition, two 
other FGF-2-HBD peptides (Sequence ID Nos. 5 and 7, Fig. 2.1) were able to 
bind to heparin in a concentration-dependent manner, but were not 
subsequently used for chromatography, as previously explained (see Fig. A2). 
This further supported the results of the 
3
H-heparin assay, and the combination 
of results enabled the narrowing down of the FGF-2-HBD peptides from the 
original ten (Fig. 2.1) to just three. 
 
Figure 2.8. Binding capacities of FGF-2-HBDs for heparin. Heparin was immobilized onto 
the GAG-binding 96-well plates (Iduron) by electrostatic interaction, which did not affect 
their protein binding capabilities. The Gandhi-G, Cardin-C and Baird-B FGF-2-HBD peptides 
had their binding ability for immobilized heparin assessed by dint of their biotinylated portion 
yielding a colourimetric reaction. 
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Finally, the binding affinity of the three FGF-2-HBD peptides for 
HS
pm
, the commercially available source of heparan sulfate (Celsus 
Laboratories, USA) was tested. It was necessary to confirm that these peptides 
were indeed able to bind to HS
pm
, as they were to be used to harvest active HS 
fractions in the chromatographic steps. As shown in Figure 2.9, all three 
peptides gave rise to a dose-dependent increase in heparin binding. The 
binding affinities of these peptides for HS
pm
 were similar to the binding 
affinities to heparin, wherein FGF-2-HBD-Gandhi (G) > FGF-2-HBD-Cardin 
(C) > FGF-2-HBD-Baird (B). With these results a strong foundation was laid 
down for the isolation of higher affinity HS from crude HS
pm
.     
 
 
Figure 2.9. Binding ability of FGF-2-HBD to HS
pm
.  HSpm was immobilized onto the GAG-
binding 96-well plates (Iduron) by electrostatic interaction in such a way that its protein-
binding capabilities were not affected. The binding capacity of FGF-2-HBD peptides Gandhi-
G, Cardin-C and Baird-B, for immobilized heparin was assessed via the biotinylated portion 
of the FGF-2-HBD peptides, and yielded a measurable colourimetric reaction. 
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2.3.3. Affinity chromatography 
2.3.3.1. Affinity chromatography – HS8G 
As the peptides were able to bind both heparin and HS
pm
, they were 
used to derivatise streptavidin columns for affinity chromatography. The FGF-
2-HBD Gandhi (G) peptide was tested first. The column was saturated with 
biotin-peptide 1 ml each (1 mg/ml), up to 3 ml in total, until excess peptide 
(pink trace) was observed in the flow-through at 215 nm (Figs. 2.10 and 2.11). 
To check the binding affinity between the immobilized streptavidin and the 
biotinylated peptides, the column was challenged by washing with a 1.5 M 
high salt buffer (brown trace, Fig. 2.11). No peptide eluted off the column, 
indicating that the columns were saturated with strongly bound peptides that 
would not dissociate during the later elution of HS variants. The column was 




Next the column was loaded with increasing amounts of HS
pm
 (2, 2.5 
and 3 mg) in order to determine the optimum amount of HS
pm
 to be used 
(Figs. 2.12 and 2.13). The fractionated HS was dubbed HS8 (and was given 
the variant name HS8G). The HS that did not bind to the peptide (red trace) 
was designated as the HS8G
-ve
 variant. Bound variants were eluted from the 
column using a one-step 1.5 M NaCl elution (brown trace), and collected as 
the HS8G
+ve
 variant (red trace). The height of the HS8G
+ve
 variant curve 
increased with increasing amount of HS
pm
 injected to the column, wherein 2.5 
mg of HS
pm
 triggered a 240 mAU peak and 3 mg triggered a 245 mAU peak. 
Although the peak of HS8G
+ve





 curve started to get broader, indicating that the 
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streptavidin column was saturating. In addition, this indicated that the 
unbound HS8G
+ve 
was present in the flow-through after 3 mg of HS
pm
 loading. 
Hence, 2.5 mg of HS
pm
 was selected to be injected for each cycle of HS8G 
isolation. After running for 160 separate cycles of HS8G variant isolation, the 
NaCl was removed by a desalting step using HiPrep 26/10 desalting columns 
(Fig. 2.14). From 400 mg of starting HS
pm
, 36.2 mg (9.05 %) of HS8G
+ve
 and 
173.3 mg (43.33 %) of HS8G
-ve
 were isolated; the rest of the weight was 
constituted by NaCl.   
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Figure 2.10. Biotinylated FGF-2-HBD Gandhi (G) peptide coupling. (A) A first 1 mg and 
(B) a second 1 mg of peptide were loaded into the streptavidin column and excess peptide 
flowing out of the column was monitored at 215 nm.  
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Figure 2.11. Biotinylated FGF-2-HBD Gandhi (G) peptide coupling and challenge with 
high salt buffer. (A) The third 1 mg of peptide was loaded into the streptavidin column and 
excess peptide that flowed out of the column was monitored at 215 nm. (B) Columns were 
washed with 1.5 M high salt buffer to ensure peptide is tightly bound to the column. 
 




Figure 2.12. Chromatograms depicting HS8G
+ve
 isolation. HS8G+ve variant was isolated 
from the starting (A) 2 mg and (B) 2.5 mg of HSpm mixture using streptavidin column pre-
bound with FGF-2-HBD Gandhi (G) peptide. A high salt wash (1.5 M) (brown trace) released 








Figure 2.13. Chromatogram depicting HS8G
+ve
 isolation.  HS8G+ve variant was isolated 
from the starting 3mg of HSpm mixture using streptavidin columns pre-bound with FGF-2-
HBD Gandhi (G) peptide. A high salt wash (1.5 M) (brown trace) released the HS8G+ve 








Figure  2.14. Elution profile of desalted HS8G variants.  The high molecular weight HS 
eluted first, while NaCl eluted later. (A) Elution profile of HS8G+ve variant (B) Elution profile 
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2.3.3.2. Affinity chromatography – HS8C 
 Next, the FGF-2-HBD Cardin (C) peptide was used to isolate HS8 
variants from the commercial HS
pm
 source; the isolated variant was dubbed 
HS8C. Similar to the isolation of HS8G, steptavidin columns were first 
saturated with biotin-peptide 1 ml each (1 mg/ml), up to 3 ml, in total until 
excess peptide (pink trace) was observed in the flow-through at 215 nm; the 
column was challenged with 1.5 M high salt buffer (brown trace) and it was 
confirmed that the peptide was strongly bound to the column (Figs. 2.15 and 
2.16). Then the column was loaded with increasing amounts of HS
pm
 (2, 2.5 
and 3 mg). For the HS8C
+ve
 curves, 2.5 mg of HS
pm
 yielded a 160 mAU peak, 
and with 3 mg HS
pm
, a 165 mAU peak was observed (Figs. 2.17 and 2.18). As 
above with HS8G, 2.5 mg of HS
pm
 was selected as the optimum amount to be 
injected for each cycle of HS8C isolation. After 40 cycles of isolation, a 
desalting step (Fig. 2.19) was carried out to separate HS8C variants from 
NaCl. A yield of 5.06 mg (5.06 %) of HS8C
+ve
 and 67 mg (67 %) of HS8C
-ve
 
were isolated from 100 mg of starting HS
pm
.   
 




Figure 2.15. Biotinylated FGF-2-HBD Cardin (C) peptide coupling. (A) A first 1 mg and 
(B) a second 1 mg of peptide were loaded into the streptavidin column and excess peptide that 
flowed out of the column was monitored at 215 nm.  
 




Figure 2.16. Biotinylated FGF-2-HBD Cardin (C) peptide coupling and challenge with 
high salt buffer. (A) A third 1 mg of peptide was loaded into the streptavidin column and 
excess peptide that flowed out of the column was monitored at 215 nm. (B) The column was 
washed with 1.5 M high salt buffer to ensure peptide was tightly bound to the column. 




Figure 2.17. Chromatograms depicting HS8C
+ve
 isolation. The HS8C+ve variant was 
isolated from the starting (A) 2 mg and (B) 2.5 mg of HSpm mixture using streptavidin column 
pre-bound with FGF-2-HBD Cardin (C) peptide. A high salt wash (1.5 M) (brown trace) 
released the HS8C+ve variant (red trace) and was collected. 
 




Figure 2.18. Chromatogram depicting HS8C
+ve
 isolation.  HS8C+ve variant was isolated 
from the starting 3 mg of HSpm mixture using streptavidin column pre-bound with FGF-2-
HBD Cardin (C) peptide. A high salt wash (1.5 M) (brown trace) released the HS8C+ve variant 
(red trace) and was collected. 
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Figure 2.19. Elution profile of desalted HS8C variants. The high molecular weight HS 
eluted first, while the NaCl eluted later. (A) Elution profile of the HS8C+ve variant (B) Elution 
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2.3.3.3. Affinity chromatography – HS8B 
The FGF-2-HBD Baird (B) peptide was used to isolate HS8 variants 
from the HS
pm
 mixture and the isolated variant was dubbed HS8B. Similar to 
the  isolation of HS8G, the steptavidin column was first saturated with biotin-
peptide 1 ml each (1 mg/ml) up to 3 ml in total until excess peptide (pink 
trace) was observed in the flow-through at 215 nm, whereafter the column 
with the peptide bound was challenged with 1.5 M high salt buffer (brown 
trace) (Figs. 2.20 and 2.21). No peptide was eluted off the column, confirming 
the strong interaction of biotinylated peptide with the streptavidin column. The 
column was equilibrated with low salt buffer then loaded with increasing 
amounts of HS
pm
 (2, 2.5 and 3 mg) while observing the peak height of the 
HS8B
+ve
 curve. A peak of 70 mAU arose from 2.5 mg of HS
pm
 loaded and a 
peak of 65 mAU with 3 mg HS
pm
 (Figs. 2.22 and 2.23). As above with HS8G, 
2.5 mg of HS
pm
 was selected as the optimum amount to be injected for each 
cycle of HS8B isolation. After 40 cycles of HS8B isolation and a desalting 
step (Fig. 2.24), 100 mg of starting HS
pm
 yielded 2.24 mg (2.2.4%) of HS8B
+ve
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Figure 2.20. Biotinylated FGF-2-HBD Baird (B) peptide coupling. (A) A first 1 mg and 
(B) a second 1 mg of peptide were loaded into the streptavidin column and excess peptide that 
flowed out of the column was monitored at 215 nm.  
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Figure 2.21. Biotinylated FGF-2-HBD Baird (B) peptide coupling and challenge with 
high salt buffer. (A) A third 1 mg of peptide was loaded into the streptavidin column and 
excess peptide that flowed out of the column was monitored at 215 nm. (B) The column was 








Figure 2.22. Chromatograms depicting HS8B+ve isolation.  The HS8B+ve variant was 
isolated from the starting (A) 2 mg and (B) 2.5 mg of HSpm mixture using streptavidin column 
pre-bound with FGF-2-HBD Baird (B) peptide. A high salt wash (1.5 M) (brown trace) 
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Figure 2.23. Chromatogram depicting HS8B
+ve
 isolation. HS8B+ve variant was isolated 
from the starting 3 mg of HSpm mixture using streptavidin columns pre-bound with FGF-2-
HBD Baird (B) peptide. A high salt wash (1.5 M) (brown trace) released the HS8B+ve variant 
(red trace) and was collected. 
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Figure 2.24. Elution profile of desalted HS8B variants. The high molecular weight HS 
eluted first, while NaCl eluted after. (A) Elution profile of HS8B+ve variant (B) Elution profile 
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2.4. Discussion 
In the past, affinity separated heparin variants have been isolated not 
using peptides, but rather using native protein. For example, Barzu et al. used 
oligosaccharides generated from nitrous acid depolymerisation of standard 
heparin and separated them by affinity chromatography on Sepharose-
immobilised FGF1 (Bârzu et al., 1989). Furthermore, Brickman et al. used 
FGF-2-coupled Sepharose packed into small columns to isolate HS chains 
with high affinity for FGF-2 (Brickman et al., 1995). Moreover, heparin 
variants of high affinity for fibronectin (Falcone and Salisbury, 1988),  heparin 
co-factor II (Kim and Linhardt, 1989; Sinniger et al., 1993) and anti-thrombin 
III (Höök et al., 1976; Scully et al., 1988; Sinniger et al., 1993) have been 
isolated using native proteins as the bait in affinity chromatography 
approaches. Although promising results were noted, usage of full length 
proteins is prohibitively costly and such columns cannot be re-used. 
McCaffrey et al. demonstrated the heparin-binding capacity of transforming 
growth factor-βl (TGF-βl) using synthetic peptides derived from various 
regions of TGF-βl, and isolated two sugar variants (with high and low TGF-β1 
binding affinity) from heparin mixtures (McCaffrey et al., 1992). However, a 
major problem is that heparin was used as the starting material, which is 
clearly not suitable for clinical applications because of its inherent 
anticoagulant activity and capacity for non-specific binding.   
 The isolation of HS described here consisted of several steps, including 
affinity chromatography. The first involved the identification of suitable FGF-
2-HBD peptides from the candidates already described in the available 
literature for the derivatisation of affinity columns. Next, the candidate HBD 
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peptides were engineered in such a way that a hydrophobic spacer was 
attached, so that biotinylation at both N-terminal or C-terminal was possible.  
Prior to the exploitation of these peptides in the affinity column, their FGF-2 
binding capabilities were confirmed by means of 
3
H-heparin and GAG ELISA 
association assays. Thereafter, the solid phase affinity chromatography 
platform was constructed, wherein streptavidin columns saturated with the 
FGF-2-HBD biotinylated peptides, rather than full length proteins as earlier 
described, (Bârzu et al., 1989; Brickman et al., 1995) were exposed to raw HS 
preparations. In comparison to McCaffrey et al., commercially available 
porcine intestinal mucosal HS was used instead of heparin to start the 
fractionation, an affinity method sufficiently novel to allow patenting 
(#2009292236) (McCaffrey et al., 1992; Murali et al., 2013). Using such 
approaches and techniques, our Glycotherapeutics group has built up a library 
of patent-protected heparan sulfates targeted to a variety of clinically relevant 
growth factors. Thus the platform resembles a relatively straightforward 
method of sugar ligand “fishing”, as described in the literature review (Fig. 
1.1). Here the FGF-2-HBD peptide was the “bait”, and proved able to pull 
down the “prey”, an HS sugar subfraction thereafter dubbed HS8+ve. 
Incorporation of the linker Ahx in the peptide design helped its free movement 
and better allowed it to engage susceptible, complementary sugar chains (Fig. 
2.2 and 1.1) from the mixture of HS
pm
 starting material. In addition, the 
biotin’s strong interaction with streptavidin maintained peptide fidelity, and 
the same column could be used for more than 40 extraction cycles without loss 
of selective capacity (Figs. 2.2 and 1.1). As described by our collaborators at 
GlycoSyn, (now the Ferrier Institute, Victoria University of Wellington, New 
 Confidential  76 
 
Zealand), in referring to a similar scale-up process of for the BMP-2 binding 
HS variant dubbed HS3 (Murali et al., 2013), 20 ml column lifetimes can be 
most accurately evaluated through affinity chromatography performance 
following one month storage (in 20 % aqueous ethanol with 20 mM phosphate 
buffer at 4 °C) of the affinity column. They have shown that under otherwise 
identical conditions, the peak area of the retained HS is > 90 % of that seen in 
a fresh column. Here, the 1 ml streptavidin derivatised columns were used 
within 2-3 days of synthesis for the pull-down assays.  
 In addition, as indicated by the analysis of the pooled HS3 sample, our 
collaborators were able to determine the sodium chloride levels, not 
previously possible due to insufficient material.  The desalting was almost to 
purity, albeit not 100% efficient using the HiPrep column. The HiPrep 26/10 
column packed with Sephadex G-25 Fine does a group separation of a sample 
into high molecular weight substances, which are excluded from the gel and 
thus elute first, from low molecular weight substances that enter the pores 
freely and thus elute later (Amersham Biosciences). As per the manufacturer’s 
advice, the HiPrep 26/10 column can separate proteins/peptides larger than 
5000 g/mol from molecules with a molecular weight less than 1000 g/mol. 
The molecular weight of  the eluting NaCl is 58.44 g/mol and the linear, 
sulfated glycosaminoglycans have both real and apparent molecular masses 
that typically range from 10 to 100 kDa (Gandhi and Mancera, 2008). Thus 
the HiPrep 26/10 was an appropriate medium with which to gently separate 
NaCl from the HS. Subsequent findings by our collaborators, and the 
difficulties of salt contamination of final product, could theoretically be solved 
by one of two means. A second pass through the desalting column would be 
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the simplest, if least elegant solution, albeit some loss of sugar, due to its 
extraordinarily high charge density, could be anticipated. Alternatively, 
dialysis could be employed along with in-process (conductivity) testing to 
confirm salt removal. The latter would allow partial concentration of the HS8 
solution prior to freeze-drying which would have the advantage of yielding 
smaller, more manageable volumes from which the HS8 product is isolated. 
All-in-all, although complete salt removal is difficult, and has always been 
through the history of heparin/HS preparation, the use of repeated desalting on 
such columns as the HiPrep 26/10, or via dialysis, could overcome these 
problems without compromising specific activity. 
This chapter describes how ten initial custom-made FGF-2-HBD 
peptides were narrowed down to just three candidates by filtering them 
through 
3
H-heparin and GAG ELISA assays.  These were then used in affinity 
chromatography to three HS8 variants: HS8G, HS8C and HS8B. The next aim 
was to select the best of these HS8 variants to be developed further. For that 
reason the yield of each variant after affinity chromatography was carefully 
checked. As shown in the Table 2.2, the isolation of HS8G
+ve
 yielded the 
highest yield extraction percentage (9.05 %) of the HS8
+ve
 eluates. In 
comparison, HS8B
+ve
 isolation yielded the lowest percentage extraction (2.24 
%) from the starting HS
pm
 mixture (while HS8C was intermediate at 5.06 %). 
The yields corresponded to the HS8
+ve
 peak heights, where HS8B
+ve
 had the 
lowest, and HS8C height was middling at 160 mAU. Interestingly, there was a 
relationship between the binding efficiencies of peptides for heparin and HS
pm
 
in the GAG ELISA assay, and the final yield (Figs. 2.7 and 2.8 and Table 2.1). 
FGF-2-HBD Gandhi (G) had the highest binding efficiency, and consequently 
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the highest yield: ~ 9 %. FGF-2-HBD Baird (B) had the weakest binding and 
the least yield (~ 2 %). The intermediate level of HS8C
+ve
 yield also correlated 
to the peptide binding performance towards heparin and HS
pm
. This constitutes 
a remarkable consistency, presaging the intrinsic reliability of the method. In 
addition, another relationship was observed between the length of the 
synthesized peptide and the yield. HS8G
+ve
 had the highest yield, but with the 
least length of the FF-HBD peptide; in contrast, HS8B
+ve
, with the lowest 
yield, was the longest FGF-2-HBD peptide. Finally, it can be noted that the 
HS8G
+ve
 yield (~ 9 %) was comparable to other HS variants with affinity 
directed towards other growth factor proteins isolated (often ~ 10-12 %) by 
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2.5. Summary 
This chapter serves to establish a reliable means of reproducibly 
synthesising an HS variant with relative affinity for FGF-2. Once synthesized, 
the peptide could be stored in a -20 °C freezer until required for affinity 
chromatography. Despite this precaution, observations made during bulk HS3 
synthesis have noted degradation of at least one peptide from a purity of 88.86 
% to 71.37 % after storage for 5 months. A contributing factor to this 
degradation may be high levels of residual TFA, present as a result of HPLC 
purification. Given this information I instituted a process where the peptide 
was prepared “on demand” and not held in storage for any significant amount 
of time. Scale-up of affinity chromatography was attempted based on equal 
linear velocity of solvent through the packed bed. However due to the low 
pressure rating of the polypropylene columns, a reduced flow rate (50 % of the 
scale-equivalent rate) was mandatory. Thus scale-up must be monitored 
carefully, and should take into account the maximal gel bed volume. 
Nevertheless, these data indicate that HS8G isolation was the most 
rewarding, particularly in respect of % yield. The next aim was to examine the 
biological activities of each of the HS8 variants separately before to be able to 
come to a final conclusion. Thus the next chapter explores each isolated HS8 





















CHAPTER 3: CHARACTERIZATION 
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3.1 Introduction 
The previous chapter described a method to create a scalable means for 
isolating HS variants with increased binding affinity for FGF-2. In this 
chapter, a range of biochemical assays are described that were employed to 
determine the relationship between HS affinity for FGF-2 and subsequent 
bioactivity. 









), isolated by affinity chromatography, could 
drive best the actions attributable to FGF-2. This was done by a combination 
of GAG ELISA binding assays and hMSC short-term proliferation assays. In 
particular, the binding assays were conducted to confirm the ability of this 
purified HS8
+ve





 material. Two different hMSC preparations were used: those 
selected through plastic-adherence and those selected by virtue of their STRO-
1 expression. Additional binding assays, together with the assessment of 
unwanted anti-coagulant properties, the disaccharide composition and as well 
as differential scanning fluorimetry were also performed. Thereafter any 
synergistic effect of HS8 on FGF-2 was monitored by means of proliferation 
assays and cell signaling studies. Finally, the means by which the HS8 variants 
mediated the action of FGF-2 were studied by the blocking of FGF signaling 
with specific antibodies. The results of the studies allowed the selection of the 
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3.2 Material and Methods 
3.2.1. GAG ELISA  







) for FGF-2, and other heparin-binding 
domain proteins, GAG ELISA was performed. This assay has been well 
described by our laboratory for other HS isolates (Bramono et al., 2012; 
Murali et al., 2011; Murali et al., 2013; Wang et al., 2014). HS variants were 
immobilized onto specifically prepared glycosaminoglycan-binding 96-well 
plates (Iduron) by electrostatic interaction in a way that does not substantially 
affect their protein-binding capabilities. Binding abilities were assessed by 
sandwich antibodies, which yield a colourimetric reaction as per the 
manufacturer’s guidelines (Fig. 3.1)  
 
Figure 3.1. Diagram illustrating the GAG ELISA assay for HS8 variants and FGF-2.          
 
Wells were incubated overnight (16 h) at room temperature protected 
from light with 200 μl of 2.5, 5, 10 μg/ml GAGs in standard assay buffer 
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(SAB: 100 mM NaCl, 50 mM NaAc, (v/v) 0.2 % Tween 20, pH 7.2). In initial 
optimization experiments to determine the concentration which saturates the 
plate surface, all the three concentrations of GAGs were used to coat the 
GAG-binding plates. After optimizatio, 5 μg/ml of each GAG was used. Wells 
were then washed carefully with 250 μl of SAB three times and blocked with 
0.4 % (w/v) fish gelatin (Sigma Aldrich) in SAB (blocking buffer) for 1 h at 
37 °C protected from light. Then wells were washed with SAB three times and 
FGF-2 (R&D Systems) in blocking buffer at different concentrations (0, 25, 
50, 100 ng/ml equivalent to 0, 0.781, 1.56, 3.125 nM) was added (200 μl each) 
into the wells and incubated at 37 °C for 2 h. Wells were again washed three 
times with SAB and 200 μl of biotinylated anti-FGF-2 (250 ng/ml) R&D 
Systems) added into the wells and incubated at 37 °C for 1 h. Next, wells were 
washed with SAB (3 times) to remove unbound antibody and ExtrAvidin (200 
μl of 220 ng/ml) (Sigma Aldrich) added and incubated for 30 min at 37 °C. 
Wells were finally washed with SAB (3 times) and 200 μl of development 
reagent SIGMAFAST™ p-nitrophenyl phosphate (Sigma Aldrich) in DI water 
added into the wells to be incubated at room temperature for 40 min. 
Colourimetric absorbance was read at 405 nm with a Victor multiplate reader 
(Perkin Elmer, Massachusetts, USA). 
 To investigate the affinity of binding of above HS8 variants to other 
heparin-binding proteins such as BMP-2, PDGF-BB, VEGF, FGF-1, FGF-7 
(0, 0.781, 1.56, 3.125 nM) (R&D Systems) in comparison to the FGF-2, GAG 
ELISA assay was also performed. Here different proteins, other than FGF-2, 
were incubated with corresponding biotinylated antibodies (250 ng/ml; R&D 
Systems) to identify the bound proteins.  
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) to FGF-2. The wells were 
incubated overnight (16 h) at room temperature protected from light with 200 
μl of 5 μg/ml different HS8 variants in SAB and the assay conducted as above.   
 
3.2.2. Isolation and characterization of human mesenchymal stem cells 
  The human mesenchymal stem cells (hMSCs) used here were isolated 
from the Poietics
® 
bone marrow mononuclear cells (BMMNCs) of young 
healthy adult human donors (Lonza, USA) aged between 18 and 45. The 
Poietics
® 
BMMNCs were employed in two different ways to isolate human 
mesenchymal stem cells: plastic adherence and magnetic-activated cell sorting 
(MACS). 
 
3.2.2.1. Isolation of hMSCs by adherence 
 
The precursors of non-hematopoietic tissues in the bone marrow, 
essentially the MSCs, were initially referred to as plastic-adherent cells or 
colony forming-unit fibroblasts in the literature (Colter et al., 2000; 
Friedenstein et al., 1976). I adopted the plastic adherence method for isolation 
of hMSCs established by Friedenstein et al (Friedenstein et al., 1976).  
 
3.2.2.1.1. Thawing of Poietics
® 




bone marrow mononuclear cells were initially thawed as 
per the manufacturer’s specifications. The pre-warmed basal media consisting 
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of Dulbecco's Modified Eagle's medium-low glucose (DMEM-LG 1000 mg/l) 
supplemented with 10 % fetal calf serum (FCS), 50 units/ml penicillin and 50 
µg/ml streptomycin and 2 mM L-glutamine with DNase 1 (20 u/ml) (Roche) 
was used to quickly thaw the vial of 2x10
8
 frozen mononuclear cells (Lonza, 
Product No. 2M-125A, Lot No. 0F4312B from 20 year old male Hispanic) in a 
37 °C water bath. The outside of the vial was wiped with 70 % ethanol and the 
cells were aseptically transferred to a 50 ml conical tube. The vial was rinsed 
with another 1 ml of medium that was added drop-wise to the cells with gentle 
swirling. Then a further 2 ml of culture medium was added drop-wise to the 
cells, with gentle swirling after each addition of several drops of medium.   
Next, the volume of the tube was brought to 45 ml by adding 1 ml to 2 ml 
volumes of medium drop-wise, while gently swirling. Then the cell suspension 
was centrifuged for 15 min at 200 g at room temperature. The supernatant was 
removed without disturbing the cell pellet and gently resuspended in 30 ml of 
medium with gentle swirling. The cell suspension was centrifuged for 15 min 
at 200 g at room temperature. The supernatant was removed and the pellet was 
gently resuspended in 10 ml of culture medium. The cells were incubated for 1 
h in a humidified incubator at 37 °C with 5 % CO2 and counted before 
seeding.  
 
3.2.2.1.2. Isolation of hMSCs by adherence 
 The bone marrow mononuclear cells (1x10
7
) were then seeded into 
T175 flasks (Nunc) in hMSC basal media (Dulbecco's Modified Eagle's 
medium-low glucose (DMEM-LG 1000 mg/l) supplemented with 10 % FCS, 
50 units/ml penicillin and 50 µg/ml streptomycin) and the cells allowed to 
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adhere for 5 days before the first media change. The cells were cultured in 
basal medium with a media replacement every 3 days.  Cells were detached 
with 0.125 % trypsin/Versene (pH 7.0) upon reaching 75–80 % confluence 
and then washed once in basal medium before being re-plated at a density of 
3000 cells/cm
2
. All cultures were maintained under humidified atmosphere at 
37 °C with 5% CO2.  
 
3.2.2.2. Isolation of STRO1
+ve
 human mesenchymal stem cells by magnetic     
activated cell sorting (MACS)  
The use of MACS allowed the fractional purification of the bone 
marrow mononuclear cell population and the processing of large numbers of 
bone marrow mononuclear cells without compromising overall stem cell yield. 
The STRO-1
+ve
 cells were isolated from BMMNCs by magnetic-activated cell 
sorting (MACS) as per the method described by Gronthos et al (Gronthos and 
Zannettino, 2008; Gronthos et al., 1999; Gronthos et al., 2003).   
 
3.2.2.2.1. Thawing of Poietics
® 
bone marrow mononuclear cells for STRO-
1 isolation 
As for the isolation of hMSCs by plastic adherence, the Poietics
® 
bone 
marrow mononuclear cells were thawed as per manufacturer’s specifications. 
The pre-warmed basal media, consisting of α-modified Eagle’s medium (α-
MEM) supplemented with 20 % FCS, 100 µM L-ascorbate-2-phosphate, 50 
units/ml penicillin and 50 µg/ml streptomycin and 2 mM L-glutamine with 
DNase 1 (20 u/ml) (Roche), was used to quickly thaw the vials of 2x10
8
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frozen mononuclear cells (Lonza, Product No. 2M-125A, Lot No. 091295A, 
from male Hispanic 21 y old) in a 37 °C water bath. The next steps were 
identical to the steps followed in the isolation of hMSCs by adherence 
discussed above. 
 
3.2.2.2.2. Isolation of STRO1
+ve
 hMSCs by MACS 
The isolation procedure follows the method described by Gronthos et 
al (Gronthos and Zannettino, 2008; Gronthos et al., 1999; Gronthos et al., 
2003). After incubation for 1 h in a humidified incubator at 37 °C with 5% 
CO2, the BMMNCs were resuspended in 0.5 ml of blocking buffer (HHF 
supplemented with 5% (v/v) normal human serum) and further incubated on 
ice for 30 min to reduce the possibility of Fc receptor-mediated-binding of 
antibodies. BMMNCs were pelleted by centrifugation at 400 g at 4 °C for 10 
min and resuspended in 500 μl of STRO-1 supernatant per 5 x 107 BMMNCs 
and incubated on ice for 60 min with occasional, gentle mixing. Then the 
BMMNCs were washed twice in HHF wash buffer and resuspended in 0.5 ml 
of HHF containing biotinylated goat anti-mouse I (μ-chain specific) at a 1/50 
dilution and incubated at 4 °C for 45 min. Next the BMMNCs were washed 
again three times in HHF and resuspended in 450 μl of MACS buffer (Ca2+ 
and Mg
2+
-free PBS supplemented with 1 % BSA in PBS, 5mM EDTA and 
0.01 % sodium azide) to which 50 μl of streptavidin microbeads were added 
(10 μl of microbeads/107 cells in 90 μl MACS buffer). The mixture was 
incubated on ice for 15 min. After one wash in ice-cold MACS buffer, a small 
aliquot of cells was removed for flow cytometric analysis (pre-sample). The 
remaining cells were then placed onto a mini MACS column (column capacity 




cells, Miltenyi Biotec, MS). The STRO-1
−ve
 cells (negative fraction) are 
not retained within the column and passed through into a fresh 2 ml 
polypropylene tube, under gravity into the effluent, while the STRO-1
+ve
 cells 
remained attached to the magnetised matrix. The column was washed 3 times 
with 0.5 ml MACS buffer to remove any nonspecifically-bound STRO-1
−ve
 
cells, which were collected in a fresh 2 ml polypropylene tube. The STRO-1
+ve
 
cells (positive fraction) were recovered by flushing the column with MACS 
buffer into a fresh 2-mL polypropylene tube after withdrawing the column 
from the magnetic field. The STRO-1
+ve
 cells were then counted and 
processed for two-color FACS. Small samples (0.5–1.0 x 105 cells) from each 




 fractions were removed into 
separate 2 ml polypropylene tubes containing 0.2 ml of streptavidin-FITC 
conjugate (1/50 in dilution). The cell samples were then incubated for an 
additional 5 min on ice to enable assessment of the enrichment procedure. A 
sample of (1.0 x10
5 
cells) unlabeled pre-MACS cells served as a negative 
control. These samples were washed twice in HHF, fixed in FACS Fix 
solution and subsequently analyzed by flow cytometry to assess purity and 
recovery. 
The partially purified STRO-1
+ve
 BMMNCs were passaged 2-4 times. 




 initially, in a medium 
containing α-MEM supplemented with 10 % FCS, 100 µM L-ascorbate-2-
phosphate, 50 units/ml penicillin and 50 µg/ml streptomycin and 2 mM L-
glutamine at 37 °C in 5% CO2. Cells were detached with 0.125 % 
trypsin/versene (pH 7.0) upon reaching 75–80 % confluence and re-plated at a 
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density of 3000 cells/cm
2 
in later passages. All cultures were maintained under 
humidified atmosphere at 37 °C with 5% CO2.  
 
3.2.2.3. Cryopreservation and thawing of hMSCs 
Cells were cryopreseved in FCS (Hyclone, Thermo Scientific) 
containing 10 % (v/v) dimethyl sulfoxide (DMSO, Sigma Aldrich). Cells were 
detached with 0.125 % trypsin/Versene (pH 7.0) upon reaching 75–80 % 
confluence and collected for cryopreservation. The cell pellet was resuspended 
at a concentration of 2 x10
6
 cells per ml in FCS and maintained on ice. An 
equal volume of freeze mix (20 % DMSO in cold FCS) was then added 
gradually while gently mixing the cells to give a final concentration of 1 x 10
6 
cells per ml in 10 % DMSO/FCS. One-milliliter aliquots were then distributed 
into 1.8 ml cryoampoules (Nalgene) pre-cooled on ice, then frozen at a rate of 
-1 °C per min using a “Mr. Frosty” cryopreservation container (Nalgene) and 
placed in a -80 °C freezer overnight. The frozen vials were then transferred to 
liquid nitrogen for long-term storage at -196 °C.  
Recovery of the frozen stocks was achieved by rapid thawing the cells 
in a 37 °C water bath. Once thawed, the cells were resuspended in pre-warmed 
hMSC culture media in a 15 ml Falcon tube. This preparation was centrifuged 
at 300 g for 5 min to remove DMSO/FCS. The cell pellet was resuspended in 
appropriate culture media and plated for expansion.  
 
3.2.3. Characterization of hMSCs 
hMSCs possess substantial therapeutic potential and have been 
intensively studied. Dominici et al. have remarked about the major issues in 
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comparing and contrasting study outcomes, as different researchers use 
different methods of isolation and expansion, and different approaches in 
characterizing the cells. They went on to highlight that the Mesenchymal and 
Tissue Stem Cell Committee of the International Society for Cellular Therapy 
have proposed a minimal criteria to define hMSCs (Dominici et al., 2006). 
Firstly, MSCs must be plastic-adherent when maintained in standard culture 
conditions; must be positive for certain surface markers while negative for 
certain surface markers; and retain the capacity to differentiate into 
osteoblasts, adipocytes and chondroblasts in vitro. Thus the first task was to 
determine whether the plastic adherent and STRO-1
+ve
 hMSCs met these 
minimal criteria.  
 
3.2.3.1. Colony-forming units-fibroblastic (CFU-F) Assay 
Plastic adherence is a well-described property of hMSCs; if cells are 
maintained and expanded in normal culture conditions they should adhere to 
the plastic surface and form mesenchymal stem cell colonies when plated at 
low densities (Friedenstein et al., 1976; Pochampally, 2008). Hence the next 
step was to perform CFU-F assays to determine the  CFU-F capacities of 
isolated and expanded hMSCs were consistent with the laboratory’s 
previously published work (Rider et al., 2008). The hMSCs were seeded at a 
seeding density of 150 cells per 100 x 15 mm Petri dish (Nunc) in triplicates in 
10 ml of culture basal media. The cells were cultured for 14 days in standard 
culture conditions as described earlier with a medium change at day 7. At day 
14, cultures were terminated and stained with crystal violet (Sigma-Aldrich) to 
visualize the colonies. The media was removed and the cells carefully washed 
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twice with PBS. Then each 10 ml/dish received 0.5% crystal violet in 100 % 
methanol and was incubated for 30 min at room temperature. Excess stain was 
washed once each with PBS and, and the plates were dried. The colonies were 
counted when they were greater than 50 cells in size and not in contact with 
another colony. The CFU-F efficiency was calculated as a percentage of 
colonies formed against the number of cells seeded.  
 
3.2.3.2. Flow cytometry analysis for surface markers 
Flow cytometric analysis of hMSCs (gated at 1% of the isotype 
control) was performed to determine whether they fulfill the minimal criteria 
to conform to the definition of multipotent MSCs (Dominici et al., 2006). It 
needed to be demonstrated that the hMSCs used in this study were positive for 
the surface markers CD73, CD90, CD105, and negative for CD14, CD19, 
CD34, CD45, HLA-DR, when compared to isotype-matched controls IgG1, 
IgG1 and IgG2b. All the antibodies for flow cytometry were conjugated 
with either PE or FITC (BD Biosciences, USA) and details of the antibodies 
and their corresponding isotypes are provided in the Appendix B. 
The hMSCs were detached with 0.125 % trypsin/versene upon 
reaching 75–80 % confluence and then washed once with PBS before being 
used for flow cytometry. Cells (1x10
5
) were aliquoted into 600 µl Eppendorf 
tubes and blocked for 1 h on ice with 200 µl of blocking buffer (PBS, 5% 
FCS, 1% BSA and 10 % human serum). Cells were spun down for 2 min at 
4000 rpm and washed thrice with PBS. Next the cells were resuspended in 100 
µl of staining buffer (PBS, 2 % FCS, 0.02 % sodium azide) with pre-diluted 
respective antibodies and incubated for 1 h on ice. Again cells were pelleted 
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by centrifugation at 4000 rpm for 2 min and washed 3 times with PBS. Cells 
were resuspended in 150 µl of staining buffer and analyzed on a BD FACS 
Array
TM
 Bioanalyzer with FlowJo software (Tree Star, Inc.). 
 
3.2.3.3. Multi-lineage differentiation  
 
In order to verify the multipotentiality of hMSCs, the cells were treated 
to differentiate into either adipogenic, osteogenic, or chondrogenic lineages as 
previously described by Rider et al (Rider et al., 2008). The hMSCs were 
detached with 0.125 % trypsin/Versene upon reaching 75–80% confluence and 
then washed once in maintenance medium before being used for 
differentiation assays. 
 
3.2.3.3.1. Osteogenic differentiation 
For osteogenesis, hMSCs were seeded at 3,000 cells per cm
2
 in basal 
medium (Dulbecco's Modified Eagle's medium-low glucose (DMEM-LG 1000 
mg/l) supplemented with 10% FCS, 50 units/ml penicillin and 50 µg/ml 
streptomycin and 2 mM L-glutamine) in 6-well, 12-well and 24-well plates for 
24 h in a humidified atmosphere at 37 °C with 5% CO2.  The next day the 
medium was changed either to osteogenic medium (maintenance medium, 10 
nM dexamethasone, 25 µg/ml ascorbic acid, and 10 mM β-glycerophosphate) 
or fresh basal medium. Cells were then maintained for up to 28 days, with a 
medium change every 3 days.  After 28 days, the cells were stained with 
Alizarin Red S for calcium and with von Kossa staining method for calcium 
phosphate.  
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3.2.3.3.2. Alizarin Red Staining 
The media were removed from the cells and washed three times with 
PBS. Then the cells were fixed in 4 % paraformaldehyde (PFA) for 10 min in 
the fume hood, and carefully washed three times with double distilled water. 
Next the cells were incubated in 0.1 % solution of Alizarin Red S (Sigma-
Aldrich, USA) for 30 min with gentle shaking (100 rpm). The excess stain was 
rinsed with distilled water three times and the stained calcific depositions were 
scanned and analyzed.  
 
3.2.3.3.3. von Kossa staining 
The cells were carefully washed and fixed as described earlier for the 
Alizarin Red staining. Then the cells were incubated in 1 % silver nitrate 
solution for 45 min under ultra-violet illumination and then rinsed with ultra-
pure water three times. The plates were then treated with 5 % sodium 
thiosulphate for 2 min and washed twice with ultra-pure water.  Cells with 
brownish-black calcium phosphate depositions were scanned and analyzed.  
 
3.2.3.3.4. Adipogenic differentiation 
 
For adipogenesis, cells were seeded at 18,000 cells per cm
2
 in 
maintenance media (Dulbecco's Modified Eagle's medium-low glucose 
(DMEM-LG 1000 mg/l) supplemented with 10 % FCS, 50 units/ml penicillin 
and 50 µg/ml streptomycin and 2 mM L-glutamine) in 6-well, 12-well and 24-
well plates for 24 h in a humidified atmosphere at 37 °C with 5% CO2.  The 
cells were cultured till 100 % confluence (for 2 days) in a humidified 
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atmosphere at 37 °C with 5% CO2. The medium was removed, and cells were 
washed once in PBS before the addition of adipogenic maintenance medium 
(90 % Dulbecco's Modified Eagle's medium-high glucose (DMEM-HG 4500 
mg/l) supplemented with 10 % FCS, 50 units/ml penicillin and 50 µg/ml 
streptomycin and 2 mM L-glutamine) or adipogenic medium (adipogenic 
maintenance media with 10 µg/ml insulin, 115 µg/ml methyl-isobutylxanthine, 
1 µM dexamethasone, and 20 µM indomethacin).  Cells were then maintained 
for up to 28 days, with a medium change every 3 days. After 28 days, the cells 
were stained with Oil Red O (Sigma-Aldrich, USA) to visualize the lipid 
droplets.  
 
3.2.3.3.5. Oil Red O staining 
The media were removed from the cells and washed three times with 
PBS. Then the cell were fixed in 4 % paraformaldehyde (PFA) for 1 h, and 
carefully washed once with double distilled water. Then the cells were 
incubated with 0.36 % Oil Red O solution for 1 h. Next cells were washed 
twice with 60 % 2-propanol followed by 5 washes with water. The stained 
lipid droplets were scanned and analyzed.  
 
3.2.3.3.6. Chondrogenic differentiation 
 
For chondrogenesis, cells were counted and resuspended at 5x10
5
 cells 
per milliliter in chondrogenic medium (Cambrex chondrogenic single aliquots) 
with or without 10 ng/ml TGFβ3 (R&D Systems), and then 500 µl aliquots 
were put into 15 ml Falcon tubes. The cells were pelleted with centrifugation 
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at 150 g at room temperature for 10 min and incubated for 2 days in a Falcon 
tube (loosened cap) in a humidified atmosphere at 37 °C with 5% CO2. After 2 
days, the pellets attained loose round shapes and the pellets were cultured for 
28 days with a medium change every 3 days. After 28 days, the cells were 
stained with Alcian blue (Sigma-Aldrich, USA) to visualize 
glycosaminoglycans.  
 
3.2.3.3.7. Alcian blue staining 
The chondrogenic pellet sectioning and Alcian blue staining was 
carried out at the Histopathology Facility of Institute of Cell and Molecular 
Biology, A*STAR, Singapore. Media were aspirated and the pellets washed 
with PBS twice. They were then fixed in 4 % paraformaldehyde (PFA) 
overnight in 4 °C with slow shaking. The pellets were embedded in paraffin 
using plastic cassette systems and sectioned into 5 µm thick sections, using a 
standard bench-top rotary microtome. The paraffin sections were first 
deparaffinised by washing in the following order; 3 min washes in xylene for 
3 times, 2 min washes in 100 % ethanol 3 times, 2 min in 95 % ethanol once, 2 
min in 80 % ethanol once, 2 min in 70 % ethanol once and 5 min in deionised 
water once. Next the sections were incubated with 1 % Alcian blue solution 
(pH 1.0) for 30 min at room temperature. Then the sections were washed with 
0.1 M HCl for 3 min to remove excess stain. Lastly the sections were 
dehydrated by washing with solutions used to deparaffinise but in reverse 
order; 5 min in deionised water once, 2 min in 70 % ethanol once, 2 min in 80 
% ethanol once, 2 min in 95 % ethanol once, 2 min washes in 100 % ethanol 3 
times and 3 min washes in Xylene 3 times. Then the slides were mounted in 
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Neomount. Micrographs of the chondrogenic pellet sections were taken and 
analyzed. 
 
3.2.4. Cell Proliferation Assays (Short-term growth) 
Next the effect of HS variants on hMSC proliferation when used as a 
“stand-alone” media supplement were investigated. The hMSC proliferation 
assays were conducted by two means, namely BrdU incorporation assay and 
the GUAVA Viacount
®
 assay.  The BrdU incorporation assay is a 
colourimetric immunoassay based on the measurement of BrdU incorporation 
during the DNA synthesis, a non-radioactive alternative to the 
3
H-thymidine 
incorporation assay. The GUAVA Viacount
®
 assay uses a mixture of two 
DNA binding dyes to provide sensitive, accurate detection of viable, 
apoptotic, and dead cells. 
 
3.2.4.1. BrdU incorporation proliferation assay  
 
A BrdU incorporation proliferation assay (Cell Proliferation ELISA, 
BrdU (Colorimetric) Roche) was conducted to establish the effect of HS 
variants on hMSC proliferation. BrdU is incorporated in place of thymidine 
into the DNA of proliferating cells and followed with an ELISA assay which 
detects the subsequent substrate colour development that directly correlates to 
the amount of DNA synthesis and thereby to the number of proliferating cells 
in the respective microcultures. Here the dose-responses of hMSCs to HS 
variants were monitored by BrdU incorporation over 36 h according to 
manufacturer’s specifications. The cells were seeded at a density of 5000 cells 
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per well in 96 well plate (Nunc) with 190 µl of culture media per well. The 
cells were incubated in a humidified atmosphere of 37 °C and 5 % CO2 for 6 
h. Afterwards, different doses (0.3125, 0.625, 1.25, 2.5, 5, 10 of FGF-2 
(ng/ml) and GAGs (µg/ml) of treatments in 10 µl of media were added to 
designated wells as in the experimental layout. Then the cells were further 
incubated for another 36 h in the usual humidified environment. Each well 
was added with 20 µl of 100 µM BrdU labeling solution (5-bromo-2-
deoxyuridine) to achieve final concentration of 10 µM BrdU and incubated for 
another 2 h. The labeling medium was removed by tapping off the plate on 
clean C-fold towels and the cells were fixed for 30 min at 15-25 °C by adding 
200 µl of FixDenat fixative solution to each well. The FixDenat solution was 
removed thoroughly by flicking and tapping. Then 100 µl of anti-BrdU-POD 
working solution (monoclonal antibody from mouse-mouse hybrid cells (clone 
BMG 6H8) conjugated with peroxidase) was added per well and incubated for 
90 min at 15-25 °C. The antibody conjugate was removed by flicking and the 
wells were rinsed thrice with 250 µl of washing solution (1x PBS) per well. 
Following the last wash and removal of the washing solution by tapping, 100 
µl TMB substrate solution (tetrmethyl-benzide) was added to each well and 
incubated for 30 min at 15-25 °C. Finally the optical density was determined 
within 30 min, using a Bechmark Plus Spectophometer (Bio-Rad) set to 370 
nm with a wavelength correction made by subtracting the readings at 492 nm. 
All samples were measured in triplicate. The fold increase in proliferation of 
hMSCs in relation to different treatments was calculated against the controls.  
In addition, this assay was used to determine the dose-responses of 
hMSCs to HS8
+ve






. The HS8 
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variants were used at 0.3125, 0.625, 1.25, 2.5, 5, 10 µg/ml and the assay 




 assay  
 





) was performed to monitor dose-
responses of hMSCs to HS variants over 6 days according to manufacturer’s 
specifications. The Viacount flex reagent (Millipore) uses two DNA binding 
dyes. One membrane-permeant dye stains all nucleated cells while another 
membrane-impermeant dye stains only damaged cells thus indicating 
apoptotic and dying cells. These stained cells were then detected within a 
microcapillary flow cytometry platform.  
The cells were seeded at a density of 3000 cells/cm
2 
in 24 well plates 
(Nunc) with 500 µl of culture media. The cells were incubated in humidified 
atmosphere of 37 °C and 5 % CO2 for 16 h overnight allowing cells to be 
attached to the plate. Next day, different doses (0.156, 0.3125, 0.625, 1.25, 
2.5, 5, 10 (ng/ml) of FGF-2 and GAGs (µg/ml) as treatments in 500 µl of fresh 
media were added to designated wells as in the experimental layout. Then the 
cells were further incubated for another 6 days in the usual humidified 
environment. The media was changed either every 2 days or every 3 days. 
Cells were harvested at designated time points (day 2, day 4 and day 6) with 
100 µl of 0.125 % trypsin/Versene (pH 7.0±0.3) and neutralized with 100 µl 
of media (day 2) or 300 µl of media (day 4 and 6). The Viacount flex reagent 
was added to the cell suspension (1 µl for 200 µl of media) and incubated for 
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10 min. Finally these stained cells were detected by the microcapillary flow 
cytometry platform of the EasyCyte™ Plus System and analyzed by 
EasyCyte™ Plus System (Millipore). All samples were measured in triplicate. 
The fold increase in proliferation of hMSCs in relation to different treatments 
was calculated against the controls.  
In addition, this assay was used to determine the dose-responses of 
hMSCs to HS8 variants namely HS8G, HS8C and HS8B. The HS8 variants 
were dosed at 2.5 µg/ml and the assay was conducted as above.   
 
3.2.5. Heparin-Agarose bead competition assay  
 
Heparin-Sepharose bead competition assays were performed to further 







) for FGF-2 according to Ono et al (Ono et al., 1999). In 
addition, the comparative ability of each HS variant to compete with highly 
sulfated heparin was also investigated.   The reasoning was that an HS variant 
with strong affinity for FGF-2 should compete against the affinity of FGF-2 
for heparin. The assay was done at room temperature. First a “master mix” of 
bead slurry was prepared to reduce error. Equal amounts of (20 µl) of heparin-
Agarose beads Type 1 (Sigma Aldrich) and polyacrylamide gel (Biogel P-30, 
Biorad) were mixed and used for each reaction. The total volumes required for 
all the reactions were calculated and brought together to form the “master 
mix” where the height of the suspension was marked for later resuspension. 
The bead suspension was washed 3 times with 1 ml of 1 % BSA (Sigma 
Aldrich) in PBS. Between the washes the beads were spun down at 2000 rpm 
for 1 min initially and later allowed to settle to the bottom of the tube for 1 
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min. After the last wash, beads were left to settle and resuspended back to the 
original height using the initial marked height. From the master mix, aliquots 
(40 µl) of bead slurry were separated into individual 1.5 ml Eppendorf tubes 
for binding experiments. 
 
Protein optimization was first carried out with the intension of 
optimizing the amount of FGF-2 needed to achieve sub-optimal binding to 
beads. Varying concentrations of FGF-2 (0, 5, 10, 20, 40, 80 ng/ml) in 100 µl 
volume were added in triplicates to the 40 µl of beads and incubated for 30 
min under constant rotation. The beads were spun down at 2000 rpm for 1 
min, allowed to settle for 1min, and washed twice each, with 1 ml of 1 % BSA 
(Sigma Aldrich) in PBS and with 1 ml of 0.02 % Tween20 (Sigma Aldrich) in 
PBS. Excess wash buffer was removed from the last wash. To each tube, 100 
µl of biotinylated anti-FGF-2 (R&D Systems) prepared in 1 % BSA in PBS 
(using the FGF-2 conjugate – Part no: 890657 from the FGF-2 Quantikine 
ELISA kit – R&D Systems Catalog #: DFB50, 1-in-10 dilution) was added 
and incubated at room temperature for 1 h with constant rotation. The beads 
were washed again as previously described and 100 µl of TMB substrate 
(R&D Systems) (using the TMB substrate – Parts #: 895000 and 895001 from 
the FGF-2 Quantikine ELISA kit - R&D Systems Catalog #: DFB50, 1-in-10 
dilution) was added and the mixture incubated for 30 min at room temperature 
under constant rotation to develop the colour. The reaction was stopped at 30 
min by adding 50 µl of 2 M H2SO4.  Beads were centrifuged at 2000 rpm for 1 
min and allowed to settle to the bottom of the tube for 1 min. Subsequently 
100 µl of the supernatant was removed and added into 96-well plates (Nunc) 
to be read at 450 nm. 
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Results were plotted and sub-optimal concentrations of FGF-2 (10 
ng/ml) used for the subsequent competition assay. The competition was 
carried out with the objective of investigating the binding affinities of the 
GAGs to FGF-2, as well as how much they can compete with heparin in 
binding to FGF-2. Different concentrations (0, 5, 50 and 100 μg) of GAGs 
were pre-incubated with FGF-2 (10 ng/ml) in 100 µl in triplicates for 30 min 
with constant rotation. Assays were continued after this step similar to the 
FGF-2 optimization, in being washed with 40 µl of bead slurry as previously 
prepared, was added to each reaction mixture and incubated for a further 30 
min under constant rotation. Results were expressed as “percentage bound” by 
normalizing to readings from control (uncompleted) beads. 
Immunoblotting was performed to confirm the results from the 
competition assay.  Here the competition was performed and the beads were 
washed as above. Then the beads were boiled at 95 °C for 5 min with 30 μl of 
2x Laemmli buffer (Sigma Aldrich). Next the beads were centrifuged at 2000 
rpm for 1 min and 20 μl of the supernatant was loaded into each lane of Novex 
4-12 % Bis-Tris SDS PAGE gels, 15 well (Invitrogen, Catalog # 
NP0323BOX). The gel was run at 150 V for 1 h in 1x MOPS buffer and 
transferred to nitrocellulose membranes and run at 100 V for 90 min in 1x 
transfer buffer. Next the nitrocellulose membranes were stained with Ponceau 
S solution (Sigma Aldrich) and cut into strips according to the size of the 
protein of interest. Membrane was blocked in 5 % BSA (Sigma Aldrich) in 
TBST for 1 h at room temperature with slow shaking (100 rpm). The 
membrane was then probed with the human FGF basic biotinylated primary 
antibody (R & D Systems, Catalog #: BAF 233) (1:2000) in 5 % BSA at room 
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temperature for 1 h. Afterwards, membranes were washed with TBST 3 times 
for 5 min each. Then, the membrane was probed with 1- drop streptavidin 
peroxidase (Invitrogen, Catalog no: 50-242Z) in 1 ml of PBS and incubated 
for 15 min at room temperature with slow shaking (100 rpm). Membranes 
were finally washed 3 times with TBST for 5 min each and exposed to 
LumiGLO ReserveTM chemiluminescent substrate (Kirkegaard & Perry 
Laboratories) to visualize the bands on X-ray films. 
 
3.2.6. Capillary electrophoresis –disaccharide analysis  





, capillary electrophoresis (CE) was performed. CE 
is a sensitive technique to determine the composition of HS by separating the 
samples based on charge and molecular weight (Lamari et al., 2001). The 
disaccharide analysis was performed with the assistance of GlycoSyn, IRL, 
(now The Ferrier Institute, Victoria University of Wellington, New Zealand).  
Twelve disaccharide standards, derived from the digestion of high-
grade porcine heparin by bacterial heparinases and a synthetic derivative of a 
non-naturally occurring disulfated disaccharide (ΔUA,2S-GlcNCOEt,6S) (as 
an internal standard) were used in this assay (Iduron Ltd, Manchester, UK). 
Capillary electrophoresis (CE) analysis was completed on an Agilent3D CE 
(Agilent Technologies, Waldbronn, Germany) instrument using uncoated 
fused silica capillary tubes (75 mm ID, 64.5 cm total and 56 cm effective 
length, Polymicro Technologies, Phoenix, AZ, Part # TSP075375). Heparin 
lyase I (Heparitinase, EC 4.2.2.8, also known as heparitinase I), heparin lyase 
II (heparitinase II, no EC number assigned) and heparin lyase III (heparinase, 
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EC 4.2.2.7, also known as heparitinase III) and keratin sulfate (KS) were 
obtained from Seikagaku Corporation, Japan. The enzymes, supplied as 
lyophilized powders (0.1 U/vial), were dissolved in 0.1 % BSA to five 
solutions containing 0.5 mU/µl. Aliquots (5 µl; 2.5mU) were frozen (-80 °C) 
until needed. 
 
3.2.6.1. Digestion of HS preparations with heparan lyase enzymes 
HS preparations (1 mg) were each dissolved in 500 ml of sodium 
acetate buffer (100 mM containing 10 mM calcium acetate, pH 7.0) and 2.5 
mU each of the 3 enzymes added. The samples were incubated at 37 °C 
overnight (24 h) with gentle inversion (9 rpm) of the tubes. A further 2.5 mU 
each of the 3 enzymes was added to the samples which were incubated at 37 
°C for a further 48 h with gentle inversion (9 rpm) of the tubes. Digests were 
halted by heating (100 °C, 5 min) and then lyophilized. The digests were 
resuspended in 500 µl water and an aliquot (50 µl) taken for analysis by CE. 
 
3.2.6.2. Capillary electrophoresis (CE)  
The capillary electrophoresis operating buffer was made by adding an 
aqueous solution of 20 mM H3PO4 to a solution of 20 mM Na2HPO4.12H2O to 
give pH 3.5. The column wash was 100 mM NaOH (diluted from 50 % w/w 
NaOH). The operating buffer and the column wash were both filtered using a 
Millipore filter unit fitted with 0.2 µm cellulose acetate membrane filters 
(47mm ø; Schleicher and Schuell, Dassel, Germany).  
Stock solutions of the 12 disaccharide standards were prepared by 
dissolving the disaccharides in water (1 mg/ml). To determine the calibration 
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curves for the standards, a mix containing all twelve standards was prepared. 
The stock solution of the 12 standard mix contained 10 µg/100µl of each 
disaccharide and a dilution series containing 10, 5, 2.5, 1.25, 0.625, 0.3125 
µg/100 µl was prepared; including 2.5 µg of internal standard (ΔUA,2S-
GlcNCOEt,6S). The digests of HS were diluted (50 (ΔUA,2S-
GlcNCOEt,6S)l/ml) with water and the same internal standard was added (2.5 
µg) to each sample. This internal standard was added because of its distinct 
migration time from the Δ-disaccharide standards and thus could be utilized 
for the determination of each disaccharide unit from its relative migrational 
shift. The solutions were freeze-dried and re-suspended in water (1 ml). The 
samples were filtered using PTFE hydrophilic disposable syringe filter units 
(0.2 µm; 13mm ø; Advantec, Toyo Roshi Kaisha, Ltd., Japan). 
The analysis was performed using an Agilent
3D
CE (Agilent 
Technologies, Waldbronn, Germany) instrument on an uncoated fused silica 
capillary tube (75 µm ID, 64.5 cm total and 56 cm effective length, Polymicro 
Technologies, Phoenix, AZ, Part Number TSP075375) at 25
0
C using 20 mM 
operating buffer with a capillary voltage of 30 kV. The samples were 
introduced to the capillary tube using hydrodynamic injection (50 mbar x 12 
sec) at the cathodic (reverse polarity) end to generate the electropherogram. 
Before each run, the capillary was flushed with 100 mM NaOH (2 min), with 
water (2 min) and pre-conditioned with operating buffer (5 min). A buffer 
replenishment system replaced the buffer in the inlet and outlet tubes to ensure 
consistent volumes, pH and ionic strength were maintained. Water only blanks 
were run at the beginning, middle and end of the sample sequence. 
Absorbance was monitored at 232 nm. All data was stored in a Chemstore 
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database and was subsequently retrieved and re-processed using ChamStation 
software. The area-under the-peak was then measured and compared to a 
standard curve to derive the concentrations. Molar percentages of each sample 
were then calculated from the molecular weight of each standard. 
 
3.2.7. Anti-coagulation assay 






) were assessed for 
their effect on antithrombin III activity. If any fragment should show such 
activity, it would be useless as a prospective therapy. The assay was 
performed using the COATEST Heparin kit (Chromogenix) according to 
Bramono et al. where the absorbance values were represented as the relative 
inhibition of excess Factor Xa activity when compared to the treatment group 
containing no GAG (Bramono et al., 2012). 
All assay reagents were downscaled for 96-well plates based on the 
recommended protocol from COATEST Heparin kit (Chromogenix, Catalog 
#: 25553963).  HS variants were diluted in kit buffer added with human 
plasma and antithrombin to produce 0.3125, 0.625, 1.25 and 2.5 μg/ml of 
GAG solution through serial dilution. The wells were added with 50 μl of 
sample or positive control and incubated for 3 min at 37 °C. Then 25 μl of 
Factor Xa was added, mixed and incubated for 30 sec at 37 °C. The wells were 
supplemented with 50 μl of chromogenic substrate S-2222, mixed and 
incubated for exactly 3 min at 37 °C. Next 75 μl of 20 % acetic acid was 
added and mixed. The wells containing 50 μl of prepared blank were added 
with 75 μl of 20 % acetic acid and 75 μl of water. Colourimetric absorbance 
was read at 405 nm with a Victor multiplate reader (Perkin Elmer, 
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Massachusetts, USA). The blank readings were subtracted from the samples 
and positive control and sample readings were normalized to the positive 
control. 
 
3.2.8. FGF-2 stability assay – Quantikine 
It was next necessary to test whether HS8
+ve
 could stabilize FGF-2. 
FGF-2 is known to be highly unstable, with its integrity dependent on the 
solvent used to dissolve it. In addition, Caldwell et al (Caldwell et al., 2004) 
have shown that heparin is known to stabilize FGF-2 from degradation in 
culture media by quantikine assay for FGF-2 from R&D systems. To 






) stabilization of 
FGF-2, solid phase sandwich ELISA was performed similar to Caldwell et al 
(Caldwell et al., 2004).  
FGF-2 at 2.5 ng/ml was incubated alone or in the presence of 2.5 






) with 1 ml of hMSC 
culture media (DMEM with 10mg/l glucose, 10 % FCS, 1 % Pen/Strep, 2 mM 
L-glutamine) in 1.5 ml Eppendorf tubes in triplicates in a humidified incubator 
at 37 °C with 5 % CO2. The media (150 µl) was collected at indicated time 
points (0 h, 24 h, 48 h and 72 h) and stored at -80 °C. Samples were analyzed 
avoiding repeated freeze-thaw cycles. 
The FGF-2 standard was reconstituted as recommended with calibrator 
diluent RD5-14 to produce a stock solution of 640 pg/ml. After the standard 
was mixed with gentle agitation for 15 min 0, 10, 20, 40, 80, 160, 320, 640 
pg/ml standard solutions were made through serial dilution. All reagents and 
working standards were brought to room temperature and all standards, 
 Confidential  107 
 
samples and controls were assayed in duplicates. Firstly, each well of the 
microplate strips was added with 100 μl of assay diluent RD1-43. Afterwards, 
100 μl of standard, control, or sample was added per well and the microplate 
covered with the adhesive strip and incubated for 2 h at room temperature. 
Each well was aspirated and washed, repeating the process three times for a 
total of four washes using 400 μl of wash buffer (dilute 20 ml of wash buffer 
concentrate in 500 ml of deionized or distilled water) per well. After the last 
wash the microplate was inverted and blot dried against clean paper towels to 
remove liquids completely. Then 200 μl of FGF-2 conjugate was added to 
each well, covered with the adhesive strip and incubated for 2 h at room 
temperature. Wells were aspirated and washed as earlier. Then 200 μl of 
substrate solution (colour reagents A and B mixed in equal volumes) was 
added to each well and incubated for 30 min at room temperature while 
protecting from light. Next 50 μl of stop solution was added to each well while 
observing any colour change from blue to yellow. Finally the optical density 
was determined within 30 min, using a Bechmark Plus Spectophometer (Bio-
Rad) set to 450 nm with a wavelength correction made by subtracting the 
readings at 540 nm.  Optical density readings of the standards were used to 
plot the standard curve. The best-fit line was determined by regression 
analysis and the equation yielded used to determine the FGF-2 concentrations 
of the samples.  
 
3.2.9. Differential Scanning Fluorimetry (DSF)  
Differential Scanning Fluorimetry (DSF) assays were performed to 
further investigate the thermal stability of FGF-2 by HS variants (Heparin, 








) according to Uniewicz et al (Uniewicz et al., 2010). 
As described previously by Niesen et al (Niesen et al., 2007), this experiment 
employs a ABI PRISM
®
 7500 PCR machine (Applied Biosystems) and a 
Sypro Orange dye (Invitrogen). This dye binds and detects the exposed core 
residues of denatured proteins when the samples are subjected to a heating 
cycle (Uniewicz et al., 2010). 
 Heparin and HS variants (20 % v/v), FGF-2 stock solutions (R & D 
Systems) (40 % v/v), and Dulbecco’s phosphate-buffered saline without 
CaCl2/MgCl2 (Gibco) (30 % v/v) were added to a Fast Optical 96 Well 
Reaction Plate (Applied Biosystems) maintained on ice. Freshly prepared 
water-based dilutions of Sypro Orange 5000 (Invitrogen) were added as 10 % 
v/v. Each sample was assayed in triplicate. The final volume of the reaction 
mixture was 10 μl. After sealing with an Optical Adhesive Film (Applied 
Biosystems), the plate was gently vortexed for 300 rpm for 1 min and directly 
analyzed in the real-time polymerase chain reaction (RT-PCR) instrument. 
The heating cycle comprised a 120 sec prewarming step at 31 °C and a 
subsequent gradient between 32 and 81 °C in 99 steps of 20 sec, each of 0.5 
°C ramp. Data were collected using the calibration setting for TAMRA dye 
detection (λex 560 nm; λem 582 nm) installed on the instrument.  
Initially the experiment was performed only with FGF-2 without the 
heparin and HS variants. This was done in order to find out the optimum 
protein concentration for later experiments.  FGF-2 at the concentrations of 
2.5, 5, 7.5 and 10 μM were used. Next, a gradient of heparin (Sigma) 
concentrations (2.5, 5, 10 and 20 μM) were used with the optimum FGF-2 (10 
μM) in order to calculate the optimum heparin versus FGF-2 concentration. 
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Heparin and HS variants are comprised of pools of different oligosaccharides 
and therefore the molarity is difficult to define. Hence the concentration range 
expressed in μg/ml was selected to compare their stabilization effects. Thus, 
the effective concentration of heparin was chosen (for instance, 160 μg/ml 
corresponding to ~10 μM), and all other HS variants were used at the same 
w/v ratio (160 μg/ml).  
The data were analyzed using the Origin Pro 8 software by application 
of an exponential correlation function approximation of the first derivative for 
each melting curve as described earlier (Uniewicz et al., 2010). The average of 
triplicate samples was used to calculate distinct melting curves and the highest 
values were used to calculate the mean Tm (melting temperature). After the 
Tm values were measured the data were normalized to compare between the 
stabilization effects of FGF-2 by HS variants relative to heparin. Firstly, the 
difference between the Tm of the FGF-2 in PBS (Tm
FGF-2
) and the Tm of the 
FGF-2 in the presence of the HS variants (Tm
HS
) were calculated as below. 
   
Next, the difference between Tm
FGF-2
 and Tm of the FGF-2 in the presence of 
the heparin (Tm
Heparin
) were calculated using the formula given below.  
    
The relative stabilization potency, was calculated using 
   
      
Two independent experiments in triplicate were analyzed and the final Tm is 
the mean of all obtained values.  
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3.2.10. Synergistic effect of HS8 variants on FGF-2  
Heparan sulfate regulates FGF signaling by direct molecular 
association with FGFRs (Pellegrini, 2001). Therefore the higher binding 
affinity HS8
+ve
 should greatly potentiate the FGF signaling by assembling the 
trimeric signaling structure on cell surface. Any synergistic effect of HS8
+ve
 on 
FGF-2 and how it effects hMSC proliferation should be readily detectable.  
  
3.2.10.1. Proliferation assay – GUAVA viacount®  
This assay was performed as described earlier. The cells were seeded 
at a density of 3000 cells/cm
2 
in 24 well plates (Nunc) with 500 µl of culture 
media (DMEM-LG 1000 mg/l supplemented with 10 % FCS, 50 units/ml 
penicillin and 50 µg/ml streptomycin and 2 mM L-glutamine). The cells were 
incubated in humidified atmosphere of 37 °C and 5% CO2 for 16 h overnight 
allowing the cells to be attached to the plate. Next day, FGF-2 (0.156 ng/ml 
and 2.5 ng/ml) alone or FGF-2 (0.156 ng/ml) with various concentrations of 
HS variants (0.156, 0.3125, 0.625, 1.25, 2.5, 5, 10 µg/ml) in 500 µl of fresh 
media were added to designated wells as in the experimental layout. Then the 
cells were further incubated for another 4 days in the usual humidified 
environment with a fresh media changed after 2 days. Cells were harvested 
with 100 µl of 0.125% trypsin/Versene (pH 7.0±0.3) and neutralized with 300 
µl of media. The Viacount flex reagent (Millipore) was added to the cell 
suspension (1 µl for 200 µl of media) and incubated for 10 min at room 
temperature. Finally these stained cells were detected by the microcapillary 
flow cytometry platform of the EasyCyte™ Plus System and analyzed by 
EasyCyte™ Plus System (Millipore). All samples were measured in triplicate. 
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3.2.10.2. Cell signaling assays - immunoblotting 
Immunoblotting was performed to confirm the results of synergistic 
effect of HS8
+ve
 and FGF-2 on hMSC proliferation. The cells were seeded 
(10,000 cells/cm
2
) on 6-well plates (Nunc) with 2 ml/well of maintenance 
media (DMEM-LG 1000 mg/l supplemented with 10 % FCS, 50 units/ml 
penicillin and 50 µg/ml streptomycin and 2 mM L-glutamine). Cells were 
allowed to adhere to the plastic surface for 16 h in humidified atmosphere. The 
following day when the plate was 50 % confluent, maintenance media was 
removed and the cells were washed once with PBS. Then 2 ml of serum-free 
media (DMEM-LG 1000 mg/l supplemented with 0.2 % FCS, 50 units/ml 
penicillin and 50 µg/ml streptomycin and 2 mM L-glutamine) was added to 
each well and further incubated for 2 days. After 48 h of serum starvation the 
required amounts of GAGs (2.5 g/ml) and/or FGF-2 (0.156 ng/ml), dissolved 
appropriately in serum-free media, was added at 10 µl/well. The cells were 
harvested in 100 µl/well with 1.5 X laemmli buffer (Sigma Aldrich) at 
different time points (30 min, 6 h and 24 h). The cell lysates were heated for 5 
min at 95 °C and stored at -20 °C. Samples were freeze-thawed only once and 
20 µl/well of sample was loaded into each lane of Novex 4-12 % Bis-Tris SDS 
PAGE gel, 10 well (Invitrogen). The gel was run at 180 V for 50 min with 1x 
MOPS buffer. Then the resolved protein bands were transferred to 
nitrocellulose membrane at 100 V for 90 min in 1x transfer buffer. Next the 
nitrocellulose membranes were stained with Ponceau S solution (Sigma 
Aldrich) and cut into strips according to the size of the protein of interest. The 
membranes were then blocked in either 5 % BSA (Sigma Aldrich) or 5 % non-
fat dry milk (Anlene) in TBST for 30 min to 1h at room temperature with slow 
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shaking (100 rpm). Primary antibodies of recommended dilutions (phospho-
FRS2a (Cell Signaling, 1:1000 in 5% BSA), phospho-ERK1/2 (Cell Signaling, 
1:2000 in 5% BSA), total ERK1/2 (Cell Signaling, 1:1000 in 5% BSA) and 
actin (Millipore, 1:8000 in 5% milk)) were then incubated overnight at 4 °C 
with slow shaking (100 rpm). The blots were then washed three times with 
TBST for 5 min each. Secondary antibodies of recommended dilutions (goat 
anti mouse (Jackson ImmunoResearch, 1:10000) and goat anti rabbit (Jackson 
ImmunoResearch, 1:10000) either in 5% milk or 5% BSA) were then 
incubated for 1 to 2 h at room temperature with slow shaking (100 rpm). 
Membranes were finally washed 3 times with TBST for 5 min each and 
exposed to LumiGLO ReserveTM chemiluminescent substrate (Kirkegaard & 
Perry Laboratories) to visualize the bands on X-ray films. In case of reblotting, 
the membranes were stripped by incubating with Restore western blot 
stripping buffer (thermo Scientific) at room temperature for 10 min. Blots 
were then washed 3 times with TBST for 5 min each. Thereafter, membranes 
were re-blocked and immunolabeled as desired. 
 
3.2.11. HS8 can mediate the action of FGF-2  
 
The final part of this chapter is dedicated to determining how HS8
+ve
 
might be mediating the action of FGF-2. Heparan sulfate is a coreceptor for 
the FGF/FGFR complex and FGFR1 is a high affinity receptor for FGF-2 
binding (Chellaiah et al., 1999; Dombrowski et al., 2009; Pellegrini, 2001).  
FGF-2 inhibition via a neutralizing antibody (R & D Systems), was employed, 
as well as FGF receptor inhibitors, either the neutralizing antibody IMBR1 
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(Ling et al., 2006) or the chemical inhibitor SU5402 (Calbiochem, Millipore) 
respectively, in the following studies.  
The three assays, FGF-2 neutralization, SU5402 and IMBR1, utilized 





Briefly, in the BrdU incorporation proliferation assay, 5000 cells/well 
were seeded into 96-well plates (Nunc) with 190 µl of culture media and 
incubated for 6 h. Different treatments were added to the existing media with 
10 µl of media and further incubated for another 36 h.  Then the substrate 
colour development that directly correlates to the amount of DNA synthesis 
yielded the number of proliferating cells in the respective microcultures.  




were seeded in 24-
well plates (Nunc) with 500 µl of culture media and incubated 16 h. Then 
different treatments were added in 500 µl of fresh media and further incubated 
for another 4 days with a fresh media changed after 2 days. Stained cells with 
viacount flex reagent (Millipore) were detected by the microcapillary flow 
cytometry platform of the EasyCyte™ Plus System and analyzed by 
EasyCyte™ Plus System (Millipore).  
 
3.2.11.1. FGF-2 neutralizing antibody assay  
FGF-2 neutralization (R & D Systems) was effected with affinity 
purified polyclonal goat IgGs. The basis of this assay relies on the antibody 
(Ab) neutralization of FGF-2 activity, thereby inhibiting hMSC proliferation 
induced by FGF-2 and HS8
+ve 
media supplements. In the proliferation assay 
cells were cultured with FGF-2 (2.5 ng/ml) and HS8
+ve
 2.5 µg/ml with or 
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without FGF-2 neutralizing Ab (2 µg/ml). Cells cultured with media alone or 
with FGF-2 neutralizing Ab (2 µg/ml) served as controls.  
 
3.2.11.2. SU5402 Assay  
SU5402 (Calbiochem, Millipore), a chemical inhibitor of FGF receptor 
activity was also used. In proliferation assays, cells were cultured with FGF-2 
(2.5 ng/ml) and HS8
+ve
 2.5 µg/ml with or without two doses of SU5402 (10 
and 25 µM) in DMSO. Cells cultured with media alone or with two doses of 
SU5402 (10 and 25 µM) in DMSO served as controls.  
 
3.2.11.3. IMBR1 Assay  
In this assay I used IMBR1, an affinity purified polyclonal rabbit IgG 





Ig loop of FGFR (Ling et al., 2006). This strategy relies on inhibition 
of FGF-2 signaling by inhibit FGFR1 signaling using IMBR1. Hence IMBR1 
inhibition of hMSC proliferation usually induced by FGF-2 and HS8
+ve 
media 
supplements was monitored in this assay. In the proliferation assay, cells were 
cultured with FGF-2 (2.5 ng/ml) and HS8
+ve
 2.5 µg/ml with or without two 
doses of IMBR1 (1:2000 and 1:1000). Cells cultured with media alone or with 
two doses of IMBR1 (1:2000 and 1:1000) served as controls.  
 
3.2.12. Statistical analysis 
All data values are reported as the mean ± standard deviation (SD) 
taken from triplicate experiments. Where appropriate, mean differences 
between samples were analyzed using SPSS statistics software (IBM, USA) 
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by performing an exploratory data analysis and homogeneity of variance test, 
followed by ANOVA and Tukey's or Games–Howell posthoc testing. 
Statistical significance was defined as >0.05. Graphs were plotted and data 
transformed using Sigma plot software (Systat software Inc, USA) and Adobe 
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3.3. Results  
3.3.1. GAG ELISA – HS8G variants and FGF-2 
In the previous chapter the isolation and purification of a novel FGF-2-
binding HS from a commercially available porcine mucosal heparan sulfate 
source (Celsus Laboratories) suitable for scale up and which can be readily 
upgraded for use in the clinic was described. Custom-made peptide fragments 
were utilized and were successful in isolating three prospective HS8 variants. 
Here the HS variants’ binding ability for bioactive, full length FGF-2, 
employing a GAG-ELISA binding assay was first investigated. The GAG 
binding plates are manufactured by cold plasma polymerization where 
microtitre plate surfaces are coated with allyl amine (Mahoney et al., 2004; 
Marson et al., 2009). The GAGs thereby non-covalently immobilize to these 
allyl amines without hindering their ability to interact with proteins. The initial 







) required to completely saturate the GAG plate 
surface.  
Three concentrations of GAGs, namely 2.5, 5 and 10 μg/ml, were used 
to coat the wells and their FGF-2 binding ability investigated (Fig. 3.2). Even 
with the various heparin concentrations, similar FGF-2 binding was observed 
(Fig. 3.2A). For the HS
pm
 coatings, a dose-dependent increase in FGF-2 
binding was observed, albeit the increase in FGF-2 binding was less 
significant between 5 μg/ml and 10 μg/ml HSpm (Fig. 3.2B). Similar trends 




 variants (Fig. 3.2 C and D). 
As significant differences were not observed between the 5 and 10 μg/ml for 
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any of the GAGs, the 5 μg/ml concentration was adopted generally as it was 
sufficient to completely saturate the wells with sugar. 
 
 




Figure 3.2. Determination of saturating amounts of GAGs for the GAG ELISA. Different 
concentrations (2.5, 5, 10 µg/ml) of (A) heparin, (B) HSpm, (C) HS8G-ve and (D) HS8G+ve 
were coated onto the wells and FGF-2 binding ability were analyzed  with GAG binding 
plates (Iduron). The 5 µg/ml dose was selected for all HS species as no significant difference 
observed at either 5 or 10 μg/ml. Uncoated wells (No GAG) served as the negative control. 











 was next investigated for its relative specificity for FGF-2 as 




 (Fig. 3.3). Irrespective of GAG, there 
was a dose-dependent increase in FGF-2 binding as shown by the respective 
binding curves. HS8G
+ve
 variants had a significantly higher affinity for FGF-2, 
almost as good as the heparin positive control. In addition, HS8G
+ve
 binding to 
FGF-2 was significantly better than either the crude unfractionated HS
pm
 




 showed the weakest 
binding, as expected, while HS
pm
 showed only a moderate binding to FGF-2, 
again as predicted. 
 
 
Figure 3.3. Binding profile of various GAGs to FGF-2. Heparin, HSpm, HS8G+ve and HS8G-
ve were coated (5 µg/ml) onto the wells and their binding ability for different concentrations of 
FGF-2 (0, 0.781, 1.56 and 3.125 nM) analyzed on GAG binding plates (Iduron). HS8G+ve 
variants had a significantly higher affinity for FGF-2 almost as good as the heparin positive 
control, and significantly better than the raw starting material HSpm and the flow-through 
HS8G-ve. Significant difference is represented as * when compared to HS8G+ve at equivalent 
dose (p<0.05).  
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To understand more fully how selective the HS fractions were for 




binding, to other heparin-binding growth factors (HBGFs), namely BMP-2, 
FGF-1, FGF-7, PDGF-BB and VEGF (Fig. 3.4). The binding curves revealed 
that irrespective of GAG, there was a significant difference in the individual 
binding of BMP-2, FGF-1 and FGF-2 as compared to individual binding of 
FGF-7, PDGF BB and VEGF at all the doses tested. Considering the binding 
of each GAG to BMP-2, FGF-1 and FGF-2, the HS8G
-ve 
fraction had a 
decreasing order of binding of HS8G
-ve









, such that FGF-2 > BMP-2 > FGF-1. By taking into account the  




Figure 3.4. Binding profile of GAGs to heparin-binding growth factors (HBGFs). 
Comparative ability of immobilized (A) HSpm, (B) HS8G-ve and (C) HS8G+ve (5 µg/ml) 
binding to BMP-2, FGF1, FGF-2, FGF7, PDGF-BB and VEGF (0, 0.781, 1.56 and 3.125 nM) 
were analyzed with GAG binding plates (Iduron).  The HSpm preferentially binds to FGF-2 
(Fig. 3.4A) while HS8G-ve had a preference in binding to BMP2 over all of the other HBGFs 
(Fig. 3.4B). The HS8G+ve fraction preferentially binds to FGF-2 (Fig. 3.4C) similar to HSpm 
but with almost two-fold greater preference for FGF-2 over other HBGFs when compared to 
HSpm. Significant difference is designated as * when compared to FGF-2 binding at equivalent 
dose (p<0.05) and # when each of BMP-2, FGF-1 and FGF-2 was compared to each of FGF-7, 
PDGF BB and VEGF at all the doses tested (p<0.05). 
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difference in absorbance (405 nm) in binding between FGF-2 and BMP-2 at 
the lowest, but supraphysiological dose of 0.781 nM, HS8
+ve
 (1.64) had a ~ 
2.5-fold higher difference than HS
pm
 (0.66) and ~ 16-fold higher difference 
than HS8
-ve 
(0.09). Similarly, between FGF-2 and FGF-1, HS8
+ve
 (1.76) had a 
~ 2-fold higher difference than HS
pm
 (0.87) and ~ 5.5 fold higher difference 
than HS8
-ve 
(0.30). These data suggest that HS8
+ve
 is more selective for FGF-2 







variants’ binding affinity to FGF-2 as compared to 
HS
pm 
(Fig. 3.5). All HS8
+ve





) and HS8 Baird (HS8B
+ve
), dose-dependently had increases 
in their binding ability for FGF-2 without any significant difference. All of 
them individually had significantly higher binding for FGF-2 than crude HS
pm
. 
This assay further validates our affinity chromatography platform for the 
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Figure 3.5. Binding profile of various HS8
+ve 
variants to FGF-2. HS8+ve variants (HS8G+ve, 
HS8C+ve and HS8B+ve) and HSpm were coated (5 µg/ml) onto wells surfaces and their binding 
preferences for different concentrations of FGF-2 (0, 0.781, 1.56 and 3.125 nM) analyzed via 
GAG binding plates (Iduron). All HS8+ve variants had similar binding affinities for FGF-2, 
and all were significantly higher than HSpm. Significant difference is represented as * when 
compared to each HS8+ve variant at equivalent dose (p<0.05). 
  
3.3.2. Proliferation studies of hMSCs with HS variants 
3.3.2.1. Isolation and characterization of hMSCs 
 
The hMSCs that were used in the short-term proliferation studies were 
isolated from the Poietics
® 
bone marrow mononuclear cells of young healthy 
adult human donors. Isolation was done by two means: plastic adherence and 
magnetic-activated cell sorting (MACS) as described. After successful 
isolation, and prior to the proliferation studies, the hMSCs (at passage 3) were 
subjected to a series of tests in order to determine whether they conformed to 
the minimal criteria for mesenchymal stem cells according to the International 
Society for Cellular Therapy (Dominici et al., 2006).  
As hMSCs must demonstrate adherence, and form colonies when 
passaged under normal culture conditions, both hMSC types were first 
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subjected to CFU-F assay. It was confirmed that both hMSC types were 
capable of forming colonies after adhering to tissue culture plastic, as revealed 
by the crystal violet staining (Fig. 3.6 A and 3.7 A). The STRO-1
+
 hMSCs had 
a higher CFU-F efficiency rate (48.4±3.15) than that of the plastic adherent 
hMSCs (31.5±1.37). Furthermore, single-color flow cytometry analysis 
revealed that the hMSCs were positive for the MSC-related markers CD73, 
CD90, CD105 (> 99% positive) while negative for haematopoeitic markers (< 
2% positive) of CD14, CD19, CD34, CD45 and HLA-DR (Fig. 3.6 B and 3.7 
B). There weren’t any differences in either hMSCs cell types in relation to 
their positive and negative MSC-related markers. Thus it can be concluded 
that other cell types were not contaminating the hMSCs. Finally, hMSCs were 
directed to trilineage differentiation, and, after culturing in vitro for 28 days, 
the hMSCs readily differentiated into osteoblasts, adipocytes, and 
chondroblasts. This was confirmed by positive staining with Alizarin Red, von 
Kossa, Oil Red O, and Alcian blue respectively (Figures 3.6 C and 3.7 C). The 
STRO-1
+
 hMSCs displayed qualitatively slightly higher rates of osteogenesis 
compared to plastic adherent hMSCs, albeit adipogenesis and chondrogenesis 
rates were lacking any such differences. Collectively, the data confirmed both 
hMSC types met the criteria stated above and were suitable for the 
proliferation studies.   




Figure 3.6. Characterization of plastic adherent human mesenchymal stem cells. (A) 
Colonies of adherent cells formed when passaging hMSCs (P3) were seeded on to tissue 
culture plastic as depicted by crystal violet staining (B) Single-color flow cytometry as 
represented by phycoerythrin (PE) and Fluorescein isothiocyanate (FITC) histograms were 
performed on passage 3 hMSCs after examination for the expression of surface markers 
CD73, CD90, CD105, CD14, CD19, CD34, CD45 and HLA-DR. The hMSCs expressed the 
MSC-related markers CD73, CD90, CD105 at significantly high levels (> 99% positive) while 
lacking the expression of haematopoeitic markers (< 2% positive) of CD14, CD19, CD34, 
CD45 and HLA-DR indicating that the hMSCs are not confounded by other cells. Red lines 
represent isotype IgG controls gated at 1 % and blue lines represent surface markers under 
study. (C) Passage 3 hMSCs were subjected to osteogenic, adipogenic, or chondrogenic in 
vitro differentiation to for 28 days. Mineralization in osteogenic cultures stained positively 
with Alizarin Red (AR) and von Kossa (VK). The lipid droplets in adipogenic cultures and 
glycosaminoglycans in sections of the chondrocyte pellets were detected by Oil Red O (OR) 
and Alcian blue (AB) staining respectively.  





Figure 3.7. Characterization of STRO-1 isolated human mesenchymal stem cells. (A) 
Colonies of adherent cells formed when passaging hMSCs (P3) were seeded on to tissue 
culture plastic as depicted by crystal violet staining (B) Single-color flow cytometry as 
represented by phycoerythrin (PE) and Fluorescein isothiocyanate (FITC) histograms was 
performed on passage 3 hMSCs examining the expression of surface markers CD73, CD90, 
CD105, CD14, CD19, CD34, CD45 and HLA-DR. The hMSCs expressed the MSC-related 
markers CD73, CD90, CD105 at significantly high levels (> 99% positive) while lacking the 
expression of haematopoeitic markers (< 2% positive) of CD14, CD19, CD34, CD45 and 
HLA-DR indicating that the hMSCs are not confounded by other cells. Red lines represent 
isotype IgG controls gated at 1 % and blue lines represent surface markers under study. (C) 
Passage 3 hMSCs were subjected to osteogenic, adipogenic, or chondrogenic in vitro 
differentiation to for 28 days. Mineralization in osteogenic cultures stained positively with 
Alizarin Red (AR) and von Kossa (VK). The lipid droplets in adipogenic cultures and 
glycosaminoglycans in sections of the chondrocyte pellets were detected by Oil Red O (OR) 








 enhances hMSC proliferation; BrdU incorporation assay 
Having established that HS8
+ve
 variants generally have a higher 
affinity for FGF-2, next it was necessary to determine whether the HS variants 
have the ability to drive hMSC proliferation. For this, both preparations of 
hMSCs were again utilised. First a BrdU incorporation proliferation assay was 
employed, where BrdU incorporates in place of thymidine into the DNA of 
proliferating cells and is measured photometrically using TMB substrate.  
Passage 4-6 cells were seeded at a density of 5000/cm
2
 and cultured for 
36 h with different HS variants added to maintenance media as stand-alone 
media supplements. After 2 h exposure to BrdU, cell proliferation was 
measured photometrically. Irrespective of GAGs, for both preparations, hMSC 
proliferation showed an upward trend with low doses, peaked with 
intermediate doses and a slight reduction with higher doses of HS variants 
(Fig. 3.8). For almost all the doses proliferation was equal or better than 
unsupplemented control cells in maintenance media. HS8
-ve
 yielded the least 
induction of fold increase absorption (maximum ~ 1.2-fold) while HSpm had 
an intermediary effect on proliferation (maximum ~ 1.2-1.3 fold). In contrast, 
HS8G
+ve
 had the highest effect on hMSC proliferation, with a maximum fold-
increase of 1.5 – 1.6-fold. The statistical testing by one-way ANOVA of 
plastic adherent cells revealed that, the fold-increase in absorption with HS8
+ve
 
at concentrations of 1.25, 2.5, 5 and 10 µg/ml were significantly greater than 
the controls. In addition, in STRO-1
+
 cells exposed to HS8
+ve
, the significance 
was evident at concentrations of 0.625, 1.25, 2.5, 5 and 10 µg/ml. The fold-





 were not significantly different from the 
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unsupplemented control at any of the concentrations tested. The effect of 
HS8G
+ve
 on hMSC proliferation was consistent with its higher affinity to  




 enhances hMSC proliferation. Cells were seeded at 5000/well in 96-
well plates and cultured for 36 h with different doses of the HS variants (0, 0.156, 0.3125, 
0.625, 1.25, 2.5, 5 and 10 µg/ml) as stand-alone media supplements.  BrdU incorporation into 
the DNA of proliferating cells was measured photometrically using TMB substrate. The 
graphs show the dose responses of (A) plastic adherent hMSCs (B) STRO-1 hMSCs in the 
presence of unfractionated HSpm, HS8-ve and HS8G+ve. Significant difference is represented as 
* when compared to control (0 µg/ml GAG) (p<0.05). 




 enhances hMSC proliferation; GUAVA Viacount
®
 assay 
BrdU assays provide a snap-shot of proliferation; the next investigation 
of cell proliferation utilized the GUAVA Viacount
®
 assay. Cells were seeded 
at 3000 cells/cm
2 
in 24-well plates and incubated for 6 days with or without 
the HS8G
+ve
 fraction. The existing media was changed once every 2 or 3 days 
with fresh media with or without HS8G
+ve
. Counts of viable cells at periodic 
intervals were obtained after staining with the Viacount flex reagent and 
detected by microcapillary flow cytometry (Guava EasyCyte™ Plus 
System/CytoSoft
TM
 software).  
Irrespective of the media change interval (note the 3 day media change 
data on Fig. 3.10), and the day of the viability count, hMSCs showed the same 
trends of proliferation as with BrdU (Fig. 3.9). The hMSCs showed an upward 
trend in proliferation as shown by the fold-increase in viable cell counts with 
low doses, peaked with 2.5 µg/ml doses and displayed a slight reduction with 
higher doses of HS8G
+ve
. The cell proliferation with 2-day media changes was 
higher than with media changes at 3-day intervals (Fig. 3.10). The effect of 2.5 
µg/ml HS8G
+ve
 variant was evident even at day 2 (~ 1.15-fold) where the 
hMSCs have reached around ~ 40 % confluence by day 2, and the maximum 
effect (~ 1.4-fold) which was significantly higher than the controls, seen by 
day 4 when the cells reached ~ 80 % confluence (Fig. 3.9 A and B). Even 
though hMSCs were 100 % confluent by the 6
th
 day, they still showed an 
increase in proliferation with the HS8G
+ve 
fraction. 





 enhances plastic adherent hMSCs proliferation. Cells were seeded at 
3000/cm2 in 24-well plates and cultured for 6 days with HS8G+ve at different doses (0, 0.156, 
0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) as stand-alone media supplement with media change 
every 2 days. The cells were stained with Viacount flex reagent (Millipore) and viable cells 
detected by the microcapillary flow cytometry platform of Guava EasyCyte™ Plus 
System/CytoSoftTM software (MilliporeTM). (A) The graph shows the dose-dependent fold 
increase in viable cell counts of plastic adherent hMSCs to HS8G+ve at every 2 days of culture. 
(B) Phase-contrast photomicrographs of plastic adherent hMSCs cultured with 2.5 µg/ml 
HS8G+ve variant. Bar represents 200 um. Significant difference is represented as * when 
compared to the control at equivalent day of cell count (0 µg/ml GAG) (p<0.05). 
 
 





 enhances plastic adherent hMSCs proliferation at different media 
change intervals. Cells were seeded at 3000/cm2 in 24-well plates and cultured for 6 days 
with HS8G+ve at different doses (0, 0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) as stand-
alone media supplement with media change every 2 and 3 days. The cells were stained with 
Viacount flex reagent (Millipore) and viable cells detected by the microcapillary flow 
cytometry platform of Guava EasyCyte™ Plus System/CytoSoftTM software (MilliporeTM). 
The graph shows the dose-dependent increase in viable cell counts of plastic adherent hMSCs 
to HS8G+ve at (A) every 2 days and at (B) every 3 days of culture. Significant difference is 
represented as * when compared to the control at equivalent day of cell count (0 µg/ml GAG) 
(p<0.05). 
 




 hMSCs were also cultured for 4 days with or without 
HS8G
+ve
 (Fig. 3.11). Similar to the proliferation with plastic adherent hMSCs, 
the HS8G
+ve
 fraction at 2.5 µg/ml showed the highest fold stimulus of STRO-1 





 enhances STRO-1 hMSC proliferation. Cells were seeded at 
3000/cm2 in 24-well plates and cultured for 4 days with HS8G+ve at different doses (0, 0.156, 
0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) as stand-alone media supplement with media change 
at every 2 days. The cells were stained with Viacount flex reagent (Millipore) and viable cells 
detected by the microcapillary flow cytometry platform of Guava EasyCyte™ Plus 
System/CytoSoftTM software (MilliporeTM). The graph shows the dose-dependent fold increase 
in viable cell counts of STRO-1 hMSCs to HS8G+ve after 4 days of culture. Significant 












 has similar effect on hMSCs 
proliferation 
As confirmed by the GAG ELISA assay all the HS8
+ve
 fractions, HS8 
Gandhi (HS8G
+ve
), HS8 Cardin (HS8C
+ve
) and HS8 Baird (HS8B
+ve
), dose-





effect on hMSC proliferation were examined by means 
of BrdU incorporation (Fig. 3.12) and GUAVA Viacount
®
 proliferation assays 
(Fig. 3.13). The BrdU incorporation assay over 36 h showed a similar cell 
proliferation for all three HS8
+ve
 fractions (Fig. 3.12). The statistical testing of 
one-way ANOVA in plastic adherent cells revealed that, the fold-increase in 
absorption with HS8G
+ve
 at concentrations of 1.25, 2.5, 5 and 10 µg/ml were 
significantly greater than the controls. In addition, with HS8C
+ve
 the 
significance was evident at concentrations of 0.3125, 0.625, 1.25, 2.5, 5 and 
10 µg/ml and with HS8B
+ve 
the significance was evident at concentrations of 
0.625, 1.25, 2.5, 5 and 10 µg/ml. Furthermore, with GUAVA, where cells 
were cultured for 4 days with 2.5 µg/ml of any of the three HS8
+ve
 fractions, 
each showed similar fold-increases in their viable cell count, without any 
significant difference between them (Fig. 3.13).  
These data confirmed that the three HS8
+ve
 fractions (HS8G, HS8C 
and HS8B) are able to stimulate similar levels of biological activity. As seen 
in chapter 2, HS8G
+ve
 fractions had the highest yield after isolation by affinity 
chromatography (table 2.1). Thus, henceforth through this thesis, all 
subsequent experiments were performed with the HS8G
+ve
 fraction, which will 
hereafter be referenced as the HS8
+ve
 fraction variant.  









 have similar effects on hMSC proliferation. 
Cells were seeded at 5000/well in 96-well plates and cultured for 36 h with different HS8+ve 
fractions (HS8G+ve, HS8C+ve and HS8B+ve ) at different doses (0, 0.3125, 0.625, 1.25, 2.5, 5 
and 10 µg/ml) as stand-alone media supplements.  BrdU incorporated in place of thymidine 
into the DNA of proliferating cells was measured photometrically using TMB substrate. The 
graph shows the dose-responses of plastic adherent hMSCs in the presence of different HS8+ve 
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Figure 3.13. . HS8G+ve, HS8C+ve and HS8B+ve have similar effects on hMSC 
proliferation. Cells were seeded at 3000/cm2 in 24-well plates and cultured for 4 days with 
2.5 µg/ml of three HS8+ve variants (HS8G+ve, HS8C+ve and HS8B+ve ) as stand-alone media 
supplement with media change every 2 days. The cells were stained with Viacount flex 
reagent (Millipore) and viable cells detected by the microcapillary flow cytometry platform of 
Guava EasyCyte™ Plus System/CytoSoftTM software (MilliporeTM). The graph shows the 
proliferation of plastic adherent hMSCs over 4 days in the presence of HS8G+ve, HS8C+ve and 
HS8B+ve. A similar fold increase in viable cell counts were observed with each of the variant 
tested. Significant difference is represented as * when compared to 2.5 µg/ml of HS8G+ve 
variant (p<0.05). 
  
    
3.3.2.5. HS8
+ve
 expands more hMSCs than other GAGs preparations 
Lastly, while still exploiting short-term proliferation assays, it was 
necessary to confirm whether HS8
+ve
 had greater effects on cell proliferation 
than either crude HS
pm




Irrespective of HS 
fraction, hMSCs proliferated in similar manner, an upward trend with low 
doses, peaking with intermediate doses and a slight reduction with higher 
doses. However, the fold-increase in viable cell counts with HS8
+ve
 at 
concentrations of 1.25 and 2.5 µg/ml were significantly greater than the 
controls. The fold-increases for cells with media supplemented with of HS
pm
 




 were not significantly different from the unsupplemented control at 
any of the concentrations tested. The highest fold-increase (~ 1.4-fold) was 
shown by HS8
+ve




 had their greatest fold-
increase at the 1.25 µg/ml concentration (~ 1.1-fold). In statistical testing by 
one-way ANOVA, the HS8
+ve
 stimulus was significantly greater than for 
HS
pm
. Therefore, for the long-term proliferation assays that will be described 
in Chapter 4,I was able to optimize the concentrations for each HS fraction 
(HS8
+ve








 expands more hMSCs compared to other GAGs. Cells were seeded at 
3000/cm2 in 24-well plates and cultured for 4 days with HSpm, HS8-ve and HS8G+ve at different 
doses (0, 0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) as stand-alone media supplement 
with media change every 2 days. The cells were stained with Viacount flex reagent (Millipore) 
and viable cells detected by the microcapillary flow cytometry platform of Guava EasyCyte™ 
Plus System/CytoSoftTM software (MilliporeTM). The graph shows the dose dependent fold-
increase in viable cell counts of plastic adherent hMSCs to HS8+ve at 4 days of culture. 
Significant difference is represented as * when compared to control (0 µg/ml GAG) (p<0.05) 
and # when compared to 2.5 µg/ml of HS8+ve dose (p<0.05). 
  
 
 Confidential  136 
 
3.3.3. Heparin-Sepharose bead competition assay  
Heparin-Sepharose bead competition assays were performed to further 
explore the relative affinity of HS variants for FGF-2. This assay measures the 
ability of each HS variant to competitively inhibit the relatively strong binding 
of FGF-2 to heparin. In the case of a successful challenge one would expect 
lower FGF-2 binding to the heparin beads at the end of the assay, indicating 
that the particular HS fraction binds to FGF-2 with a higher affinity.   
First it was necessary to establish an optimal working concentration of 
FGF-2. Various FGF-2 concentrations (0-80 ng/ml) were used and their 
binding to heparin beads detected by ELISA. The FGF-2 saturation curve 
revealed that FGF-2 binds to heparin in concentration-dependent manner, with 
maximal binding occurring at 40 ng/ml of FGF-2 (Fig. 3.15A). A sub-optimal 
FGF-2 concentration (10 ng/ml) which was statistically significant when 
compared to the maximal binding of FGF-2 to heparin (40 ng/ml), chosen to 
forestall false positive results from non-specific binding, was selected from the 
saturation curve and from the immunoblots (Fig. 3.15 A and B).   
In the subsequent competition assay I used 10 ng/ ml of FGF-2 as the 
control, and its absorbance was used as the 100 % “FGF-2 bound” to the 







 each (5, 50 and 100 μg) and the results normalized to 
the absorbance of 100 % FGF-2-bound beads. The values were plotted as % 
bound to beads relative to this 100 % level (Fig. 3.16A). The HS fractions that 
more specifically bound to FGF-2 would competitively inhibit the binding of 
the FGF-2 to the heparin beads. The soluble heparin control (100 μg), being 
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the most negatively charged variant, could almost completely inhibit FGF-2 
binding (down to only ~ 8 % binding) to the heparin beads. 
 
 
Figure 3.15. FGF-2 binding profile on heparin beads. (A) Beads were incubated with 
different amounts of FGF-2 (0, 10, 20,40 and 80 ng/ml), at sub-optimal binding levels. To 
prevent non-specific binding, to prevent false positive results, 10 ng/ml of FGF-2 was used for 
all subsequent competition assay.  (B) Immunoblot images of FGF-2 incubation with heparin 
beads. Significant difference is represented as * when compared to maximal binding of FGF-2 











 fraction had the weakest binding affinity for FGF-2, as 
shown by the high proportion of “compatibility”. Increasing amounts of HS8-
ve
, even at 100 μg, could only partially inhibit the interactions between FGF-2 
and the beads, with a substantially higher amount (~ 55 %) remaining bound 
to the beads. Intermediate binding affinity to FGF-2 was shown by HS
pm
, 
where, with 100 μg, ~ 51 % was still bound to the beads. In contrast, with 
increasing amounts of HS8
+ve
, a concentration-dependent inhibition of FGF-2 
binding to the beads was observed, in a manner not significantly different to 





 have much less competitive binding affinity 
for FGF-2 as compared to the heparin and the HS8
+ve
. The findings followed 
our prediction that the binding affinity of HS8
+ve
 for FGF-2 should be the 
greater, and that unfractionated HS
pm
, which still contains a proportion of 
HS8
+ve
, should have an intermediate binding capacity, and that the denuded 
HS8
-ve
 should have relatively little competitive capacity. The band intensities 
of the immunoblotting results also revealed the same descending order of 






 (Fig. 3.16B). 
Collectively this assay further validated the GAG-ELISA results and thus our 
affinity chromatography platform approach for purifying better targeted HS 
fractions to FGF-2 from the starting HS
pm
 mixture. 
        
 





Figure 3.16. Inhibitory effects of HS variants on the binding of FGF-2 to heparin beads. 
(A) The competition assay was performed with exogenous soluble heparin (as a positive 
control), and the other HS fractions. Soluble heparin binds to most avidly to FGF-2, followed 
by HS8+ve, HSpm and HS8-ve. (B) Immunoblot images of the FGF-2 left on the beads after 
competition. Significant difference is represented as * when compared to soluble heparin 
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3.3.4. Capillary Electrophoresis (CE)  
Capillary electrophoresis (CE) is a sensitive and powerful technique 
for the separation of individual heparin disaccharides based on size and charge 





 with the assistance of our collaborators at GlycoSyn, 
IRL (now Callaghan Innovation, Wellington, New Zealand).  
Eleven of the 12 disaccharides in the standard mix were separated 
while the 12
th
 disaccharide, ΔUA-GlcN, did not migrate under the conditions 
used (Fig. 3.17), notwithstanding this disaccharide has not been reported to 
occur naturally in heparan sulfates. The R
2 
values for the standard calibration 





were injected and out of the 11 disaccharides separated from 
the standard mix, only eight were detected in the HS digests. They were ΔUA-
GlcNAc without any sulfation, mono-sulfates; ΔUA-GlcNS containing only 
N-sulfation, ΔUA-GlcNAc,6S containing only 6-O-sulfation, ΔUA2S-GlcNAc 
containing only 2-O-sulfation, di-sulfates; ΔUA-GlcNS,6S containing 6-O- 
and N-sulfation, ΔUA,2S-GlcNS containing 2-O- and N-sulfation, ΔUA2S-
GlcNAc,6S containing 2-O- and 6-O-sulfation and tri-sulfates; and ΔUA,2S-
GlcNS,6S containing 2-O-, 6-O- and N-sulfation.            
The disaccharide composition of each digested HS variant is shown in 
Table 3.1. The HS
pm
 digests revealed a larger complement of ΔUA-GlcNAc 
(37 %) and ΔUA-GlcNS (25 %), ΔUA-GlcNAc,6S (10 %), ΔUA2S-GlcNAc 
(10 %) that corresponds to a combination of mono- and un-sulfated 
disaccharides.  It has a decreased proportion (16 % in total) of disulfated 
disaccharide (ΔUA-GlcNAc,6S, ΔUA-GlcNS,6S and ΔUA2S-GlcNAc,6S) 
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and only a small proportion (7 %) of trisulfated disaccharide (ΔUA,2S-
GlcNS,6S). The distinctive feature of the  
 
 
Figure 3.17. Δ-disaccharide standard curve. Different dilutions of each standard (Iduron) 
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disaccharide analysis of HS8
+ve
 is the relative enrichment of the trisulfated 
disaccharide (increased from 7 % to 13 %), the depletion of mono- and un-
sulfated disaccharide (ΔUA-GlcNAc reduced from 37 % to 32 % and ΔUA-
GlcNS reduced from 25 % to 15 %) compared with HS
pm
. In addition, there 
was a clear increase from 9 % to 16 % in the di-sulfated disaccharide ΔUA-
GlcNS,6S  as compared to HS
pm
.  
The assays served to confirm that the differing biological activities of 
the HS fractions were subserved through sugar chains with different 
compositions. 
 
3.3.5. Anti-coagulation assay: HS8
+ve
 has no anti-coagulant activity 
 
 In the reactive phase of fracture healing, the formation of a haematoma 
plays an important role in the initiation of bone healing. Hence it made sense 
 Confidential  143 
 
to determine the anticoagulation activity of the HS8 variants, to confirm their 
suitability for use in fracture healing situations. Obviously HS fractions that 
prevent coagulation would be of little clinical use in regenerative medicine. 
The relative anti-coagulant activity of each HS variant was analyzed after 
complexing with antithrombin (Fig. 3.18).  
In this assay pre-incubated antithrombin (AT) was combined with each 
HS variant together with excess Factor Xa (FXa). If the AT is activated during 
the pre-incubation after binding to HS variants, it leads to inactivation of FXa. 
Only the uninhibited FXa can cleave the chromogenic substrate S-2222 and 
release a chromophore (Fig. 3.17). Heparin, the supreme example of an anti-
coagulant, activated AT, resulting in the inhibition of FXa even at the lowest 
concentration tested. It also showed a dose-dependent inhibition of FXa 






 I observed only a slight 
reduction in inhibition of FXa. In the presence of HS
pm
 at a concentration of 
2.5 μg/ml, FXa activity was significantly reduced, whereas HS8-ve and HS8+ve 
did not significantly activate antithrombin at any of the doses tested.  
 





 has minimal anti-coagulant activity compared to heparin. At the 
indicated concentration, HS variants were pre-incubated with antithrombin (AT) before the 
addition of excess factor Xa (FXa). Any FXa that was not inhibited by AT was measured 
photometrically using chromogenic substrate S-2222. Relative inhibition was measured by 
normalizing the values to that of the treatment group containing no GAG (NT). Significant 
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3.3.6. Quantikine FGF-2 stability assay: HS8
+ve
 prolonged FGF-2 stability 
FGF-2 is highly unstable, with its viability dependent on the solvent 
used to dissolve it. Heparin is known to stabilize FGF-2 at an optimum culture 
temperature of 37 °C (Caldwell et al., 2004). The next test was whether 
HS8
+ve







 on FGF-2 was investigated against a heparin positive 
control.  
The amount of exogenously added FGF-2 detectable in media 
subsequently decreased to a very marked degree over a 3-day test period (Fig. 
3.19). FGF-2 levels dropped to 13 % within the first 24 h, and by 72 h, only 
1.8 % was detectable in the culture media. As documented earlier in the 
presence of heparin, 74% of the FGF-2 could be detected after 24 h and 60 % 
after 72 h. All the other HS fractions tested were able to stabilize FGF-2 at 
intermediate levels as compared to heparin. When considering the three HS 
fractions in particular, HS8
-ve 
showed the weakest levels of stabilization, 
where only 17 % of FGF-2 was detectable at the end of the 72 h incubation 
period. HS
pm
 stabilization of FGF-2 was at an intermediate level, with 56 % 
detectable after 24 h and 21 % after 72 h. The highest levels of stabilization of 
FGF-2 were offered by HS8
+ve
, where 59 % of the growth factor could be 
detected after 24 h and 31 % after 72 h. By taking into account the initial and 
final amounts of FGF-2 present in solution after 48 h, the apparent half-life of 
FGF-2 (t1/2 ≈ 10 h) was improved ~ 4-fold in the presence of HS8
+ve










 prolongs FGF-2 stability. FGF-2 (2.5 ng/ml) was incubated alone or in 
the presence of 2.5 µg/ml of GAGs (Heparin, HSpm, HS8+ve and HS8-ve) in 1 ml of hMSC 
culture media at 370C with 5% CO2. Samples were collected at 0, 24, 48 and 72 h and 
analyzed by solid phase sandwich ELISA (R & D Systems). Significant difference is 
represented as * when compared to soluble heparin (positive control) at equivalent dose 
(p<0.05) and # when compared to HS8+ve at equivalent dose (p<0.05). 
    
3.3.7. Differential Scanning Fluorimetry (DSF): HS8
+ve
 stabilize FGF-2 
against thermal denaturation 
FGF-2 is highly unstable and heparin is known to stabilize FGF-2 from 
thermal denaturation (Prestrelski et al., 1992; Vemuri et al., 1994). DSF can 
be used to measure protein-sugar interactions by means of a sensitive dye, 
Sypro Orange (Uniewicz et al., 2010). This dye binds and detects the exposed 
core residues of denatured proteins when the protein samples are subjected to 
a heating cycle. Hence I sought to determine the possibility of using DSF to 






) variants’ ability to 
stabilize FGF-2. First I needed to determine an optimal working concentration 
of FGF-2; various FGF-2 concentrations (2.5, 5, 7.5 and 10 µM) were used to 
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examine the thermal effect on FGF-2 (Fig. 3.20). The denaturation curves 
revealed that greater fluorescence was evident, in a concentration-dependent 
manner, compared to the negative control; the best signal was achieved when I 
used 10 µM of FGF-2 (Fig. 3.20A). The first derivatives of the denaturation 
curves were plotted, where the maxima defined the Tm of FGF-2 as 57.5 °C 
(Fig. 3.20B and Table 3.2). 
Next, the optimal concentration of 10 µM of FGF-2 was used as the 
constant baseline and tested against a range of heparin concentrations (2.5, 5, 
10 and 20 µM) (Table 3.3). The denaturation curves show that a stabilizing 
effect is apparent from 2.5 μM heparin (heparin-FGF-2 molar ratio 1:4), and 
that the stability increased with increasing concentrations of heparin (Fig. 
3.21A). The plotted first derivatives of the denaturation curves showed an 
increasing Tm of FGF-2 with the increasing amounts of heparin used (Fig. 
3.21B and Table 3.3). Hence DSF clearly showed that heparin has a 
concentration-dependent effect on FGF-2 stability, and can offer a means of 
comparison for the other HS fractions.  
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Figure 3.20. Thermal effect on FGF-2. (A) Melting curve profile of different concentrations 
of FGF-2 (2.5, 5, 7.5 and 10 μM) (B) The first derivatives of each melting curve where each 
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Table 3.2. Concentrations of FGF-2 assayed and their corresponding mean Tm values, 







My aim was to find out whether the different HS variants have 
differing stabilization effects corresponding to their different binding affinities 
to FGF-2. The molar ratio of 1:1 of FGF-2:heparin was chosen for this 
experiment because of the medium-to-high stabilization effect seen, which in 
turn corresponded to the results of Uniewicz et al (Uniewicz et al., 2010). For 
the HS variants, the same concentration (160 μg/ml) was employed. The 
collected data were analyzed as detailed earlier and normalized to reveal the 
ability of each compound to stabilize FGF-2 relative to heparin (Fig. 3.22). 
The least thermal stabilizing affect was shown by HS8
-ve
 and the greatest by 
HS8
+ve
 as compared to heparin. In addition, HS
pm
 afforded an intermediate 
level of thermal stability of FGF-2. The stabilizing affect shown by HS8
+ve
 




. The previous GAG ELISA and 
heparin-Sepharose bead competition assays established that the HS variants 






.  This 
was also evident in this assay, where among the HS variants tested, HS8
+ve
 
possessed the highest affinity for FGF-2 and correspondingly displayed the 
highest thermal stability for FGF-2.  





Figure 3.21. Heparin effect on thermal stabilization of FGF-2. (A) Melting curves of 10 
μM FGF-2 in the presence of different concentrations of heparin (0, 2.5, 5, 10 and 20 μM). (B) 
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Table 3.3: Ratios of assayed concentrations of FGF-2 and heparin with their 








Figure 3.22. Relative thermostabilizing effect of HS variants on FGF-2 calculated 
according to equation (3) as compared to heparin. Results are the mean ± SD of two 
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3.3.8. Synergistic effect of HS8
+ve
 and FGF-2 on hMSCs proliferation 
  As there was a statistically significant increase in hMSC proliferation 
when cells were cultured for 4 days with HS8
+ve
 (1.25 and 2.5 µg/ml), it was 
used as a media supplement. Of course, FGF-2, as a media supplement, also 
increased hMSC growth (Fig. 3.23). The highest fold-increase in viable cell 
counts with statistical significance was triggered with 2.5 ng/ml of FGF-2.  
Next, the proliferation response of hMSCs with a combination of an 






) was examined together with 
FGF-2. The cells were seeded at 3000 cells/cm
2 
in 24-well plates and 
incubated for 4 days with suboptimal doses of FGF-2 (0.156  ng/ml) with or 
without increasing doses of each HS variant (0, 0.156, 0.3125, 0.625, 1.25, 
2.5, 5 and 10 µg/ml) and the additive effect on FGF-2 mediated proliferation 
monitored (Fig. 3.24). Cells cultured in maintenance media (baseline control) 
supplemented with 2.5 ng/ml of FGF-2 served as positive control. FGF-2, 
even at a sub-optimal dose (0.156 ng/ml) increased hMSC proliferation by ~ 
1.3-fold. The crude HS
pm
 and the flow-through HS8
-ve
, even with increasing 
concentrations, were unable to increase cell proliferation beyond this 1.3-fold 
point. In contrast, HS8
+ve
, even with only 0.3125 µg/ml added, together with 
0.156 ng/ml of FGF-2, markedly increased the cell proliferation (~ 1.7-fold). 
This fold-increase in cell number was similar to the cell proliferation with 2.5 
ng/ml of FGF-2 (~1-6 - 1.7-fold). Thus, I was able to reach the maximum 
fold-increase in hMSC proliferation with 16-times less FGF-2 (from 2.5 to 
0.156 ng/ml) combined with 8-times less HS8
+ve
 (from 2.5 to 0.3125 µg/ml). 
In addition, HS8
+ve
 was also able to bind and increase the stability of FGF-2 
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under the culture conditions, as previously shown by binding assays and 
stability assays.    
 
 
Figure 3.23. Heparin and FGF-2 (Positive controls) enhances plastic adherent hMSC 
proliferation. Cells were seeded at 3000/cm2 in 24-well plates and cultured for 4 days with 
Heparin and FGF-2 at different doses (0, 0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) as 
stand-alone media supplement with media change every 2 days. The cells were stained with 
Viacount flex reagent (Millipore) and viable cells detected by the microcapillary flow 
cytometry platform of Guava EasyCyte™ Plus System/CytoSoftTM software (MilliporeTM). 
The graph shows the dose dependent fold-increase in viable cell counts of plastic adherent 
hMSCs to (A) heparin and (B) FGF-2 at 4 days of culture. Significant difference is 
represented as * when compared to control (0 µg/ml GAG) (p<0.05). 





 enhances FGF-2-mediated MSC growth. Cells were seeded at 
3000/cm2 in 24-well plates and cultured for 4 days with HSpm, HS8-ve and HS8+ve at different 
doses (0, 0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) with or without FGF-2 (0.156 
ng/ml) with media change at every 2 days. Cells cultured in maintenance media and with 2.5 
ng/ml of FGF-2 served as baseline control and positive control respectively. The cells were 
stained with Viacount flex reagent (Millipore) and viable cells detected by the Guava 
EasyCyte™ Plus microcapillary flow cytometry platform and System/CytoSoftTM software 
(MilliporeTM). The graph shows the dose-dependent fold-increase in viable cell counts of 
plastic adherent hMSCs with varying doses of HS variants with a fixed dose of FGF-2. 
Significant difference is represented as * when compared to 0.156 ng/ml FGF-2 (p<0.05).  
 
Immunoblotting was performed to confirm the results of additive effect 
of HS8
+ve
 and FGF-2 on hMSC proliferation as shown by viability assays.  
As discussed in the introduction, activation of the ERK cascade is 
required for FGF-induced mitogenesis. Thus, it was necessary verify that 
HS8
+ve
 in the presence of FGF-2 could induce ERK activation in low serum 
conditions.  Here, cells were seeded (10,000 cells/cm
2
) on 6-well plates 
(Nunc) and allowed to adhere to the plastic surface for 16 h in a humidified 
atmosphere. After 48 h of serum starvation cells were stimulated with GAGs 
(2.5 g/ml) and/or FGF-2 (0.156 ng/ml) and monitored for FRS2a 
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phosphorylation and ERK1/2 phosphorylation after 30 min, 6 h and 24 h post 
stimulation. Although a marked increase with lower doses of HS8
+ve
 (0.3125 
µg/ml; Fig. 3.25), was seen, in this experiment I used the 2.5 µg/ml GAG dose 
to mimic the scenario wherein I added HS variants as stand-alone media 
supplements. 
FGF-2 rapidly elevated both FRS2a phosphorylation and ERK1/2 
phosphorylation from 30 min after the treatment and sustained it until 6 h, 
after which the signal started to decline over 24 h (Fig. 3.25). When HS8
+ve 
was present, the levels of FRS2a and ERK1/2 phosphorylation were higher 
than with stimulation through FGF-2 alone at 30 min and 6 h. In addition, 
HS8
+ve
 with FGF-2 managed to sustain signaling even at 24 h after which the 
cells in FGF-2 alone showed reduced levels phosphorylation levels of FRS2a 
and ERK 1/2. I next examined whether HS8
+ve
-mediated FGF-2 signaling was 
superior to the other HS variants. Here heparin used as a positive control. As 
expected, the highly negative charged heparin sustained FRS2a and ERK1/2 
phosphorylation to 24 h, similar to HS8
+ve
 (Fig. 3.26), albeit that the levels of 




 were lower 
than of HS8
+ve
.  My results thus confirmed the additive effect of HS8
+ve
 and 









 sustains FGF-2 signaling. The cells were seeded (10,000 cells/cm2) on 
6-well plates and were allowed to adhere to the plastic surface for 16 h.  The cells were then 
serum starved for 48 h. Immunoblots showing FRS2a phosphorylation and ERK1/2 and 
phosphorylation at 30 min, 6 h and 24 h post stimulation with FGF-2 (0.156 ng/ml) with or 
without HS8+ve (2.5 µg/ml). 
 
 
      
Figure 3.26. HS8
+ve




. The cells 
were seeded (10,000 cells/cm2) on 6-well plates and were allowed to adhere to the plastic 
surface for 16 h.  Afterwards cells were serum starved for 48 h. Immunoblots showing FRS2a 
phosphorylation and ERK1/2 phosphorylation at 24 h post stimulation with FGF-2 (0.156 
ng/ml) with or without GAGs (2.5 µg/ml). 




 enhance hMSC proliferation via FGF-2-FGFR signaling. 
HS is a coreceptor for the FGF/FGFR complex, and FGFR1 is a high 
affinity receptor for FGF-2 binding (Chellaiah et al., 1999; Dombrowski et al., 
2009; Pellegrini, 2001). Inhibitor studies were next used to show that the 
mechanism for triggering the proliferation by the HS8
+ve
 involved FGF-2. 
First it was necessary to inhibit the FGF-2 in the culture media with a 
neutralizing antibody (Ab; R & D Systems). The presence of the FGF-2-
neutralizing Abs had a clear inhibitory effect on the basal growth of hMSCs 
(Fig. 3.27). HS8
+ve
 (2.5 µg/ml) and FGF-2 (2.5 ng/ml) significantly increase 
hMSC proliferation while the FGF-2 neutralizing antibody significantly 
prevented HS8
+ve
 and FGF-2 induced proliferation as revealed by BrdU 
incorporation and GUAVA Viacount
®
 assays (Fig. 3.27). This blocking of 
fold-increases in viable cell counts in HS8
+ve
 and FGF-2 grown cells was 
similar to the controls as evident in the GUAVA Viacount
®
 assay. Similarly, 
in the BrdU incorporation assay prevention of fold-increases in absorbance 
with HS8
+ve
 was similar to the control but with FGF-2 it was significantly 
dissimilar. This may be due to BrdU constituting only a snap shot of 
proliferation and the amount of FGF-2 neutralizing antibody might not have 
been sufficient to neutralize the amount of FGF-2 in culture at the examined 
time point.   
This further strengthens the hypothesis that HS8
+ve
 increases hMSC 
proliferation via FGF-2, as previously indicated by the additive effect of 
HS8
+ve
 and FGF-2 (Figs. 3.24 and 3.25).  
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Figure 3.27. FGF-2-neutralizing antibody reduces the hMSC proliferation. The cells were 
cultured with FGF-2 (2.5 ng/ml) and HS8+ve 2.5 µg/ml with or without FGF-2 neutralizing Ab 
(2 µg/ml) (R & D Systems). Cells cultured with media with or without FGF-2 neutralizing Ab 
(2 µg/ml) served as controls. The graphs show the inhibition of the hMSC growth usually 
induced by FGF-2 and HS8+ve supplementation (A) BrdU incorporation assay (Roche) (B) 
GUAVA Viacount® assay (Millipore). In BrdU incorporation assay cells were seeded at 
5000/well in 96 well plates, cultured for 36 h and BrdU incorporation into DNA of 
proliferating cells was measured photometrically using TMB substrate. In GUAVA Viacount® 
assay cells were seeded at 3000/cm2 in 24 well plates, cultured for 4 days, stained with 
Viacount flex reagent and viable cells detected by Guava EasyCyte™ Plus System/CytoSoftTM 
software. Significant difference is represented as * when compared to control, # when 
compared to control with FGF-2 neutralizing Ab (2 µg/ml) and + when significant among 
respective bars (p<0.05). 
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 It was next necessary to verify the importance of FGFR signaling for 
hMSC proliferation under HS8
+ve
 stimulation. Two forms of FGFR1  
inhibition were used: either the chemical inhibitor SU5402 (Calbiochem, 
Millipore) or the neutralizing antibody IMBR1 (Ling et al., 2006). Clearly, if 
the HS8
+ve
 variant was involved in the direct binding of FGF-2 to FGFR1, the 
effect on proliferation should be blocked by FGFR1 inhibitors as compared to 
the controls. Pulsing SU5402 at two different doses (10 and 25 µM) had a 
statistically significant dose-dependent inhibitory effect on the basal growth of 
hMSCs (Fig. 3.28). HS8
+ve
 (2.5 µg/ml) and FGF-2 (2.5 ng/ml) significantly 
increase hMSC proliferation; SU5402 successfully prevented HS8
+ve
/FGF-2-
induced proliferation as evident in the GUAVA Viacount
®
 assay.  This 
prevention of fold-increases in viable cell counts in HS8
+ve
 and FGF-2 
exposed cells was significantly similar to the controls. Similarly, in the BrdU 
incorporation assay prevention of fold-increases in absorbance with HS8
+ve
 
was similar to the control but with FGF-2 and SU5402 (10 µM) it was 
significantly dissimilar. This may be due to BrdU is providing only a snap shot 
of proliferation and that the amount of SU5402 was not sufficient to inhibit the 
FGFR1 activation by the amount of FGF-2 in culture at that time point.   
Almost identical results were seen with the FGFR1-neutralizing 
antibody IMBR1 with few exceptions. The difference in absorbance (BrdU 
assay) with FGF-2 and IMBR1 (1:1000 and 1:2000) and the difference in fold 
increase (GUAVA assay) with IMBR1 (1:2000) were significantly dissimilar 
when compared with equivalent control groups (Fig. 3.29). This may be due to 
both doses of IMBR1 in BrdU assay and the lower dose in GUAVA assay 
were not sufficient in inhibiting the potent FGF-2’s effect on FGFR1 
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activation  as compared to controls.  Nevertheless, these results indicated that 
the mechanism involved in triggering the proliferation by the HS8
+ve
 was 
indeed via FGF-2-FGFR1 signaling. 
 
Figure 3.28. SU5402 inhibits hMSC proliferation. Cells were cultured with FGF-2 (2.5 
ng/ml) and HS8+ve 2.5 µg/ml with or without SU5402 (10 and 25 µM) in DMSO (Calbiochem, 
Millipore). Cells cultured with media alone with or without SU5402 (10 and 25 µM) in 
DMSO served as controls. The graphs show the inhibition of hMSC growth usually induced 
by FGF-2 and HS8+ve media supplements (A) BrdU incorporation assay (Roche) (B) GUAVA 
Viacount® assay (Millipore). In BrdU incorporation assay cells were seeded at 5000/well in 96 
well plates, cultured for 36 h and BrdU incorporation into DNA of proliferating cells was 
measured photometrically using TMB substrate. In GUAVA Viacount® assay cells were 
seeded at 3000/cm2 in 24 well plates, cultured for 4 days, stained with Viacount flex reagent 
and viable cells were detected by Guava EasyCyte™ Plus System/CytoSoftTM software. 
Significant difference is represented as * when compared to control, # when compared to 
control with SU5402 (10 µM), ^ control with SU5402 (25 µM) and + when significant among 
respective bars (p<0.05). 
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Figure 3.29. IMBR1 inhibits hMSC proliferation. The cells were cultured with FGF-2 (2.5 
ng/ml) and HS8+ve 2.5 µg/ml with or without IMBR1 (1:2000 and 1:1000) (Ling et al., 2006). 
Cells cultured with media alone with or without IMBR1 (1:2000 and 1:1000) served as 
controls. The graphs show the inhibition of hMSCs growth usually induced by FGF-2 and 
HS8+ve media supplements (A) BrdU incorporation assay (Roche) (B) GUAVA Viacount® 
assay (Millipore). In BrdU incorporation assay cells were seeded at 5000/well in 96-well 
plates, cultured for 36 h and BrdU incorporation into DNA of proliferating cells was measured 
photometrically using TMB substrate. In GUAVA Viacount® assay cells were seeded at 
3000/cm2 in 24 well plates, cultured for 4 days, stained with Viacount flex reagent and viable 
cells were detected by Guava EasyCyte™ Plus System/CytoSoftTM software. Significant 
difference is represented as * when compared to control, # when compared to control with 
IMBR1 (1:2000), ^ control with IMBR1 (1:1000) and + when significant among respective 
bars (p<0.05). 
 




 binds both FGF-2 and FGFR1 
In order to act as a coreceptor for the FGF/FGFR complex, an HS 
chain must have sufficient length to couple both FGF-2 and FGFR1 within 
one, or at most two sulfated domains. To explore the importance of length, 
hMSCs were cultured for 4 days with both full-length heparin, and a smaller 
heparin fragment, of d.p. (degree of polymerization) 10 (dp10) at different 
doses (0, 0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) with or without 
FGF-2 (0.156 ng/ml), and the additive effect on FGF-2-mediated proliferation 
monitored (Fig. 3.30). As noted above, the highly negatively charged heparin, 
even at 0.156 µg/ml, together with FGF-2, increased cell proliferation 
considerably more than with FGF-2 alone at an otherwise sub-optimal dose 
(0.156 ng/ml). The cell proliferation with 0.625 µg/ml heparin and 0.156 
ng/ml of FGF-2 was similar to the cell proliferation with 2.5 ng/ml of FGF-2. 
These data were similar to the additive effect of HS8
+ve
 on FGF-2-mediated 
hMSC proliferation (Fig. 3.24). In contrast, the dp10 fragment at increasing 
concentrations was unable to increase cell proliferation beyond the 1.3-fold 
point when FGF-2 was at sub-optimal concentrations. Furthermore, a dose-
dependent antagonistic effect was shown by dp10 on FGF-2-mediated cell 
growth. This might have been because dp10 was binding to FGF-2 but lacked 
the length to cross-bind to FGFR1 and mediate cell proliferation. 
As HS8
+ve
 clearly enhances FGF-2 mediated cell growth, it can 
concluded that HS8
+ve
 has a length exceeding dp10.   
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Figure 3.30. Full-length heparin enhances FGF-2 mediated MSC growth, but not dp10 
heparin.  Cells were seeded at 3000/cm2 in 24-well plates and cultured for 4 days with heparin 
and dp10 at different doses (0, 0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) with or 
without FGF-2 (0.156 ng/ml) with media change at every 2 days. Cells cultured in 
maintenance media and with 2.5 ng/ml of FGF-2 served as baseline control and positive 
control respectively. The cells were stained with Viacount flex reagent (Millipore) and viable 
cells detected by the microcapillary flow cytometry platform of Guava EasyCyte™ Plus 
System/CytoSoftTM software (MilliporeTM). The graph shows the dose-dependent fold-
increase in viable cell counts of plastic adherent hMSCs in varying doses of heparin and dp10 
with a fixed, suboptimal  dose of FGF-2. Significant difference is represented as * when 
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3.4. Discussion 
Glycosaminoglycans (GAGs), large, unbranched, yet complex 
carbohydrate molecules, constitute an important structural and functional 
compartment of the extracellular matrix ((ECM) (Gandhi and Mancera, 2008). 
The role of HS becomes particularly important during phases of tissue 
building, in the embryo, and during phases of tissue regeneration in the adult. 
Like all GAGs, HS is a polymer of repeating disaccharide units (Ori et al., 
2009). It binds and regulates a wide variety of proteins, now thought to be 
over 400, and participates in many biological processes; in the stereotypical 
example, HS regulates the FGF signaling by direct molecular association with 
FGFRs to nucleate a trimeric complex (Pellegrini, 2001). In Chapter 2, the 
possibility of fine tuning and enhancing the endogenous FGF-2 activity of 
MSCs through judicious use of targeted HS was examined. The successful 
isolation of a highly scalable HS fraction variant with higher binding affinity 
for FGF-2 was performed. A full range of biochemical assays was then 
deployed to examine the suitability of such an HS for the putative expansion 
of hMSCs.    
In order to effectively exploit GAGs in tissue engineering, there is an 
essential need to understand the interactions between GAGs and proteins. 
Therefore the assays utilised should allow sufficient attachment of GAGs to a 
surface without hindering their binding properties to proteins. Marson and 
colleagues have discussed the limitations  of covalent coupling of GAGs to 
bovine serum albumin and  binding of biotinylated GAGs to immobilized 
proteins as methods to adhere GAGs to plastic surfaces (Mahoney et al., 2004; 
Marson et al., 2009). To overcome those limitations they have described a 
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way, by means of cold plasma polymerization whereby microtitre plate 
surfaces are coated with allyl amine (Mahoney et al., 2004; Marson et al., 
2009). The GAGs thereby non-covalently immobilized to these allyl amines 





 and starting material HS
pm
 for FGF-2 
was compared using GAG-ELISA and heparin-Sepharose beads competition 
assays in chapters 3.3.1 and 3.3.3. In addition, the binding specificity of 
HS8
+ve
 was compared with other heparan-binding proteins. The results 
confirmed that HS8
+ve





. These results further validated our affinity 
chromatography platform for the isolation of HS variants that HS8
+ve
 bind 
with high affinity to FGF-2 similar to other HS variants isolated by our group 
for BMP-2 and VEGF165 (Murali et al., 2013; Wang et al., 2014). 
 Next two types of hMSCs, plastic adherent and STRO-1-positive, in 
short-term proliferation studies were used to examine the suitability of HS8
+ve
 




. These data also showed 
that, HS8
+ve





 (Figs. 3.8, 3.9, 3.11 and 3.14). The hMSC proliferation by 
HS8
+ve
 was comparable to published results that utilised embryonic form of 
heparan sulfate (HS2) which specifically binds FGF-2 (Helledie et al., 2011). 
Helledie and colleagues have shown this HS2 increased the proliferation of 
sub-confluent hMSCs over a 6-day period by ~ 65% (Helledie et al., 2011). In 
addition, the fold increase in proliferation of hMSCs with HS8
+ve
 was similar 
to that of heparin (positive control) while FGF-2 supplementation (other 
positive) yielded higher cell proliferation of ~ 1.6 (Fig. 3.23). Furthermore, 
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such assays were used to narrow down to an HS8
+ve







) (Figs. 3.12 and 3.13). HS8G
+ve
 
was selected since it gave me the better yield as described in chapter 2.4. 
Murali et al. have already described the isolation of an affinity-selected HS 
with relative specificity for BMP2 (with this platform) and successful 
employed it to trigger in vivo bone repair (Murali et al., 2013). Similarly, 
Wang et al. also described an affinity-isolated heparan sulfate 
glycotherapeutic (HS7
+ve
) that binds to, and enhances the bioactivity of, 
VEGF165 (Wang et al., 2014). 
Wang and colleagues have recently mentioned that subtle variations in 
disaccharide sequence, chain length and biosynthesis give rise to specific HS 
variants with unique characteristics of bindings to different growth factors 
(Murali et al., 2011; Murali et al., 2013; Nurcombe et al., 2007; Wang et al., 
2014). Therefore the compositional make up of HS8
+ve
 is an important aspect 
for the future if we are to design synthetic equivalents with even greater 
affinity for FGF-2.  The sensitive and powerful technique of capillary 







 was enriched for trisulfated disaccharides and was relatively 
depleted in mono- and un-sulfated disaccharide as compared with HS
pm
. In 
addition, there was a clear increase in di-sulfated disaccharides, particularly 
ΔUA-GlcNS,6S. Similarly, Murali et al., and Wang et al., have described that 





) peptide affinity columns have higher amounts of trisulfated 
disaccharide species and enriched with ΔUA-GlcNS,6S disulfide species as 
compared to the starting mixture HS
pm 
(Murali et al., 2013; Wang et al., 
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2014). A closer look across these three HS variants revealed that DHexUA,2S-
GlcNS,6S was highest (15 %) with HS3
+ve





 had an intermediary level (13 %). On the other hand 
DHexUA-GlcNS,6S was highest (15 %) with HS7
+ve





 again had an intermediary level (13 %). 
  Disaccharide analyses of heparin have been published by various 
groups (Ampofo et al., 1991; Desai et al., 1993; Jandik et al., 1994; 
Karamanos et al., 1996; Ruiz-Calero et al., 1998; Scapol et al., 1996). As 
described, the key disaccharides of porcine intestinal mucosal heparin were 
DHexUA,2S-GlcNS,6S and DHexUA-GlcNS,6S, which indicated that 
trisulfated disaccharides (2O-, 6O- and N-sulfated) and disulfated 
disaccharides (6O- and N-sulfated) are major components for the binding to 
growth factors such as FGF-2. Our data clearly suggests that an increase in 
trisulfated disaccharides and 6O- and N-sulfated disaccharides is indeed very 
important for HS binding to FGF-2. Furthermore, lack of enrichment of 
unsulfated and monosulfated (NS) compared to HS
pm
 suggests that neither 
disaccharide by itself is sufficient for FGF-2 binding. Heparin has very low 
levels of unsulfated and monosulfated (NS) disaccharides. I posit that the 
levels of disaccharides that are different to those levels in heparin and as well 




) may be the reason that 
HS8
+ve
 has a relative affinity for FGF-2 over the other heparin binding growth 
factors, notwithstanding the final arbiter are the actual disaccharide sequences 
within N-sulfated domains greater than dp 10 in length. A dodecasaccharide, 
whose sequence has been proposed as the minimal requirement to promote 
receptor signaling by FGF-2 (Guimond et al., 1993), was the reason that only 
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heparin dp 10 was utilized here to gain an insight of the length of HS8
+ve
. 
Usually the linear, sulfated glycosaminoglycans have molecular masses that 
typically range from 10 to 100 kDa (Gandhi and Mancera, 2008). In addition, 
the chain length of HS is also important in giving rise to HS variants with 
unique characteristics of bindings to different growth factors. Therefore, the 
exploration of the length and the MW of HS8
+ve
 was recommended as future 
research as described by Murali et al. (Murali et al., 2011) . This provided new 
data and the data on the composition of HS8
+ve
 in chapter 3.4.4 will be 
beneficial in artificial synthesis of HS8
+ve
. 
Various studies have presented data supporting the idea that HS’s 
varying capacity for proteins is due to differentially modified HS units.  
Lindahl’s group in Sweden have shown that 3O-sulfated glucosamine, at a 
specific position in the antithrombin-binding sequence of heparin is essential 
for its anticoagulation effects (Lindahl et al., 1980). Heparin’s anticoagulation 
activity was clearly highlighted by the data shown in chapter 3.3.5. In contrast, 
the HS8
+ve
 fraction did not show any significant anticoagulation activity, 
suggesting that it is devoid of 3O-sulfation. HS
pm
 did trigger a slight 
anticoagulation activity at higher doses, implying that it may contain some 
lesser amount of 3O-sulfation. 
 Similarly, specific disaccharide sequences within HS GAGs chains 
support the signaling of the FGF family. The FGF1-binding affinity of HS is 
reduced in the absence of 6O-sulfate groups, indicating their importance for 
this interaction (Fromm et al., 1997b; Ishihara, 1994). Similarly, FGF4 
requires both 2O- and 6O-sulfation for binding and signaling (Ashikari-Hada 
et al., 2009; Guimond et al., 1993; Ishihara, 1994). FGF-2 binding to HS 
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requires 2O-sulfation (Faham et al., 1996a; Maccarana et al., 1993). 
Furthermore, in addition to the 2-O sulfation, 6-O-sulfation of N-sulfated 
glucosamine residues is required for the promotion of FGF-2 mitogenic 
activity (Pye et al., 1998). Lundin and colleagues have also supported this idea 
by showing that FGF-2 binding requires N and 2-O-sulfate groups, whereas 
stimulation of FGFR-1 and Erk2 kinases by FGF-2 also required the presence 
of 6O-sulfate groups (Lundin et al., 2000). Furthermore, they demonstrated 
that 6O-desulfated heparin could inhibit FGF-2-induced angiogenesis in chick 
embryo chorioallantoic membranes. Thus, formation of the ternary complex of 
FGF-2-HS-FGFR1 critical for signal transduction requires 2O-, 6O- and N 
sulfation. Hence, the levels of these required sulfated disaccharides in HS8
+ve
 
might have been somewhat optimised for FGF-2 binding and signal 
propagation by the platform. This further validates our affinity 
chromatography approach as a promising technique for isolating FGF-2-
binding HS forms from a heterogeneous HS mixture.  
Stabilization of FGF-2 by HS variants in culture conditions is 
important for the enhancement of endogenous growth factor activity. The 
stability of FGF-2 afforded by heparin (as also shown by my results in chapter 
3.3.6) was comparable to published results that utilised quantikine assays 
(Caldwell et al., 2004). The affinity purified HS8
+ve 
increased the T1/2 of FGF-





. The thermal stability of FGF protein is known to be a determinant 
factor for human embryonic stem cell (ESC) self-renewal, differentiation, and 
reprogramming (Chen et al., 2012). These researchers have shown it is the 
thermal instability of FGF1, rather than receptor specificity that leads to 
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failure in ESC maintenance. These results obviously suggest that the thermal 
stability of FGF-2 under culture conditions is important for prolonged hMSC 
growth. I have shown by the differential scanning fluorimetry assay that the 
thermal stability of FGF-2 is increased by HS8
+ve







 did not afford the same level of thermal stabilization as 
heparin, this may be due to rare structures, such as heparin’s 3O-sulfation, or 
the simple fact of extra sulfation that allow for a stronger interaction (Xu et 
al., 2012). In addition, others have shown the importance of FGF-2–heparin 
interactions for the protection of the growth factor from denaturation and 
proteolytic digestion (Gospodarowicz and Cheng, 1986). Therefore, HS8
+ve
, 
with its higher binding ability for FGF-2, might well perform in a similar 
manner. 
The additive effect of HS8
+ve
 and FGF-2 were monitored by both 
proliferation assays and cell signaling studies. HS8
+ve





increased the FGF-2-mediated cell growth (Fig. 3.24). In addition, highly 
sulfated heparin when used as a positive control also increased the FGF-2-
mediated cell growth similar to that of HS8
+ve
 (Figs. 3.24 and 3.30).  
 Heparan sulfate is a coreceptor for the FGF/FGFR complex and 
FGFR1 is a high affinity receptor for FGF-2 binding (Chellaiah et al., 1999; 
Dombrowski et al., 2009; Pellegrini, 2001). X-ray crystal structures of the 
trimeric complex have shown two main models. One, with a stoichiometric 
ratio 2:2:2 of FGFR2:FGF1:heparin decasaccharide (Schlessinger, 2000; 
Turnbull et al., 1992) and the other with a stoichiometric ratio 2:2:1 of 
FGFR2:FGF1:heparin decasaccharide (Pellegrini, 2001). Both receptors in the 
FGF-2 dual receptor system must be present for FGF-2 to trigger a 
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proliferative response (Delehedde et al., 2002). Therefore the inhibitor studies 
that I exemplified clearly demonstrated that the mechanism involved in 
triggering the proliferation by the HS8
+ve
 was consistent with FGF-2-FGFR1 
signaling. In accordance with the inhibitor studies detailed here, Dombrowski 
et al also observed similar results when they used HS isolated from mouse 
embryonic tissue and FGF2 on rat MSCs (rMSCs) (Dombrowski et al., 2009). 
They have clearly shown that the inhibition of FGFR1 with either a 
neutralizing antibody (IMBR1) or the chemical inhibitor SU5402 prevented 
HS and FGF-2-induced proliferation similar to that of basal growth of rMSCs. 
They also claim that according to their results, the embryonic HS directs FGF-
2 signaling in rMSCs preferentially through FGFR1. 
Furthermore, HS, in order to qualify as a coreceptor for the FGF/FGFR 
complex, must have sufficient length and the requisite disaccharide 
compositions within its binding sites to couple both FGF-2 and FGFR1. The 
minimum oligosaccharide that can bind FGF-2 is a tetrasaccharide, as shown 
by optical NMR spectroscopy (Delehedde et al., 2002; Guglieri et al., 2008). 
In addition, an increasing gradient in affinity for FGF-2 was seen from 
tetrasaccharide to octasaccharide.  However, according to Delehedde et al., the 
oligosaccharides from tetrasaccharides to octasaccharides were less potent in 
their stimulation of the proliferation of rat mammary fibroblasts than deca- or 
longer -saccharides (Delehedde et al., 2002). In addition, a dodecasaccharide 
sequence has been proposed as the minimal requirement to promote receptor 
signaling by FGF-2 (Guimond et al., 1993), notwithstanding I have observed 
in chapter 3.3.10 that heparin oligosaccharides of  dp 10 were not sufficient  to 
enhance the FGF-2-mediated hMSC proliferation. Recently Dombrowski and 
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colleagues have shown that FGFR1 signalling activity is rate limiting for self-
renewal of hMSCs and thereby stimulates proliferation of hMSCs 
(Dombrowski et al., 2013). This is achieved by several mechanisms by 





with our group’s data that the HS8+ve variant displays maximum, plateau 
binding to FGFR1 protein in GAG-ELISA assays, I conclude that HS8
+ve
 is 
highly likely to have a relatively specific binding site for FGFR1.  
 
3.5. Summary 
The aim of this chapter was to test the HS8
+ve
 variants isolated in the 
previous chapter by means of a wide range of biochemical assays. The binding 
studies revealed that HS8
+ve







 bound to FGF-2 
with a greater propensity than other heparin-binding growth factors. 
Proliferation studies showed that HS8
+ve
 statistically increased the cell 




. Furthermore, the above assays 




out of the 
three prospective variants. 
 The compositional make up of HS8
+ve 
revealed an enrichment of 
trisulfated disaccharide with di-sulfated disaccharide (6O and NS) and a 
depletion of mono- and un-sulfated disaccharide compared with HS
pm
. This 
appeared critical for the formation of the FGF-2-HS-FGFR ternary complex 
and downstream signal transduction, which required 2O-, 6O- and N-sulfation. 
In addition, HS8
+ve
 was devoid of anticoagulation activity.  
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The affinity purified HS8
+ve 





 in culture conditions. The additive effect of HS8
+ve
 and FGF-
2 were monitored by proliferation assays and cell signaling studies, which 
revealed its enhanced effects on FGF-2-mediated hMSC growth.  Inhibitor 
studies showed the mechanism involved in triggering the proliferation by the 
HS8
+ve
 was indeed via FGF-2-FGFR1 signaling. The mechanism by which 
HS8
+ve
 mediate its action is proposed in an abstract art piece (Fig. 3.32). Thus 
I have developed a robust, highly scalable, simple and cost-effective process 
to identify a ligand that can bind to both endogenous FGF-2 and FGFR1 and 
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Figure 3.31. Abstract art depicting the proposed FGF-2-FGFR1-HS8
+ve
 trimeric 




















CHAPTER 4: LONG-TERM CELL CULTURE 












Chapter 2 described the successful isolation by affinity of three HS8
+ve
 
variants with a relatively high binding preference for particular FGF-2-derived 
HBD peptides. Chapter 3 saw extensive biochemical assaying of the variants 
and revealed that HS8
+ve
 binds FGF-2 with a higher propensity than other HS 
variants and heparin-binding growth factors.  HS8
+ve
 significantly increased 






 had little 
anticoagulant activity, increased FGF-2 stability and enhanced FGF-2-
mediated hMSC growth via FGF-2-FGFR1-HS ternary complex formation and 
subsequent signaling.  
 In this Chapter, I set out to observe the effects of HS variants on long-
term hMSC proliferation. HS variants, particularly the robust, highly scalable, 
simple and cost-effective HS8
+ve
 fraction, as well as the crude unfractionated 
HS
pm
 and flow through HS8
-ve
 fractions were used as media supplements for 
the culture of both plastic-adherent and STRO1
+
-isolated hMSCs.  The 
cumulative growth (CG) of these cells was monitored and the cells assessed in 
the colony-forming unit fibroblastic assay (CFU-F), by flow cytometric 
analysis (FC) and by multilineage differentiation (MLD) assays.  
Next, I investigated whether hMSCs isolated from bone marrow 
aspirates also responded positively to exogenous HS8
+ve
 supplementation, 
with a view to determining its direct clinical utility. To examine this 
cryopreserved bone marrow mononuclear cells (Lonza) from three human 
donors were used in this part of the study. The isolation and expansion of 
hMSCs was carried out with media supplemented with the various HS 
variants.  The cumulative growth (CG) of hMSCs was observed and the cells 
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assessed by colony-forming unit fibroblastic assay (CFU-F), flow cytometric 
analysis (FC), multilineage differentiation (MLD) as well as 
immunomodulatory analysis (IM) during their serial passaging. 
 
 
4.2. Materials and Methods 








) were used as stand-alone media 
supplements (Fig. 4.1). Two types of isolated and expanded hMSCs, plastic 
adherent and STRO-1
+
 were used at passage 3, and culture-expanded over 4 
passages in the presence of HS variants. The optimum concentration of each 
HS variant (HS8
+ve




at 1.25 µg/ml) were used as 
identified by short-term proliferation assays (Fig. 3.14). In addition, optimum 
concentrations of heparin (1.25 µg/ml) and FGF-2 (2.5 ng/ml) were used as 
positive controls (Fig. 3.23).  
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Figure 4.1. Experimental layout of long-term proliferation studies of plastic adherent 
and STRO-1
+
 hMSCs.  Plastic adherent and STRO-1+ hMSCs were culture-expanded from 
passage 3 to 7 with the exogenous addition of HS variants into culture media. The cumulative 
growth (CG) of hMSCs was observed and the cells at the beginning and end of the study were 
assessed by colony forming unit fibroblastic assay (CFU-F), flow cytometry analysis (FC) and 
multilineage differentiation (MLD). 
 
4.2.1.1. Cumulative growth (CG) 
Plastic adherent and STRO-1
+
 hMSCs at passage 3 were seeded at a 
density of 3000 cells per cm
2
 in multidish 6-well tissue culture plates (Nunc) 
with 2 ml of culture media to evaluate their cumulative population doubling 
and growth over a period of 4 passages in a humidified atmosphere at 37 °C 
with 5% CO2. Plastic adherent hMSCs were cultured in maintenance media 
containing DMEM-LG 1000 mg/l supplemented with 10 % FCS, 50 units/ml 
penicillin and 50 µg/ml streptomycin, while STRO-1
+
 hMSCs were cultured 
with maintenance media containing α-MEM supplemented with 10 % FCS, 
100 µM L-ascorbate-2-phosphate, 50 units/ml penicillin and 50 µg/ml 
streptomycin and 2 mM L-glutamine. Both maintenance medias were 
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supplemented with each of the HS variants or the positive controls and the 
media changed every 2
nd
 day of expansion. Once the cells reached 70-80 % 
confluence, the cells were harvested with 0.125 % trypsin/Versene (pH 
7.0±0.3). An aliquot of each of the triplicate wells was stained with Viacount 
flex reagent (1:200) to detect viable cells by the microcapillary flow cytometry 
platform of the EasyCyte™ Plus system and analyzed using the EasyCyte™ 
Plus software (Millipore). The rest of the cell suspension from the triplicate 
wells was pooled and reseeded at 3000 cells per cm
2
 in triplicate wells. This 
process was repeated for four subsequent passages, with a media change 
performed once every two days and cumulative cell numbers calculated and 
plotted against passage number. Excess cells were cryopreseved in FCS 
(Hyclone, Thermo Scientific) containing 10 % (v/v) dimethyl sulfoxide 
(DMSO, Sigma Aldrich). 
 
4.2.1.2. Colony forming unit fibroblastic assay (CFU-F) 
CFU-F assays (Rider et al., 2008) were performed using hMSCs at 70-
80 % confluency at the beginning and end of the expansion phase of the study 
as described in Chapter 3. Briefly, hMSCs were seeded (150 cells in 100 x 15 
mm petri dishes (Nunc)) in triplicate in 10 ml of culture maintenance media 
and cultured for 14 days with a single medium change at day 7. Colonies were 
stained with crystal violet (Sigma-Aldrich), counted as described earlier 
(Chapter 3.2.3.1) and CFU-F efficiency was calculated as a percentage of 
colonies formed against the number of cells seeded.  
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4.2.1.3. Flow cytometry analysis (FC) 
For the flow cytometry analysis, hMSCs were maintained in 140 x 20 
mm tissue culture dishes (Nunc) in triplicate with maintenance media 
supplemented with either HS, heparin or FGF-2 as positive controls. The cells 
in three plates were pooled together after reaching 70-80 % confluence and the 
FC analysis of hMSCs (gated at 1% of the isotype control) was performed as 
described in Chapter 3.2.3.2. Briefly, hMSCs were tested for positive 
expression of the surface markers CD73, CD90, CD105, and negative 
expression of CD14, CD19, CD34, CD45, HLA-DR, using isotype matched 
controls IgG1, IgG1 and IgG2b to determine whether they fulfilled the 
minimal criteria to define multipotent mesenchymal stem cells (Dominici et 
al., 2006). In addition, cells were also assayed for the expression of the surface 
markers STRO-1 (Gronthos et al., 1999), SSEA-4 (Gang et al., 2007) and 
CD49a (Rider et al., 2007) using isotype-matched controls IgM, IgG3k and 
IgG1k. All primary antibodies for flow cytometry were conjugated with either 
PE or FITC (BD Biosciences, eBioscience and Invitrogen) except for STRO-1 
(Gronthos lab) where the secondary antibody was goat anti-mouse IgM (µ) 
conjugated with PE (Invitrogen). Full details of antibodies and their 
corresponding isotype are provided in Appendix B. Next, stained cells were 
analyzed on BD FACS Array
TM
 Bioanalyzer and gating and analysis 
performed using FlowJo software (Tree Star, Inc.). 
 
4.2.1.4. Multilineage differentiation (MLD) 
Human MSCs cultured in 140 x 20 mm tissue culture dishes (Nunc) 
with maintenance media supplemented with HS and positive controls (heparin 
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or FGF-2) were pooled together after reaching 70-80 % confluency and 
induced to differentiate along the osteogenic, adipogenic or chondrogenic 
lineages as previously reported by our research group (Rider et al., 2008) over 
28 days, with a medium change every 3 days as previously described (Chapter 
3.2.3.3). Osteogenic differentiaiton was assessed by Alizarin Red S (Sigma-
Aldrich) staining for calcium and von Kossa (Sigma-Aldrich) staining for 
calcium phosphate. Whilst, adipogenic and chondrogenic differentiation was 
detected by Oil Red O (Sigma-Aldrich) (to visualize lipid droplets) and Alcian 
blue (Sigma-Aldrich) (to visualize chondrogenic glycosaminoglycans) stains 
respectively. The capacity for multilineage differentiation was then quantified 
by Quantity-One
®
 1-D analysis software (Bio-Rad Laboratories) based on 
stain density. 
4.2.2. Long-term proliferation study of hMSC for direct clinical utility  
To determine the effect of HS8
+ve
 on hMSC proliferation during long-
term serial passaging, naïve hMSCs were isolated from bone marrow 
mononuclear cells (Lonza) from three donors (Table 4.1) and cultured in 






) until passage 6 (Fig. 
4.2).  HS dose (HS8
+ve







µg/ml), was based on earlier screening assays in Chapter 3 (Fig. 3.14). In 
addition, heparin (1.25 µg/ml) and FGF-2 (2.5 ng/ml) were used as positive 
control supplements (Fig. 3.23). Cumulative growth (CG), clonegenic ability 
(colony forming unit fibroblastic (CFU-F)), biomarker expression by flow 
cytometry analysis (FC), multilineage differentiation (MLD) and 
immunomodulatory (IM) ability was also assessed during serial passaging in 
the various conditions (Fig. 4.2).  
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Table 4.1. Description of the bone marrow mononuclear cell donors used in the long-







Figure 4.2. Experimental layout of long-term proliferation assay of hMSC for direct 
clinical utility. Human MSCs were continuously dosed with HS (HSpm, HS8-ve and HS8+ve) 
until passage 6. Assessment of cumulative growth (CG), colony forming ability (CFU-F), 
biomarker expression by flow cytometry analysis (FC), multilineage differentiation (MLD) 
and immunomodulatory (IM) potential at various passages during serial expansion was 
assessed. 
 
4.2.2.1. Thawing and isolation of hMSCs by plastic adherence. 
  
Bone marrow mononuclear cells (BMMNCs) from different donors 
(Table 4.1) were thawed in complete maintenance medium as per 
manufacturer’s specifications (Lonza) as described in Chapter 3. Then the 
BMMNCs (1 x 10
7
) were seeded in T175 flasks (Nunc) in 30 ml of basal 
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media (DMEM-LG 1000 mg/l, 10 % FCS, 50 units/ml penicillin and 50 µg/ml 
streptomycin) supplemented with HS variants or positive controls (heparin or 
FGF-2) in triplicate. Cells were allowed to adhere for 5 days before the first 
media change, thereupon media replacement was performed every 3 days.  All 
cultures were maintained under humidified atmosphere at 37 °C with 5 % 
CO2. Cells were detached with 0.125 % trypsin/versene (pH 7.0±0.3) upon 
reaching 75–80 % confluency and an aliquot used to determine the number of 
viable cells by the EasyCyte™ Plus system and analyzed by EasyCyte™ Plus 
software (Millipore). The remainder of the cells were pooled and used for 
cumulative growth assays, CFU-F assays, flow cytometry analysis or 
cryopreseved in FCS (Hyclone, Thermo Scientific) containing 10 % (v/v) 
dimethyl sulfoxide (DMSO, Sigma Aldrich). 
 
4.2.2.2. Cumulative growth (CG)  
Cumulative growth assays were conducted as described earlier from P0 
to P6 using pooled cells isolated by plastic adherence (P0) or from cells at 
later passages. In addition to 6-well tissue culture plates (Nunc) cells were 
cultured in 140 x 20 mm tissue culture dishes (Nunc) at a density of 3,000 
cells per cm
2
 in 20 ml of culture media. Cells were cultured in maintenance 
media (DMEM-LG 1000 mg/l, 10 % FCS, 50 units/ml penicillin and 50 µg/ml 
streptomycin) supplemented with  HS variants, or positive controls (heparin or 
FGF-2) in triplicate from Passage 0 to Passage 6 passages in a humidified 
atmosphere at 37 °C with 5 % CO2. During serial passaging cells were 
harvested at 70-80% confluency, counted and replated as above and excess 
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cells cryopreseved in FCS (Hyclone, Thermo Scientific) containing 10 % (v/v) 
dimethyl sulfoxide (DMSO, Sigma Aldrich). 
 
4.2.2.3. Colony forming unit fibroblastic assay (CFU-F) 
CFU-F assays were performed at P0, P3 and P6 as described above and 
in Chapter 3.2.3.1. In addition, CFU-F assays were conducted on the bone 
marrow mononuclear cells (BMMNCs). Briefly, BMMNCs from different 
donors (Table 4.1) were thawed in complete maintenance medium as per 
manufacturer’s specifications (Lonza) and plated in 0.5, 1 and 2 x 106 in 100 x 
15 mm petri dishes (Nunc) with 10 ml of culture media supplemented HS and 
positive controls (heparin or FGF-2) in triplicate. Cells were then cultured for 
14 days with a single medium change at day 7.  Colonies were stained with 
crystal violet (Sigma-Aldrich), counted and CFU-F efficiency calculated.  
 
4.2.2.4. Flow cytometry analysis (FC) 
For flow cytometry analysis, cells were maintained in 140 x 20 mm 
tissue culture dish (Nunc) in triplicate with maintenance media supplemented 
with HS, heparin or FGF-2.  Cells from the three plates were pooled together 
after reaching 70-80 % confluence and FC analysis performed at P0, P3 and 
P6 as described above and in Chapter 3.2.3.2. Expression of the biomarkers 
CD73, CD90, CD105, STRO-1, SSEA-4, CD49a (expressed by MSCs) and 
CD14, CD19, CD34, CD45, HLA-DR (not expressed by MSCs) was 
determined. For comparison, FC analysis was also performed on BMMNCs 
(from the 3 donors) prior to plastic adherent isolation of P0 hMSCs. 
 Confidential  185 
 
Expression analysis was performed on BD FACS Array
TM
 Bioanalyzer and 
FlowJo software (Tree Star, Inc.). 
In addition, flow cytometry assay was employed to detect levels of 
FGF receptors (1-4) on the cell surface of hMSCs.  The hMSCs were 
harvested using TrypLE
TM
 (Invitrogen) (6 ml for each 140 x 20 mm tissue 
culture dish) and neutralized with the same amount of media, centrifuged at 
300 g for 5 min and the media aspirated. New media was added into the 
Falcon tube and the cell suspension was incubated for 30 min in humidified 
atmosphere at 37 °C, 5 % CO2.  The lid of the 15 ml tube was slightly 
loosened for air exchange and the tube on a rack was shaken every 10 min to 
prevent cells attaching to the tube. The FC analysis of hMSCs was performed 
at P3 and P6 as described. The IMBR1 antibody (Ling et al., 2006) against 
FGFR1 and against FGFRs 2-4 (R & D Systems) were used with isotype-
matched controls of IgG1 and IgG2ak. The FGFR 2-4 antibodies used for flow 
cytometry were primary antibodies conjugated with either PE except for 
IMBR1 where a secondary antibody goat anti rabbit IgG1 conjugated with AF 
(Invitrogen) was used. The details of the antibodies and their corresponding 
isotypes are provided in the Appendix. The stained cells were analyzed on BD 
FACS Array
TM
 Bioanalyzer and FlowJo software (Tree Star, Inc.). 
In addition, as described by Smith et al., flow cytometry was used to 
analyze the cell sizes of the hMSCs at P0, P3 and P6 (Smith et al., 2004). The 
hMSCs were categorized into small, fast-growing cells and large, slow-
growing cells accordingly and comparisons made between the cells expanded 
with different HS variants.   
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4.2.2.5. Multilineage differentiation (MLD) 
The hMSCs maintained in 140 x 20 mm tissue culture dishes (Nunc) 
with hMSC maintenance media supplemented with HS variants and positive 
controls were pooled together at 70-80 % confluence and used in osteogenic, 
adipogenic and chondrogenic differentiation assays (Rider et al., 2008) over 
28 days, as previously described (Chapter 3.2.3.3). Quantification of 
multilineage differentiation was performed by measurements of the respective 
staining intensity using Quantity-One
®
 1-D analysis software (Bio-Rad 
Laboratories). 
 
4.2.2.6. Immunomodulatory analysis (IM)  
Immunomodulation ability was determined by two methods. The first 
examined the ability of hMSCs to suppress the proliferation of a mixture of 
stimulatory and reactionary human peripheral blood mononuclear cells 
(PBMCs) from two different, healthy, un-matched donors. Assessment of 




 T-cells was determined by flow 
cytometry as previously published by our group (Helledie et al., 2011; Rai et 
al., 2010). The second method determined the level of TNF-α receptor type 1 
expression on hMSCs by ELISA assay (R & D systems) following the 
manufacture’s recommendations.  
 
4.2.2.6.1. Suppression of peripheral blood mononuclear cell (PBMCs) 
assay 
The immunomodulatory analysis capacity of hMSCs is widely 
assessed as a function of their therapeutic potency. Briefly, hMSCs expanded 
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in media containing different HS variants and positive controls at P3 and P6 
were seeded at 1 x 10
5
 cells/well in 96-well plates (Nunc). A mixture of 
stimulatory and reactionary human peripheral blood mononuclear cells 
(PBMCs) from two different healthy un-matched donors (Singapore Cord 
Blood Bank) was added to the wells 24 h later at different PBMC: hMSC 
ratios (1:1 and 1:10) and the cells incubated for 7 days in a humidified 




 cells was 
assessed by two colour FACS array as described below.  
The pelleted cells were resuspended in hMSC maintenance media and 
the cell suspension centrifuged at 2000 rpm for 4 min. Then the media was 
aspirated and the cells resuspended in 100 µl of FACS buffer (0.05 % BSA, 2 
mM EDTA in PBS). The cell suspension was added with 2 µl of CD3 
antibody or isotype (BD Biosciences) and incubated for 30 min at 4 °C. The 
cells were spun down at 2000 rpm for 4 min and washed twice with PBS. 
Next, the cells were resuspended in 100 µl fix perm (eBioscience) in diluent 
(eBioscience) and incubated for 30 min at 4 ˚C. Afterwards the cells were 
neutralized with 100 µl of FACS buffer, spun down and the media aspirated. 
Then the cells were resuspended in 100 µl perm buffer (eBioscience) and 
incubated for 10 min at 4 °C. Another 100 µl perm buffer was added, spun 
down and the media was aspirated. Later cells were resuspended in 50 µl perm 
buffer and 5 µl of Ki-67 antibody or isotype (BD Biosciences) and incubated 
for 30 min at 4 °C.  Then 100 µl perm buffer was added, spun down and the 
media was aspirated. The cells were washed twice with perm buffer. Then the 
sample was resuspended in 200 µl of FACS buffer and the stained cells were 
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analyzed on BD FACS Array
TM
 Bioanalyzer and FlowJo software (Tree Star, 
Inc.). 
 
4.2.2.6.1. TNF-α receptor type 1 quantitative ELISA assay  
TNF-α receptors are expressed on the surface of mesenchymal stem 
cells (Tartaglia et al., 1991) and TNFR1 is the predominant type (Vancheri et 
al., 2000). Danilkovitch et al have described that that hMSCs expression of 
TNF-α receptors may be critical for immunosuppressive, immunomodulatory, 
anti-inflammatory, tissue-repairing, and wound-healing activities, as well as 
migration to sites of inflammation (Danilkovitch et al., 2012). Therefore, a 
quantikine ELISA kit for human sTNFRI (R&D Systems) was used for the 
detection of TNFRI in cell lysates of hMSCs as per the manufacturer’s 
recommendations (Danilkovitch et al., 2012).  
 For the ELISA assay, 2.5 x 10
5
 hMSCs were lysed using 250 µl of 
mammalian cell lysis/extraction  reagent  (Sigma-Aldrich) containing a 
complete protein inhibitor cocktail (Sigma-Aldrich).  The cell lysates were 
centrifuged for 10 min at 12,000-14,000 rpm to remove any insoluble material 
from the lysis buffer solution. The cell lysates were collected in a new tube for 
use in the ELISA assay. 
The sTNF RI Standard was reconstituted as recommended with 
Calibrator Diluent RD5-5 to produce a stock solution of 500 pg/ml. After the 
standard was mixed with gentle agitation for 15 min, 7.8, 15.6, 31.2, 62.5, 
125, 250 and 500 pg/ml standard solutions were made through serial dilution. 
The Calibrator Diluent RD5-5 serves as the zero standard (0 pg/ml). All 
reagents and working standards were brought to room temperature and all 
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standards, samples and controls were assayed in duplicates. Firstly, each well 
of the microplate strips was added with 50 μl of Assay Diluent HD1-7. 
Afterwards, 200 μl of standard, control, or sample per well was added. Then 
the microplate was covered with the adhesive strip and incubated for 2 h at 
room temperature. Each well was aspirated and washed, repeating the process 
three times for a total of four washes by using 400 μl of wash buffer (dilute 20 
ml of wash buffer concentrate in 500 ml of deionized or distilled water) per 
well. After the last wash the microplate was inverted and blot dried against 
clean paper towels to remove liquids completely. Then 200 μl of sTNF RI 
conjugate was added to each well, covered with a new adhesive strip and 
incubated for 2 h at room temperature. Wells were aspirated and washed as 
earlier. Then 200 μl of substrate solution (colour reagents A and B mixed in 
equal volumes) was added to each well and incubated for 20 min at room 
temperature while protecting from light. Next 50 μl of stop solution was added 
to each well. Finally the optical density was determined within 30 min, using a 
Bechmark Plus Spectophometer (Bio-Rad) set to 450 nm and a wavelength 
correction made by subtracting the readings at 540 nm.  Optical density 
readings of the standards were used to plot the standard curve. The best-fit line 
was determined by regression analysis and the equation yielded used to 
determine the sTNF RI concentrations of the samples.  
 
4.2.3. Statistical analysis 
All data values are reported as the mean ± standard deviation (SD) 
taken from triplicate experiments. Where appropriate, mean differences 
between samples were analyzed using SPSS statistics software (IBM, USA) 
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by performing an exploratory data analysis and homogeneity of variance test, 
followed by ANOVA and Tukey's or Games–Howell posthoc testing. 
Statistical significance was defined at >0.05. Graphs were plotted and data 
transformed using Sigma plot software (Systat software Inc, USA) and Adobe 
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4.3. Results  
4.3.1. Long-term proliferation study   
4.3.1.1. HS8
+ve
 increases cumulative viable cell number in plastic adherent 
and STRO-1 hMSCs.  
In chapter 3, a significant increase (~ 1.4 fold) in hMSC proliferation 
following HS8
+ve
 supplementation was observed when cells were cultured 
over a 4 day period (Figs. 3.9, and 3.14). To determine the cumulative effect 







) for 4 passages, with media changes 
every 2 days. Cells were harvested at 70-80 % confluence and cell number 
determined by Guava EasyCyte™ Plus System/CytoSoftTM software platform 
(Millipore
TM
) and reseeded at the same cell density for the subsequent 
passage.  
Overall, irrespective of the different media with or without any 
supplementation STRO-1
+
 hMSCs had a higher cumulative cell numbers 
compared to the plastic adherent hMSCs (Fig. 4.3). In both plastic adherent 
and STRO-1
+
 hMSCs expanded in media supplemented with HS8
+ve
, 
significantly higher cumulative cell numbers were observed compared to the 
controls (Fig. 4.3). The increase in the sub-confluent hMSC number was 





triggered cell expansion was very much similar for plastic adherent hMSCs, or 
only slightly elevated in STRO-1+ hMSCs compared to the control. HS
pm 
showed an intermediate level of cell growth with STRO-1 hMSCs. On the 
other hand, the positive control FGF-2 showed the greatest cumulative cell 
number increase while negatively charged heparin showed a similar trend in 
growth compared with HS8
+ve
 (Fig. 4.3). These data revealed that HS8
+ve
 
 Confidential  192 
 
increases cumulative viable cell number and the effect of the HS variants on 




 increases cumulative viable cell number over 4 passages in (A) plastic 
adherent and (B) STRO-1+ hMSCs. Cells were seeded at 3000 cells per cm2 in multidish 6-
well tissue culture plates and cumulative viable cell number of hMSCs expanded in 
maintenance media (Control) and media supplemented with different HS variants (HSpm, HS8-
ve and HS8+ve) over 4 passages with media change at every 2 days, was plotted.  Cells were 
harvested at 70-80 % confluence, analyzed by Guava and reseeded at same cell density for 
subsequent passage. Significant difference is denoted as * when compared to control and # 
when compared to HS8+ve at equivalent passage (p<0.05). 
 




increases plastic adherent and STRO-1 hMSCs CFU-F 
efficiency. 
 Plastic adherence is a well described property of hMSCs; if cells are 
maintained and expanded in normal culture conditions they should adhere to 
the plastic surface and form mesenchymal stem cell colonies when plated at 
low densities (Friedenstein et al., 1976; Pochampally, 2008). In addition, 
hMSC cultures are known to contain a heterogeneous population of cells, 
especially in regards to the presence of naïve progenitor cells (Pochampally, 
2008). Furthermore CFU-F assays highlight the relationship between 
clonegenicity and the proportion of early progenitors in a pool of hMSCs 
(Pochampally, 2008; Reger and Prockop, 2014). Therefore, to assess the 
ability of HS to preference the expansion of naïve MSCs in the heterogenous 
pool of cultured cells, CFU-F assays were repeatedly performed during the 
serial passaging of hMSCs under HS supplementation.  
Irrespective of the HS variant and baseline media control cells, there 
was an increase in CFU-F efficiency after 4 passages (Fig. 4.4).  In addition, 
irrespective of the different media used STRO-1 hMSCs had a better CFU-F 
efficiency than plastic adherent hMSCs. In both plastic adherent and STRO-1 
hMSCs, those expanded in media supplemented with HS8
+ve 
demonstrated 
significantly higher CFU-F efficiency when compared to the controls before 
and after 4 passages. In addition, the CFU-F efficiency of HS8
+ve
 grown cells 
was significantly higher than the crude HS
pm







 showed an intermediate level and lower level of 
colony formation compared to HS8
+ve
 grown cells. This trend again resembles 
the relative affinity of HS variants to FGF-2. On the other hand, the positive 
 Confidential  194 
 
controls of heparin and FGF-2 showed lower levels of colony formation 
compared to HS8
+ve
 (Fig. 4.4). Interestingly, cells grown with FGF-2 
demonstrated significantly lower CFU-F efficiencies than the baseline control 
(Fig. 4.4). 
The data suggests that HS8
+ve
 supplementation results in an increased 
CFU-F efficiency compared with the other HS variants and heparin. Whilst, 
supplementation with FGF-2 resulted in a decrease in CFU-F efficiency, that 




increases (A) plastic adherent and (B) STRO-1+ hMSC CFU-F 
efficiency. The hMSCs were seeded at 150 cells per and cultured for 14 days. By day 14, 
cultures were terminated and stained with Crystal violet. Significant difference is represented 
as ^ when compared to starting control group, * when compared to control after 4 passages 
and # when compared to HS8+ve (p<0.05). 
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4.3.1.3. Immunophenotypic profile of plastic adherent and STRO-1 
hMSCs.  
Measures of ‘‘stemness’’ in hMSCs typically consist of the basis of 
adherence to tissue culture plastic, their immunophenotypic profile and their 
multi-lineage proliferation. Therefore I next looked at the Immunophenotypic 
profile of hMSCs after long-term HS expansion. Single-color flow cytometry 
analysis revealed that both types of hMSCs were positive for the MSC-related 
markers CD73, CD90, CD105 (> 99 % positive) but negative for 
haematopoeitic markers (< 2 % positive) of CD14, CD19, CD34, CD45 and 
HLA-DR (Table 4.2). Irrespective of media used to expand the hMSCs except 
in HS8
-ve
 grown plastic adherent cells’ CD14 haemotopoeitic marker 
(4.7±0.74). This was evident with cells grown with media supplemented with 
the positive controls, heparin and FGF-2, except for the effects of FGF-2 on 
the expression of CD90 (91±0.21) (Table 4.2).  
In addition to the MSC-related biomarkers described by (Dominici et 
al., 2006)) expression of STRO-1, SSEA-4 and CD49a was also determined.  
These additional MSC biomarkers have also shown to identify multipotent 
MSCs (Gronthos et al., 1999, Gang et al., 2007, Rider et al., 2007). Serial 
passaging of cells had an effect on these additional biomarkers. Plastic 
adherent hMSCs after 4 passages showed a statistical increase in expression of 
STRO-1, SSEA4 and CD49a irrespective of the media supplemented with or 
without HS variants (including the positive control heparin) expect for few 
notable instances. No statistical significance was observed in STRO1 
expression for HS
pm
 and CD49a expression for heparin while SSEA4 
expression in HS8
-ve 
was statistically lower than that of control cells at passage 
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3. On the other hand, FGF-2 grown cells had significantly lower expression of 
STRO1 and CD49a while SSEA4 was significantly higher than that of control 
cells at passage 3. In addition, after 4 passages, in the STRO1
+
 isolated 
hMSCs showed statistically increased expression only in STRO-1 biomarker 
with cells expanded with HS8
+ve
 and heparin.  
After 4 serial passages plastic adherent hMSCs expanded in HS8
+ve
 
showed a statistically increased expression of STRO-1, SSEA-4 and CD49a 













, higher levels of SSEA-4 and CD49a when 
compared to cells expanded in HS
pm
 and similar levels of SSEA-4 and CD49a 
HS8
-ve
. In comparison to the control cells of plastic adherent hMSCs, HS8
+ve
 
grown cells showed significantly increased levels of SSEA4, higher levels of 





expanded cells showed significantly higher levels of STRO1, higher levels of 
SSEA4 and similar levels of CD49a. On the other hand, in both plastic 




 grown cells showed 
variability in their expression of these three surface markers over the control. 
Although these cells in general showed an intermediary level of expression of 
stemness surface markers when compared to control and HS8
+ve, 
it still 
indicated the trend in the relative affinity of these HS variants to FGF-2. The 
surface marker expression of STRO-1, SSEA-4 and CD49a in cells grown 
with positive control heparin showed essentially similar expression to that of 
HS8
+ve
 (Table 4.2). In contrast, FGF-2-cultured cells showed a marked decline 
in STRO-1 and CD49a expression, even compared to control cells, and an 
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increase in SSEA-4 levels over control and all HS variant-maintained cells 
(Table 4.2). Therefore, it was evident that serial passaging of hMSCs 
supplemented with HS8
+ve
 had a beneficial effect on the cells while FGF-2 
supplementation had a detrimental effect on the expanded hMSCs. This 
further supports the idea that HS8
+ve
 may target the expansion of early 
progenitors in heterogeneous hMSC culture, in contrast to exogenous FGF-2 
supplementation, tends to expand fewer naive progenitors. 
 
Table 4.2. Immunophenotypic profile of (A) plastic adherent and (B) STRO-1 hMSC. 
Single-color flow cytometry analysis of hMSCs was performed on P3 control cells and P7 
expanded cells with or without HS variants for positivity markers, negativity markers and 
stemness markers. The level of positivity of relevant surface marker is depicted as below. 
Significant difference is represented as ^ when compared to starting control group, * when 
compared to control after 4 passages and # when compared to HS8+ve (p<0.05). 
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4.3.1.4. Multi lineage differentiation of plastic adherent and STRO-1 
hMSCs. 
Finally I looked at the multilineage differentiation potential of cells 
expanded in the different HS variants compared to the control. Irrespective of 
media used to expand them, the plastic adherent and STRO-1
+
 hMSCs were 
able to differentiate down the osteogenic, adipogenic and chondrogenic 
lineages (Fig. 4.5). In addition, after 4 passages in plastic adherent hMSCs, 
HS8
+ve
 showed statistically increased osteogenic differentiation as evident 
with calcium staining by Alizarin Red and calcium phosphate staining by von 
Kossa staining while heparin was significantly higher in von Kossa staining as 
compared to the control hMSCs at passage 3. The passage 7, control cells 
showed similar osteogenic, adipogenic and chondrogenic differentiation as 
compared to the different HS variants yielded from affinity chromatography. 
Similarity was shown in the plastic adherent hMSCs, heparin-grown cells 
(positive control), except; calcium staining by Alizarin Red, which were 
statistically lower than that of control and HS8
+ve
. The FGF-2-grown plastic 
adherent hMSCs (positive control) were lacking osteogenic differentiation 
capacity in both calcium and calcium phosphate staining by Alizarin Red S 
and von Kossa respectively (Fig. 4.5). On the other hand, STRO-1
+
 hMSCs 
tri-lineage differentiation occurred in a similar manner among different cells 
(Fig. 4.5).  
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Figure 4.5. Multilineage differentiation of (A) plastic adherent and (B) STRO-1+ hMSCs 
before and after 4 passages. hMSCs were subjected to osteogenic, adipogenic, or 
chondrogenic in vitro differentiation for 28 days. Mineralization was examined in osteogenic 
cultures stained positively with Alizarin Red (AR) and von Kossa (VK). The lipid droplets in 
adipogenic cultures and glycosaminoglycans in sections of the chondrocyte pellets were 
detected by Oil Red O (OR) and Alcian blue (AB) staining respectively. Quantification of 
multilineage differentiation was performed by measurements of the respective staining 
intensity using Quantity-One® 1-D analysis software (Bio-Rad Laboratories). Significant 
difference is represented as ^ when compared to starting control group, * when compared to 
control after 4 passages and # when compared to HS8+ve (p<0.05). 
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4.3.2. Long-term proliferation study of hMSC for direct clinical utility  
In the previous study I have successfully shown that the effectiveness 
of HS8
+ve
 for the expansion of multipotent hMSCs, while maintaining or 
increasing the measures of ‘‘stemness’’, based on adherence to tissue culture 
plastic, immunophenotypic profile and multi-lineage proliferation. The effect 
of HS8
+ve
 supplementation on hMSCs directly isolated from unfractionated 
bone marrow was investigated, with a view to determine the direct clinical 
utility of such a procedure.  Therefore a long-term proliferation study using 
cryopreserved bone marrow mononuclear cells (Lonza) was conducted from 
three male donors aged between 20-30 yrs (Table 4.1).  The cells, starting at 







) or the positive controls (heparin and FGF-
2).  
 
  4.3.2.1. HS8
+ve
 increases hMSC isolation from bone marrow aspirates 
Irrespective of the HS variant that was supplementing in the media, 
there was a fold-increase in isolated viable cell counts compared to the 
controls for the cells derived from all three donor bone marrow preparations 
(Fig. 4.6). This was evident with the positive controls as well (Fig. 4.6). For all 
three donors, media supplemented with HS8
+ve 
demonstrated significantly 
higher viable cell count when compared to controls. The isolated numbers of 
hMSCs with HS8
+ve
 was greater than that of crude HS
pm







 showed only an intermediate level of cell 
recovery, between that of control and HS8
+ve
. Positive controls heparin and 
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FGF-2 showed almost similar levels compared to HS8
+ve
 grown cells except in 
donor A; FGF-2 had a higher fold increase in viable cell isolation. 
Overall, the CFU-F efficiency (percentage number of colonies formed 
per 100,000 cells plated) of BMMNCs from donor A were the greatest, 
followed by donor C and the lowest by donor B. In addition, for all three 
donors, media supplemented with HS8
+ve 
triggered similar CFU-F efficiency 
(percentage of number of colonies formed per 100,000 cells plated CFU-F 
efficiency) as compared to controls and the other HS variants (Fig. 4.7). The 
positive control heparin showed similar results to that of HS8
+ve
 
supplementation (Fig. 4.7). Although FGF-2 supplementation increased 
isolation of hMSCs, its CFU-F efficiency was lower than baseline control, 
heparin and the other HS variants tested (Fig. 4.7). The statistical testing 
revealed that the low levels of CFU-F efficiency of FGF-2 in all 3 donors were 
significant when compared to control and HS8
+ve
. Thus indicating that, HS8
+ve
 
may target the expansion of early progenitors in heterogeneous hMSC culture, 











 increases hMSC isolation from bone marrow aspirates. BMMNCs 
were seeded in basal media supplemented with HS variants (HSpm, HS8-ve and HS8+ve) and 
positive controls (Heparin and FGF-2). The cells were allowed to adhere for 5 days with 
media replacement every 3 days.  Upon reaching confluence an aliquot was used to count the 
viable cells by the EasyCyte™ Plus System. Significant difference is represented as * when 
compared to the cells isolated with maintenance media and # when compared to the cells 





 increased the CFU-F efficiency of BMMNCs. The BMMNCs were 
plated in media supplemented with HS variants (HSpm, HS8-ve and HS8+ve) and positive 
controls (Heparin and FGF-2). They were cultured for 14 days and stained with Crystal violet. 
Significant difference is represented as * when compared to the CFU-F efficiency of cells 
grown in maintenance media and # when compared to the CFU-F efficiency of cells grown in 
HS8+ve (p<0.05). 
  








gave rise to a significantly greater cumulative cell number 
compared to the control or the other HS variants in long-term proliferation 
assays. Next, I sought to determine the cumulative effect of the HS variants on 
hMSC expansion when I assayed the cells that had encountered the HS 
variants during their isolation from BMMNCs. Therefore, cells were expanded 







, and the positive controls (heparin and FGF-2) over 6 passages with 
media change at every 2 days. Cells were harvested at 70-80 % confluence, 
analyzed via the Guava EasyCyte™ Plus System/CytoSoftTM software 
platform and pooled cells from triplicate plates reseeded at the same cell 
density for subsequent passage. Cumulative viable hMSC number was plotted 
against the passage number when cultured in 140 x 20 mm tissue culture 
dishes in triplicate.  
For all three donors, hMSCs expanded in media supplemented with 
HS8
+ve 
demonstrated significantly greater cumulative cell number controls 
(Fig. 4.8). The increases in sub-confluent hMSC number were evident from P1 
in donor C, P2 in donor A and P3 in donor B, indicating HS8
+ve
 brings about 





-expanded cells had almost similar cell counts to the control 
except in the cases of donor A and C where HS8
-ve
 grown cells had an 
elevated cumulative growth over the control, although clearly lower than the 
HS8
+ve
. The supplementation with FGF2 that served as the control positive 
showed the greatest cumulative cell number, while supplementation with 
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heparin triggered a similar extent of growth as HS8
+ve
 except with donor A; 
heparin showed a greater cumulative cell number than that of HS8
+ve
 (Fig. 
4.8). Similar results were obtained when these cells cultured in multi-dish 6-
well plates (Fig. 4.9), indicating that the effect of HS8
+ve
 is constant 
irrespective of the surface area of the culture plate.  
 





 robustly expands hMSCs isolated from bone marrow aspirates. Cells 
were seeded in either control media or media supplemented with different HS variants. Cells 
at 70-80 % confluence were analyzed and reseeded at the same cell density for cumulative 
viable cell numbers from P0 to P6. Significant difference is denoted as * when compared to 
control and # when compared to HS8+ve at equivalent passage (p<0.05).  





 robustly expands hMSCs isolated from bone marrow aspirates in 
multi-dish 6-well plates. Cells were seeded in either control media or media supplemented 
with different HS variants. Cells at 70-80 % confluence were analyzed and reseeded at the 
same cell density for cumulative viable cell numbers from P0 to P6. Significant difference is 
denoted as * when compared to control and # when compared to HS8+ve at equivalent passage 
(p<0.05).  




increases hMSCs isolated from bone marrow aspirates 
CFU-F efficiency. 
Similar to BMMNC CFU-F efficiency in established hMSCs, overall, 
the CFU-F efficiency of donor A was greatest, followed by donor C and then 
donor B. In addition, in all the donors, irrespective of the media used 
(including the positive controls) except HS8
+ve
, CFU-F efficiency increased 
from passage 0 to passage 3 and afterwards started to decline as evident in 
passage 6. In case of HS8
+ve
 in donor A and B the CFU-F efficiency was 
increasing even at the later passages (passage 6). Furthermore, irrespective of 
donor, HS8
+ve





 except in two instances; passage 0 of donor A, the 
CFU-F was lower than the control and at passage 0 of donor B, it was similar 




 had CFU-F efficiencies 
greater or similar to the control at passages 0 and 3 with all the three donors, 
but by passage 6, their CFU-F efficiency was similar to the control. At passage 
6 for all three donors, HS8
+ve
 CFU-F efficiencies were significantly higher 
than the controls across all three donors. In addition, at passage 3, this was 
evident in donor A and C while at passage 0, it was evident in donor C. This 
further confirms that HS8
+ve
 stimulates the robust expansion of a hMSC 
population with greater early progenitors, thus corroborating the results 
obtained with established hMSC cultures.  The cells in the positive heparin 
control yielded CFU-F efficiencies greater than control but lower than HS8
+ve
 
except at passage 0 of donor A and donor B (Fig. 4.10). Positive FGF-2 
control grown cells demonstrated a CFU-F efficiency lower than that of all 
GAGs and the control (Fig. 4.10). This reduction of FGF-2 CFU-F efficiencies 
were statistically significant in all the passages across all donors as compared 




, except at donor A passage 0 and donor B passage 0 and passage 3. 
Therefore this further demonstrated that although FGF-2 can mediate a rapid 





 increased the CFU-F efficiency of hMSCs isolated from Donor A, B 
and C. The hMSCs were cultured for 14 days in standard conditions. By day 14, cultures were 
terminated and stained with Crystal violet to visualize the colonies. Significant difference is 
represented as * when compared to the CFU-F efficiency of control and # when compared to 
the CFU-F efficiency of HS8+ve at equivalent passage (p<0.05). 
 
4.3.2.4. Immunophenotypic profile of hMSCs isolated from 3 donors  
I have seen that HS8
+ve
 targets the robust expansion of purer hMSC 
population. I next examined the immunophenotypic profiles of hMSCs from 
the 3 donors (Tables 4.3, 4.4 and 4.5). As expected, the single-color flow 
cytometry analysis revealed that the bone marrow aspirates of the 3 donors 
were positive for haematopoeitic markers expression across all donors; the pan 
leukocyte marker CD45 was on ~ 86 % of the cells and the hematopoietic 
progenitor marker CD34 ranged from 4.0±0.67-8.3±0.70 %. The leukocyte 
marker HLA-DR ranged from 20.4±0.64-39.5±0.07 % and the CD19 (B 
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lymphocytes) ranged from 7.9±4.0-27.4±1.13 %. In addition the 
monocyte/macrophage marker CD14 ranged from 1.8±0.17-4.7±0.51 %. In 
contrast, the MSC-related markers CD73, CD90, CD105 which usually > 99 
% positive in hMSCs, but were low in BMMNCs (ranged from 4.1±0.30-
28±0.85 %). In addition, the stemness markers (STRO-1, SSEA-4 and CD49a) 
were overall less expressed in BMMNCs.  
In contrast, hMSCs after isolation showed a distinctly different profile 
compared to the BMMNCs. On the membranes, the MSC-related markers 
CD73, CD90, CD105 showed > 99 % expression in passage 3 and 6 cells 
across all 3 donors irrespective of the HS variant and control media used to 
expand the hMSCs. At passage 0 they showed a slight deviation from normal 
(> 99 % positive) where CD73 > 98 %, CD90 > 98 % and CD105 > 99 %. The 
haematopoeitic marker expression was markedly reduced in hMSCs compared 
to the BMMNCs. The expression of CD19 and CD34 were extremely low (< 2 
% positive) across all passages and donors. CD45 was essentially the same 
except at passage 0 (< 4 % positive). The expression of the 
monocyte/macrophage marker CD14 ranged from < 1-6 % at passage 0, but 
rose into the accepted range of < 2 % by passage 3 and 6 across all passages 
and donors. The leukocyte marker HLA-DR was in the normal range (> 2 % 
positive) across all passages of donor A. In donor B there was a slight 
elevation but all were in the range of > 2-4 %.  In contrast, donor C had a 
bigger range (> 2.5±0.04-55.5±0.71 %). Passage 0 had the highest range 
amongst all the cells subjected to different media, but by passage 6 it had 
reduced to > 8 %. Interestingly, out of all the cells expanded, cells exposed to 
HS8
+ve
 displayed the lowest levels of for HLA-DR expression, but by passage 
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6 (2.5±0.04 % positive) had almost reached the normal level. This further 
validates that in culture HS8
+ve
 seems to increase hMSCs rather than the other 
progenitor cells. The positive heparin control showed similar positive and 
negative surface marker expression to that of HS8
+ve
 albeit a significant 
difference with respect to HLA-DR. Although donor A HLA-DR expression 
was in the normal range, the other 2 donors were not: in donor B it was 
6.4±1.21-10.2±0.53 % and in donor C it was 58.2±1.28-78.3±1.97 % (Tables 
4.3, 4.4 and 4.5).  The other positive control, FGF-2, caused the resultant 
expanded cells, for certain surface markers, to further deviate from accepted 
levels. The CD90 ranged from 78.2±0.62-96.0±0.21 % while HLA-DR 
expression ranged from 1.61±0.21-87.0±1.34 % on all donors, indicating FGF-
2 was driving the rapid expansion of progenitor cells other than MSCs (Tables 
4.3, 4.4 and 4.5).  
Differences were observed when I looked at the surface marker 
expression set characteristic of stemness. The hMSCs grown in HS8
+ve
 
showed greater levels of STRO-1 at almost all passages for all donors. 
Similarly, at most passages, SSEA-4 and CD49a levels were higher in HS8
+ve
 




 cells showed greater variability in 
the expression of these three surface markers over the control. The surface 
marker expression of STRO-1, SSEA-4 and CD49a in cells grown in heparin 
showed essentially similar expression to that of HS8
+ve
 except few instances 
where significant differences were noted between them (Tables 4.3, 4.4 and 
4.5). In contrast, cells grown in FGF-2 showed declines in STRO-1 and 
CD49a expression, and, on most occasions, an increase in SSEA-4 levels over 
control and all HS variant-grown cells (Tables 4.3, 4.4 and 4.5). This further 
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justifies our hypothesis that HS8
+ve
 is better at targeting the expansion of 
hMSC rather than a mixed population of progenitors, and that the opposite is 
true with respect to exogenous FGF-2 supplementation.  
 
Table 4.3. Immunophenotypic profile of Donor A. Single-color flow cytometry analysis of 
bone marrow aspirate (BMA) and hMSCs was performed for the stem cell positive markers 
CD73, CD90, CD105, the negative markers CD14, CD19, CD34, CD45, HLA-DR, and 
stemness markers STRO-1, SSEA-4, CD49a. The level of positivity of relevant surface 
marker is depicted as below. Significant difference is represented as * when compared to 
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Table 4.4. Immunophenotypic profile of Donor B. Single-color flow cytometry analysis of 
bone marrow aspirate (BMA) and hMSCs was performed for the stem cell positive markers 
CD73, CD90, CD105, the negative markers CD14, CD19, CD34, CD45, HLA-DR, and 
stemness markers STRO-1, SSEA-4, CD49a. The level of positivity of relevant surface 
marker is depicted as below. Significant difference is represented as * when compared to 













 Confidential  213 
 
Table 4.5. Immunophenotypic profile of Donor C. Single-color flow cytometry analysis of 
bone marrow aspirate (BMA) and hMSCs was performed for the stem cell positive markers 
CD73, CD90, CD105, the negative markers CD14, CD19, CD34, CD45, HLA-DR, and 
stemness markers STRO-1, SSEA-4, CD49a. The level of positivity of relevant surface 
marker is depicted as below. Significant difference is represented as * when compared to 
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4.3.2.5. Multi-lineage differentiation of hMSCs isolated from 3 donors.  
Finally I looked at the multi-lineage differentiation capacity of cells, at 
passages 3 and 6, expanded in different HS variants. Irrespective of the media 
used to expand them, and at both passages, the hMSCs were able to 
differentiate down osteogenic, adipogenic and chondrogenic lineages (Figs. 
4.11, 4.12 and 4.13) comparable to each other except for few notable 
instances. The cells of donor B grown with HS8
+ve
 at passage 6 realized the 
greatest tri-lineage differentiation potential. This evidence suggests that 
HS8
+ve
-grown cells retain their multipotentiality and may even show increased 
capacity. Cells grown in the positive control heparin and FGF-2 acted in same 
manner while FGF-2-grown cells showed marked increases in chondrogenic 
differentiation compared to the others (Figs. 4.11, 4.12 and 4.13). Here FGF-
2-grown cells differentiate down the osteogenic lineage, whereas there was a 
lack of osteogenic differentiation of plastic adherent hMSCs Long term 
proliferation in the previous study (Fig. 4.5).  
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Figure 4.11. Donor A multi lineage differentiation at (A) P3 and (B) P6. The hMSCs were 
subjected to osteogenic, adipogenic, or chondrogenic in vitro differentiation for 28 days. 
Mineralization in osteogenic cultures stained positively with Alizarin Red (AR) and von 
Kossa (VK). The lipid droplets in adipogenic cultures and glycosaminoglycans in sections of 
the chondrocyte pellets were detected by Oil Red O (OR) and Alcian blue (AB) staining 
respectively. Quantification of multilineage differentiation was performed by measurements of 
the respective staining intensity using Quantity-One® 1-D analysis software (Bio-Rad 
Laboratories). Significant difference is represented as * when compared to control after 4 
passages and # when compared to HS8+ve (p<0.05). 
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Figure 4.12. Donor B multi lineage differentiation at (A) P3 and (B) P6. The hMSCs were 
subjected to osteogenic, adipogenic, or chondrogenic in vitro differentiation for 28 days. 
Mineralization in osteogenic cultures stained positively with Alizarin Red (AR) and von 
Kossa (VK). The lipid droplets in adipogenic cultures and glycosaminoglycans in sections of 
the chondrocyte pellets were detected by Oil Red O (OR) and Alcian blue (AB) staining 
respectively. Quantification of multilineage differentiation was performed by measurements of 
the respective staining intensity using Quantity-One® 1-D analysis software (Bio-Rad 
Laboratories). Significant difference is represented as * when compared to control after 4 
passages and # when compared to HS8+ve (p<0.05). 
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Figure 4.13. Donor C multi lineage differentiation at (A) P3 and (B) P6. The hMSCs were 
subjected to osteogenic, adipogenic, or chondrogenic in vitro differentiation for 28 days. 
Mineralization in osteogenic cultures stained positively with Alizarin Red (AR) and von 
Kossa (VK). The lipid droplets in adipogenic cultures and glycosaminoglycans in sections of 
the chondrocyte pellets were detected by Oil Red O (OR) and Alcian blue (AB) staining 
respectively. Quantification of multilineage differentiation was performed by measurements of 
the respective staining intensity using Quantity-One® 1-D analysis software (Bio-Rad 
Laboratories). Significant difference is represented as * when compared to control after 4 
passages and # when compared to HS8+ve (p<0.05). 
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 4.3.2.6. hMSCs expanded in HS8
+ve
 are immunosuppressive  
After proving HS8
+ve
 expansion-without-differentiation properties, I 
sought to further examine whether continuous expansion in the presence of 
each of the HS variants had an adverse effect on cells. Immunosuppressive 
capacity was monitored by two means. For both I used cells expanded in 






) or positive 
controls (heparin and FGF-2) at passage 3 and 6. In the first assay I checked 
the ability of hMSCs to suppress the proliferation of a mixture of stimulatory 
and reactionary human peripheral blood mononuclear cells (PBMCs) from two 




 cell assessment in a two-
colour FACS array, as I have previously utilised  (Helledie et al., 2011; Rai et 




indicates a greater 
immunomodulatory capacity (Fig. 4.14).   
Irrespective of the cells expanded in different media and passage, all 
showed a potent immunosuppressive effect at a PBMC: hMSC ratio of 1:10 
compared to that of hPBMC donor A: hPBMC donor B. But, at a lower ratio 
(PBMC: hMSC ratio of 1:1) different cells showed variable 
immunosuppressive effects as compared to that of hPBMC donor A: hPBMC 
donor B. In donor A at passage 3, with the PBMC: hMSC ratio of 1:1, all the 
cell types revealed a decreased immunomodulatory effect, but by passage 6, 
the HS8
+ve
-expanded cells were showing an increased immunomodulatory 
capacity when compared to the control and the other HS variants.  A similar 
effect from HS8
+ve
-grown cells was seen at both passages of donor C. The 
only instance of a decrease in immunomodulatory effect of HS8
+ve
 grown cells 
at the lower ratio was observed at passage 3 of donor B, while at passage 6 
 Confidential  219 
 
almost similar levels were observed. The heparin- and FGF-2-expanded cells 
also displayed a potent immunosuppressive effect at the PBMC: hMSC ratio 
of 1:10, while a variable effect was seen at a PBMC: hMSC ratio of 1:1 (Fig. 
4.14). Therefore, overall, HS8
+ve
 did not impair the immunosuppressive 
effects of the hMSCs, but in most instances actually enhanced the effect, 











Figure 4.14. Immunomodulatory activity of hMSCs expanded with HS variants.  The 
hMSCs at P3 (A) and P6 (B) were seeded and a mixture of stimulatory and reactionary human 
peripheral blood mononuclear cells (PBMCs) from two different healthy un-matched donors 
(Singapore Cord Blood Bank) was added to the wells 24 h later at different PBMC: hMSC 
ratios (1:1 and 1:10). The expression of CD3+ Ki67+ cells was assessed by two colour BD 
FACSArray. The hPBMC mixed at equal amounts served as a positive control represents the 
where the % of CD3+ Ki67 + cells obtained in the absence of Hs variant- or control-expanded 
hMSCs. Significant difference is represented as * when compared to hPBMC donor A: 
hPBMC donor B, #  when compared  to HS8+ve PBMC: hMSC ratio 1:1 and ^ when compared  
to HS8+ve PBMC: hMSC ratio 1:10 (p<0.05). 
 
Secondly, I investigated the amount of TNF-α receptor type 1 
expressed on hMSC surfaces by means of a quantitative ELISA assay (Fig. 
4.15). TNF-α receptors are expressed on the surface of mesenchymal stem 
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cells (Tartaglia et al., 1991) with TNFR1 being the predominant type 
(Vancheri et al., 2000). Danilkovitch et al. have described how the hMSC 
expression of TNF-α receptors is critical for their immunosuppressive, 
immunomodulatory, anti-inflammatory, tissue-repairing, and wound-healing 
activities, as well as for migration to sites of inflammation (Danilkovitch et 
al., 2012). Therefore, a greater TNFR1 level, as measured by ELISA, indicates 
a greater potential for immunomodulatory activity (Danilkovitch et al., 2012).  
Cells from all 3 donors grown in HS8
+ve
 at passage 3 had increased 
TNFR1 levels (ranging 110 - 140 pg/ml) compared to the controls (ranging 60 
- 120 pg/ml). The statistical analysis revealed that this was significant in donor 
B and donor C.  By passage 6, the levels of TNFR1 of HS8
+ve
 cells from 
donors A and C were comparable to controls, although donor B showed the 
significant greatest level, of ~ 180 pg/ml. The HSpm- and HS8-ve-expanded 
cells expressed TNFR1 levels similar to control media-expanded cells, except 
for the passage 3, HS8
-ve
 cells of donor B, which was greater than the control. 
The heparin-expanded cells also showed similar levels to that of controls (Fig. 
4.15). The FGF-2-expanded cells displayed significant lower levels of TNFR1 
at passage 3 of donor A and donor B compared to the controls. Although by 
passage 6 FGF-2 cells showed significant higher levels especially of donor A 
and donor C (Fig. 4.15). These results further demonstrate that HS8
+ve
 does 
not impair the immunosuppressive effects of the hMSCs, but in most instances 
actually enhanced the capability.  
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Figure 4.15. TNFR1 expression of hMSCs expanded with HS variants. The hMSCs cell 
lysates were used to detect TNFRI levels of hMSCs by quantikine ELISA at passage 3 (A) 
and passage 6 (B).  Significant difference is represented as * when compared to control and # 
when compared to HS8+ve (p<0.05). 
 
 
4.3.2.7. Cells expanded in HS8
+ve 
are small, fast growing cells. 
The single-cell-derived colonies of marrow stromal cells contain two 
distinct cell types, namely spindle-shaped and large flat cells (Colter et al., 
2001). Smith and colleagues have described a light scattering assay for the 
measurement of rapidly self-renewing cells (RS cells) within preparations of 
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MSCs (Smith et al., 2004). In addition, Lee et al. have examined this subset of 
rapidly self-renewing human marrow stromal cells after their preferential 
engraftment into mice (Lee et al., 2006). Therefore I have used this assay to 
measure the cell sizes and morphology of hMSCs expanded in the different 
HS variants and positive controls (heparin and FGF-2) at passages 3 and 6 
(Fig. 4.16). The hMSCs were categorized as small fast growing cells, rapidly 
self-renewing cells (RS cells) or large slow growing cells accordingly, and 
compared (Figs. 4.16 A and B). 
Irrespective of passage and donor, addition of HS variants in to media 
tends to increase the proportion of RS cells. HS8
+ve
-expanded cells had higher 
percentages of RS cells than the controls except few occurrences. The HS8
+ve
 
proportion of RS cells were similar with that of controls at passage 6 of donor 




 proportion of RS cells at 
passage 3 of donor B were significantly lower than that of respective controls. 
When consider the large slow growing cells of HS variants, they were lower in 
most instances and similar in few instances compared to the controls. Positive 
control heparin yielded similar results to HS8
+ve 
except for few instances; the 
proportion of RS cells of HS8
+ve
 was significantly higher in passage 0 and 
passage 6 of donor B, and passage 0 of donor C (Fig. 4.16). In addition, it was 
significantly lower in passage 3 of donor A and B as compared with heparin. 
The FGF-2 grown cells showed much higher proportions of RS cells 
compared to HS8
+ve
 and controls (Fig. 4.16). These results were supported by 
the phase contrast photomicrographs taken of the cells (Fig. 4.16C). They 
revealed that the controls have more large flat cells, while FGF-2-grown cells 
consist mainly of small spindle-shaped cells. In contrast, the HS8
+ve
 cells 
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appeared as intermediate sized and spindle-shaped, with a resemblance to the 





-expanded cells are small fast growing cells. A light scattering assay by 
flow cytometry was used to analyze cell size of the hMSCs at P0, P3 and P6. (A) The hMSCs 
were categorized in-to small fast growing cells and large slow growing cells, and (B) the cells 
expanded with different HS variants compared. P1 = small rapidly growing cells and P2 = 
large slow growing cells. (C) Phase-contrast photomicrographs of hMSCs expanded in control 
media, HS8+ve and FGF-2 supplemented media. Significant difference is represented as * 
when compared to proportion of RS cells in control, # when compared to proportion of RS 
cells in HS8+ve, ^ when compared to proportion of slow growing cells in control and @ when 









 expanded cells express more FGFR1 receptors.  
In chapter 3, I demonstrated that the HS8
+ve
 variant possesses strong 
binding to FGF-2, as well as to FGFR1 protein, by GAG-ELISA. Also, HS8
+ve
 
activity is mediated by FGFR1 signaling (data from FGFR1 inhibition assays). 
I can thus posit that HS8
+ve
 has binding sites for both FGF-2 and FGFR1 that 
is important for effective FGF signaling and hMSC proliferation. Therefore I 
sought to determine the relative levels of FGFRs 1-4 on hMSC cell surfaces. 
For this purpose single-colour flow cytometry analysis was employed. The 
hMSCs were grown in control media or media supplemented with HS8
+ve
 and 
FGF-2 to passages 6. Cells were harvested using TrypLE
TM
 (Invitrogen), and 
stained with specific antibodies, including IMBR1(Ling et al., 2006) against 
FGFR1 and against FGFRs 2-4 (R & D Systems).  
The results indicate that out of the 4 receptors, the predominant 
receptor in hMSCs is FGFR1 (Fig. 4.16). Cells grown in HS8
+ve
 and FGF-2 
also revealed that FGFR1 is the receptor most elevated during cell 
proliferation. In addition, HS8
+ve
 cells showed similar or greater expression of 
FGFR1 compared to the controls (passages 3 and 6 of donor B and C). At 
passage 6 in all donors HS8
+ve
 cells showed greater levels of FGFR1 
compared to that of FGF-2 grown cells.  
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Figure 4.17. Immunophenotypic profile of FGFR 1-4 expression in multiple donors. 
Single-color flow cytometry analysis of FGF receptors (1-4) on the cell surface of hMSCs was 
employed. The hMSCs were grown in control media and media supplemented with HS8+ve 
and FGF-2 for up to 6 passages. Cells were harvested using Triple E (Invitrogen), stained with 
specific antibodies against the FGFRs. Finally stained cells were analyzed on BD FACS 
ArrayTM Bioanalyzer. Significant difference is represented as * when compared to control and 
# when compared to HS8+ve (p<0.05). 
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4.4. Discussion  
Mesenchymal stem cells (MSCs) have been posited to have significant 
therapeutic potential, and have already been trialed clinically for tissue 
regeneration and to accelerate bone marrow transplant integration (Wagner et 
al., 2009) . Caplan and Correa described the now standard view of MSCs: the 
potential they offer because of their multipotentiality, their means of tissue 
homing and integration, as well as the evolving view of their role as “cellular 
modulators” (Caplan and Correa, 2011). Most notably, they highlighted the 
trophic and immunomodulatory activities of MSCs as constituting an “injury 
drugstore”.  
The major drawback retarding the wider exploitation of hMSCs for 
cell-based therapies is the difficulty in generating sufficient cell numbers to 
meet the clinical demand, both now and in to the future. In order to address 
this major question (hMSC market supply), the in vitro mimicking of the bone 
marrow microenvironment is now a major research direction. It can be 
achieved in two broad ways: either growing hMSCs on properly re-constituted 
ECM substrates, or exogenous growth factor supplementation. Certain ECM 
substrates have been shown to increase both hMSC attachment and cumulative 
cell number (Grünert et al., 2007; Matsubara et al., 2004) but the resulting 
expanded cells appear to lose the requisite level of “stemness” for clinical 
usefulness (Cool and Nurcombe, 2005). The potent mitogen FGF-2 is 
commonly used for exogenous growth factor supplementation, as it clearly 
drives the proliferation of these cells (Dombrowski et al., 2009; Ling et al., 
2006; Sotiropoulou et al., 2006). However, as observed for the MSCs grown 
on artificial ECM substrates, MSCs cultured in the presence of exogenous 
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FGF-2 go on to generate greater and greater proportions of differentiated 
progenitors as compared to unstimulated hMSCs in control cultures (Gronthos 
et al., 1999; Walsh et al., 2000). Others have claimed that MSCs grown with 
FGF-2 supplementation resulted in cells that do maintain their multipotency, 
as well as other characteristics (Auletta et al., 2011; Sotiropoulou et al., 2006). 
Supporting this, autocrine FGF-2 has also been shown to increase the 
multipotentiality of human adipose-derived MSCs (Rider et al., 2008). 
Therefore not surprisingly, endogenous growth factor activity also seems to 
modulate hMSC behaviour  (Hudalla et al., 2011). 
 The question then becomes: is there a way of presenting hMSCs with 
the FGF-2 they need for expansion without simultaneously deviating from 
their multilineage potential, and hence having “drugstore” like qualities? In 
this thesis I sought to augment the endogenous FGF-2 already secreted by 
MSCs in order to increase proliferation while retaining its hMSC qualities 
through targeted HS fractions. This justification appeared reasonable as HS 
clearly regulates FGF signaling by direct molecular trimeric association with 
both FGFRs and FGFs (Pellegrini, 2001). In addition, Dombrowski et al. from 
our group has shown that embryonic HS can mediate the proliferation and 
differentiation of rat MSCs (Dombrowski et al., 2009). 
The work builds on the original data of Nurcombe et al. (1993) who 
demonstrated that the activity of particular FGF isoforms for murine neural 
precursor cells was tightly regulated by HS and that this interaction is a 
requirement for the binding of FGF-2 to their receptors (Nurcombe et al., 
1993). In addition, unique HS forms mediated the binding of FGF-2 to specific 
receptors via an interaction with specific cell-surface receptors on the neural 
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precursor cells (Brickman et al., 1995). In 1998, Brickman et al. provided 
further structural support for these physiological findings by isolating and 
characterizing two separate HS pools that preferentially bind and activate 
either FGF1 or FGF-2 from immortalized embryonic day 10 and 12 mouse 
neuroepithelial cells, and proving they had quite distinct binding preferences 
(Brickman et al., 1998). This led to the isolation and characterization of the 
embryonic HS preparation named HS2, which in turn was shown to be able to 
accelerate hMSC growth without significant loss of multipotentiality; cells 
grown in this HS could in turn trigger increased bone formation in mice when 
they were transplanted in vivo (Helledie et al., 2011). As a direct development 
of this work, Murali et al. extracted HS from the livers of mice which also 
increased the rates of hMSC expansion and osteogenic differentiation (Murali 
et al., 2011). These data suggested HS isolated from tissue components could 
selectively improve the growth of the hMSCs exposed to FGF-2 without 
adversely affecting their multipotentiality, notwithstanding that although liver 
is a better source of HS than embryonic mouse brain, the problem of 
scalability was not resolved. 
In chapter 2, I examined the possibility of fine tuning and enhancing 
the endogenous FGF-2 activity of MSCs through judicious use of targeted HS. 
The successful isolation of a highly scalable HS fraction variant with higher 
binding affinity for BMP-2, as our group has previously published (Murali et 
al., 2013; Wang et al., 2014) made this a possibility. Chapter 3 saw extensive 
biochemical assaying of the variants and revealed that HS8
+ve
 binds FGF-2 
with higher capacity than other HS variants and heparin-binding growth 
factors.  HS8
+ve
 significantly increased cell proliferation compared to HS
pm
 




. Furthermore, the additive effect of HS8
+ve
 and FGF-2 were 
monitored by proliferation assays and cell signaling studies, which revealed its 
enhanced effects on FGF-2-mediated hMSC growth. Moreover, HS8
+ve
 was 
non-anticoagulant, increased FGF-2 stability and enhanced FGF-2-mediated 
hMSC growth via FGF-2-FGFR1-HS ternary complex formation and 
subsequent signaling. Thus I have developed a robust, scalable, simple and 
cost-effective process to identify a ligand that can bind to both endogenous 
FGF-2 and FGFR1 and thereby better control FGF-2-mediated hMSC 
proliferation.  
In this chapter, I explored the effectiveness of this ligand (HS8
+ve
) by 
first determining its effect on long-term hMSC proliferation and then 
investigated whether hMSCs directly isolated from unfractionated bone 
marrow also positively responded to HS8
+ve
 supplementation, with a view to 
determining its direct clinical utility.  
In the long-term proliferation of hMSC (Chapter 4.3.1) I used two 
types of isolated hMSCs; plastic adherent (Friedenstein et al., 1976) and 
STRO-1 (Friedenstein et al., 1976; Gronthos and Zannettino, 2008; Gronthos 
et al., 1999; Gronthos et al., 2003). In this study irrespective of the different 
media used STRO-1
+
 hMSCs had a better cumulative cell numbers compared 
to the plastic adherent hMSCs. These results were comparable to published 
results as described by Psaltis et al where STRO-1 cells achieved 
approximately 20 % more population doublings than plastic adherent hMSCs 
resulting in higher cumulative population expansion (Psaltis et al., 2010). In 
both plastic adherent and STRO-1
+
 hMSCs expanded in media supplemented 
with HS8
+ve
, significantly higher cumulative cell numbers were observed 
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compared to the controls (Fig. 4.3). The increase in the sub-confluent hMSC 
number was evident from the first passage of expansion in this study (Fig. 
4.3). These data were comparable to the data published by Helledie et al 
where they described the embryonic form of heparan sulfate (HS2) 
supplemented cultures resulted in significantly more cells than controls in 21 
days and the effect of HS2 was evident from the second passage (Helledie et 




 triggered cell expansion was very much 
similar or only slightly elevated compared to the control. These data revealed 
that HS8
+ve
 increases cumulative viable cell number and the effect of the HS 
variants on growth was again in the order of their binding affinity for FGF-2.  
 As previously mentioned growth factors are known to influence cell 
proliferation. Ng and colleagues have shown that FGF-2, TGFβ and PDGF 
signaling pathways are essential in hMSC proliferation (Ng et al., 2008).  
They have shown that in the presence of FGF-2, TGFβ1 and PDGF BB in 
serum-free medium maintained hMSCs for 5 passages while in their absence 
hMSCs showed a more flattened morphology. In addition, Rodrigues and 
colleagues in their review paper have also highlighted the importance of 
several growth factors including TGFβ, FGF-2, FGF-4, VEGFA, PDGF BB, 
HGF, EGF and Wnt3a as mitogenic factors for MSC proliferation (Rodrigues 
et al., 2010). Furthermore, Gharibi and Hughes have used several growth 
factors including FGF-2, PDGF BB, Wnt3a, IL-6 and EGF as medium 
supplements for MSC self-renewal and differentiation potential (Gharibi and 
Hughes, 2012). They observed that out of all supplements FGF-2 has given the 
highest increase in MSC proliferation over passage 3 to 10. These data 
justified the usage of FGF-2 as a positive control in my long term proliferation 
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studies in a traditional monolayer system. In addition, I have used highly 
sulfated heparan sulfate in the form of heparin as another positive control. In 
the long term proliferation study with plastic adherent and STRO-1 hMSCs, 
the positive control FGF-2 showed the greatest cumulative cell number similar 
to published results (Auletta et al., 2011; Gharibi and Hughes, 2012; Hagmann 
et al., 2013; Sotiropoulou et al., 2006) while negatively charged heparin 
showed a similar trend in growth compared with HS8
+ve
 (Fig. 4.3).  
In the long term proliferation study aimed at direct clinical utility, the 
numbers of recoverable hMSCs from BMMNCs were assayed by GUAVA, 
while their clonability was assessed by CFU-efficiency. Plastic adherence is a 
well described property of hMSCs: if cells are maintained and expanded in 
normal culture conditions they should adhere to plastic surface, and form 
mesenchymal stem cell colonies when plated at low densities (Friedenstein et 
al., 1976; Pochampally, 2008). Hence I performed CFU-F assays (Rider et al., 
2008) on HS variant-expanded hMSCs to rigorously demonstrate that HS8
+ve
 
supplementation is indeed capable of targeting the isolation and expansion of 
early progenitors in heterogeneous hMSC culture, over the long-term in 
culture. For all three donors, media supplemented with HS8
+ve 
demonstrated 
significantly greater isolation of viable cell counts compared to the controls. In 
addition, HS8
+ve 
cells demonstrated triggered similar CFU-F efficiency as with 
the control. The greater isolation of hMSCs with HS8
+ve
 was comparable with 
the results of embryonic form of heparan sulfate (HS2) when used to isolate 
hMSCs from unfractionated bone marrow (Helledie et al., 2011). They have 
shown that bone marrow aspirates from three healthy donors strongly 
responded to HS2, both in terms of their proliferative capacity and their 
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colony forming ability. In my study, the positive control heparin showed 
similar results to that of HS8
+ve
 supplementation. Although FGF-2 
supplementation increased cell numbers, its lack of CFU-F efficiency was 
clearly evident. Supplementation of HS8
+ve
 increased hMSC isolation similar 
to FGF-2 except in one donor where FGF-2 supplementation had significant 
higher hMSC isolation (Fig. 4.6). Sotiropoulou and colleagues have isolated 
hMSCs with media supplemented with FGF-2 (Sotiropoulou et al., 2006). 
They also claimed that FGF-2 supplementation clearly affects isolation which 
resulted in vast numbers of cells, but the colony-forming ability of such cells 
does not differ significantly among the groups. Although similar to my results, 
Martin and colleagues have reported that FGF-2 supplementation in isolation 
of hMSCs from  BMMNCs significantly reduced the CFU-F efficiency 
compared to unsupplemented media (Martin et al., 1997). In addition, 
Fresciline et al claimed that rat MSC isolation from BMMNCs with FGF-2 
supplemented media had decreased amounts of CFU-F efficiencies (Frescaline 
et al., 2012). The low proportion of hMSCs within bone marrow (0.01 - 
0.0001 %) (Caplan, 2009) and the plastic adherence requirement (Friedenstein 
et al., 1970) create major limitations, primarily the yielding of low frequencies 
of colonies (Colter et al., 2001), which the platform technology I am exploring 
here seems to help rectify.  
 
In my long term proliferation study directly aimed at clinical utility, 
irrespective of the donor, hMSCs generated with the tuned HS variants had a 
significantly greater cumulative cell number compared to other methods. The 
significance of increase in the sub-confluent hMSC number was evident 
within 4-12 days of contact with the cells (chapter 4.3.2.2). These results 
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corroborate with the results obtained with HS2, where hMSCs from the 3 
donors were continuously cultured in the presence or absence of HS2 
(Helledie et al., 2011). They have shown that in all 3 donors, HS2 greatly 
accelerated the cumulative increase in cell numbers and this growth advantage 
was visible as early as 8 days in culture. Furthermore in my study, 
supplementation with positive control heparin triggered a similar extent of 
growth as HS8
+ve
 except with one donor where heparin showed a greater 
cumulative cell number than that of HS8
+ve
. On the other hand, FGF-2 showed 
the highest cumulative cell number thus corroborating with the results with 
other researchers’ evidence on FGF-2 supplementation on long term 
proliferation of hMSC (Auletta et al., 2011; Gharibi and Hughes, 2012; 
Hagmann et al., 2013; Sotiropoulou et al., 2006).  
In the long term proliferation assay (Fig. 4.4) STRO-1hMSCs had a 
better CFU-F efficiency compared to the plastic adherent hMSCs irrespective 
of the different media used, thus comparable to the results of Psaltis and 
colleagues (Psaltis et al., 2010). In addition, in both plastic adherent and 
STRO-1 hMSCs, those expanded in media supplemented with HS8
+ve 
demonstrated significantly higher CFU-F efficiency (1.3 – 1.4 fold) when 
compared to that of control (Fig. 4.4). In addition, HS8
+ve 
CFU-F efficiency 
was higher than that of crude HS
pm
 and flow through HS8
-ve
, while resembling 
the trend of the relative affinity of HS variants to FGF-2. Similar results were 
obtained when hMSCs were expanded in HS-2 showed higher rates of colony 
formation (1.4-fold) than cells in control media (Helledie et al., 2011). In 
addition, in the study when I looked at direct clinical utility, irrespective of the 
media used (including the positive controls) except HS8
+ve
 in all donors, CFU-
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F efficiency increased from passage 0 to passage 3 and afterwards started to 
decline as evident in passage 6. Usually, CFU-F decrease with increasing 
passage (Gothard et al., 2013; Hoch and Leach, 2014; Schellenberg et al., 
2013; Schellenberg et al., 2012). In case of HS8
+ve
 in two donors the CFU-F 
efficiency was increasing even in the later passages (passage 6). In addition, 
similar to CFU-F efficiency in established hMSCs, HS8
+ve
 grown cells had a 




 especially at 
later passages (Fig. 4.10). On the other hand, in both my long term 
proliferation studies the positive controls (heparin and FGF-2) showed lower 
levels of colony formation compared to HS8
+ve
 (Figs. 4.4 and 4.10). 
Interestingly, cells grown with FGF-2 demonstrated significantly lower CFU-
F efficiencies than the baseline control. This further confirms that HS8
+ve
 
stimulates the robust expansion of a hMSC population with greater early 
progenitors, over the other HS variants and heparin. In contrast, exogenous 
FGF-2 supplementation mediates a rapid expansion of cells in culture, with 
fewer naïve progenitors. 
Measures of ‘‘stemness’’ in hMSCs are assessed on the basis of 
adherence to tissue culture plastic, immunophenotypic profile and multi-
lineage proliferation (Dominici et al., 2006). In the long term proliferation 
study immunophenotypic profiling revealed that both types of hMSCs were 
positive for the MSC-related markers CD73, CD90, CD105 (> 99 % positive) 
but negative for haematopoeitic markers (< 2 % positive) of CD14, CD19, 
CD34, CD45 and HLA-DR (Table 4.2) irrespective of media used to expand 
the hMSCs except in HS8
-ve
 grown plastic adherent cells’ CD14 
haemotopoeitic marker (4.7±0.74). This was evident with cells grown with 
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media supplemented with positive controls, heparin and FGF-2 except for the 
effects of FGF-2 on the expression of CD90 (91±0.21) (Table 4.2). In 
addition, differences were observed when I looked at the “stemness” surface 
marker expression. In plastic adherent hMSCs grown in HS8
+ve
 showed 
statistically greater levels of STRO-1, SSEA-4 and CD49a when compared to 






exceptions were, statistically higher 
CD49a levels in the cells grown in HS
pm
 and statistically insignificant levels 
of CD49a grown in HS8
-ve
. When compared with the control hMSCs grown 
with HS8
+ve 
showed statistically greater levels of SSEA-4 and higher levels of 




 showed statistically 
greater levels of STRO-1 and higher levels of SSEA-4 and CD49a when 




. Helleide et al have shown that 
the expression of STRO-1 and CD49a was significantly increased in the 
presence of embryonic heparan sulfate, HS2 (Helledie et al., 2011). Gronthos 
et al have mentioned that STRO-1 antibody can be used as a single reagent to 
isolate hMSCs (Gronthos et al., 1999; Gronthos et al., 2003) while Rider and 
colleagues have shown that CD49a selection can be used for the enrichment of 
mesenchymal stem cells (Rider et al., 2007). In addition, Gang et al have 
reported that SSEA-4, an early embryonic glycolipid antigen, commonly used 
marker for undifferentiated pluripotent human embryonic stem cells, can be 
used to identify adult mesenchymal stem cell population (Gang et al., 2007). 
Therefore higher expression of these surface markers can be related to purer 
hMSCs and thereby I can interpret that HS8
+ve
 expanded hMSCs cultures have 
more hMSCs compared in the heterogeneous culture compared to the controls.  
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In the same study, the surface marker expression of STRO-1, SSEA-4 
and CD49a in cells grown in positive control heparin showed essentially 
similar expression that of HS8
+ve
 (Table 4.2). In contrast, FGF-2-cultured cells 
showed a marked decline in STRO-1 and CD49a expression, even compared 
to the control cells, and an increase in SSEA-4 levels over control and all HS 
variant-maintained cells (Table 4.2). The reduction in CD49, STRO-1 and 
CD90 in FGF-2 expanded cells as compared to controls were recently reported 
(Hagmann et al., 2013). This further supports the idea that HS8
+ve
 may target 
the expansion of early progenitors in heterogeneous hMSC culture, in contrast 
to exogenous FGF-2 supplementation, that tends to expand fewer naive 
progenitors. 
 In the long term proliferation for direct clinical utility study, the 
isolated hMSCs from 3 donors revealed that HS8
+ve
 supplementation reduces 
haematopoeitic marker expression in early passages, indicating the initial 
contamination of hMSCs cultures with other cells diminished with exposure to 
HS8
+ve
 (Chapter 4.3.2.4). The presence of significant numbers of 
contaminating cells was a major concern after the plastic adherence step for 
hMSCs from bone marrow (Colter et al., 2001). Similar to the results with 
established hMSCs long-term proliferation assay, the hMSCs grown in HS8
+ve
 
in this study showed a higher level of STRO-1 and other stemness markers. 
On the other hand, the positive heparin control showed similar positive and 
negative surface marker expression to that of HS8
+ve
 albeit a significant 
difference with respect to HLA-DR expression which deviated from the 
accepted norm. The other positive control, FGF-2, caused the resultant 
expanded cells expression of CD90 and HLA-DR to further deviate from 
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accepted levels (Table 4.3, 4.4 and 4.5). The surface marker expression of 
STRO-1, SSEA-4 and CD49a in cells grown in heparin showed essentially 
similar expression to that of HS8
+ve
 except few instances where significant 
differences were noted between them (Table 4.3, 4.4 and 4.5). In contrast, 
cells grown in FGF-2 showed declines in STRO-1 and CD49a expression, and, 
on most occasions, an increase in SSEA-4 levels over control and all HS 
variant-grown cells (Table 4.3, 4.4 and 4.5). Recently Hagmann et al reported 
the reduction in CD49, STRO-1, CD90 and HLA-DR in FGF-2 expanded cells 
as compared to controls (Hagmann et al., 2013). In addition, Gharibi et al also 
supported the reduction in CD90 in FGF-2 expanded cells (Gharibi and 
Hughes, 2012). Although FGF-2 expanded cells in my study were in the 
accepted range, others have documented that FGF-2 expanded hMSCs’ 
CD105 expression was deviated from the accepted levels (Gharibi and 
Hughes, 2012; Hagmann et al., 2013). All in all, this further justifies my idea 
that HS8
+ve
 may target the expansion of early progenitors in heterogeneous 
hMSC culture, in contrast to exogenous FGF-2 supplementation, that tends to 
expand fewer early progenitors. 
The multi-lineage differentiation potential of cells expanded in 
different HS variants compared to the control revealed that HS8
+ve
 grown cells 
retain their multipotentiality and may even increase it. Helledie et al. have 
shown similar results where, with an embryonic heparan sulfate, which 
enhanced the self-renewal and therapeutic potential of hMSCs from bone 
marrow (Helledie et al., 2011).  Murali et al. have extracted HSs from the 
livers of mice which also increased rates of hMSC expansion and osteogenic 
differentiation (Murali et al., 2011). The hMSCs grown in the positive control 
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heparin differentiated in to the three lineages similar to that of HS8
+ve
. In both 
long term proliferation assays, cells grown in the positive control FGF-2 acted 
similarly in adipogenic differentiation. In contrast FGF-2-grown cells showed 
marked increase in chondrogenic differentiation compared to the others (Figs. 
4.11, 4.12 and 4.13). Others have also reported that FGF-2 expanded cells 
have increased chondrogenic potential (Hagmann et al., 2013; Tsutsumi et al., 
2001). With regard to osteogenesis in the long term proliferation assay FGF-2 
expanded hMSCs were lacking osteogenic differentiation (Fig. 4.5) while the 
other; long term proliferation for clinical utility study, revealed that FGF-2-
grown cells differentiate down the osteogenic lineage. FGF-2 generated 
greater proportions of differentiated progenitors as compared to the 
unstimulated hMSCs in the control cultures (Gronthos et al., 1999; Walsh et 
al., 2000). In addition, Ling et al. have shown that the longer osteogenic cells 
are in contact with FGF-2, the less potential they have for osteogenic 
development (Ling et al., 2006). It needs to be kept in mind that others have 
claimed that MSCs grown with FGF-2 supplementation results in cells that do 
maintain their multipotency, as well as other characteristics (Auletta et al., 
2011; Gharibi and Hughes, 2012; Sotiropoulou et al., 2006). As such, there 
remains a conflict in this area. 
Next I wanted to examine whether continuous expansion in the HS 
variants had an adverse effect on hMSC properties; therefore, their 
immunosuppressive capacities (Abdi et al., 2008; Caplan, 2009; Caplan and 
Correa, 2011; Gebler et al., 2012; Weil et al., 2011) were measured by two 
means. First I checked the ability of hMSCs to suppress the proliferation of a 
mixture of stimulatory and reactionary human peripheral blood mononuclear 
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resembled an increased immunomodulatory property. Therefore, HS8
+ve
 does 
not appear to impair the immunosuppressive effects of the hMSCs, but in most 
instances seemed to enhance the effect, despite the accelerated growth rate. 
Helledie et al. have shown similar results where an embryonic heparan sulfate 
enhanced the self-renewal and therapeutic potential of hMSCs from bone 
marrow (Helledie et al., 2011). In addition, FGF-2 cells also showed a potent 
immunosuppressive effect generally consistent with other published literature 
(Auletta et al., 2011; Sotiropoulou et al., 2006).  
Secondly, I investigated the amount of TNF-α receptor type 1 
expressed by hMSCs (Tartaglia et al., 1991), as TNFR1 is known to be the 
predominant receptor type (Vancheri et al., 2000). Danilkovitch et al. have 
suggested that hMSC expression of TNF-α receptors may be critical for their 
immunosuppressive and immunomodulatory activities, and TNFR1-expressing 
hMSCs can inhibit the proliferation of lymphocytes, indicating a possible 
usefulness for such conditions as GvHD (Danilkovitch et al., 2012). The 
results revealed that HS8
+ve
 expanded cells have much higher TNFR1 levels 
than controls, comparable to the levels seen by Danilkovitch et al 
(Danilkovitch et al., 2012). The heparin-expanded cells also showed similar 
levels to the controls except in two instances (Fig. 4.15). The FGF-2-expanded 
cells displayed significant lower levels of TNFR1 at two donors (passage 3) 
while by passage 6, FGF-2 cells showed significant higher levels in two 
donors (Fig. 4.15). The increase of TNFR1 receptors in FGF-2 grown cells can 
be related to their  potent immunosuppressive effect as described by others 
(Auletta et al., 2011; Sotiropoulou et al., 2006). Altogether these results 
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further demonstrate that HS8
+ve
 does not impair the immunosuppressive 
effects of the hMSCs, but in most instances actually enhanced the capability.  
Next, I looked at the size and morphology of our HS8
+ve
 expanded 
cells with a light scattering assay to measure rapidly self-renewing cells (RS 
cells) (Smith et al., 2004). The single-cell-derived colonies of marrow stromal 
cells contain two distinct cell types, namely spindle-shaped and large flat cells 
(Colter et al., 2001); the subset of spindle-shaped, rapidly self-renewing 
marrow stromal cells are known to preferentially engraft in mice (Lee et al., 
2006). In general, irrespective of passage and donor, exposure to HS8
+ve
 
increased the proportions of RS cells. FGF-2 cells showed even higher 
percentages of RS cells compared to HS8
+ve
. These results were supported by 
the phase contrast photomicrographs, which revealed that controls had more 
large flat cells, and FGF-2 had more small and intermediate spindle-shaped 
cells. This further supports the idea that HS8
+ve 
expands cells via the fine-
tuning of endogenous FGF-2.  
 In the previous chapter I demonstrated that HS8
+ve
 can bind strongly to 
FGF-2. I posited that HS8
+ve
 has binding sites for both FGF-2 and FGFR1; the 
mechanism involved in triggering the proliferation by HS8
+ve
 was consistent 
with FGF-2-FGFR1 signaling (as revealed by FGFR1 inhibition studies). 
Therefore I also sought out to find the expression of FGFRs 1-4 on the cell 
surfaces of the expanded hMSCs. The results indicated the receptor most 
abundant in proliferating hMSCs was FGFR1. HS8
+ve
 cells showed continued 
high expression of FGFR1 over the other receptors even at late passages. The 
HS isolated from mouse embryonic neuroepithelial tissue also regulate the 
expression of the FGF receptors, by promoting the expression of the 
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proliferative receptor (FGFR1) while simultaneously down regulating FGFR2 
and R3 (Dombrowski et al., 2009). Coutu et al. have  shown that FGFR1 and 
2 are expressed by rare mesenchymal progenitors in MSC niches such as 
perichondrium, periosteum and trabecular marrow (Coutu et al., 2011). These 
FGFR
+ve
 cells displayed MSC phenotype in vitro when expanded with FGF-2. 
They further demonstrate that these MSCs maintain the stemness by inhibiting 
cellular senescence through a PI3K/AKT-MDM2 pathway and thus promoting 
proliferation. Therefore they posit that FGFRs may thus be involved in self-
renewal of MSC and are important to maintain stemness of MSC. In addition, 
Dombrowski and colleagues have shown that FGFR1 signaling activity is rate 
limiting for self-renewal of hMSCs and thereby stimulates proliferation of 
hMSCs (Dombrowski et al., 2013). This is achieved by several mechanisms 





the relative abundance and activity of FGFR1 might be a useful means of 
diagnosing healthy, more stem-like MSCs. Thus the relative abundance and 
activity of FGFR1 as shown by my study is a useful means of diagnosing 
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4.5. Summary 
The aim of this chapter was to utilize HS8
+ve
 for selection and 
expansion of hMSCs from bone marrow. The long term proliferation studies 
revealed that HS8
+ve
 robustly increased hMSC proliferation. They preserved or 
improved their multilineage differentiation and immunophenotypic profiling 
while ensuring normal or augmented immunosuppressive characteristics. In 
addition, with the increase in CFU-F efficiencies and the reduction of 
contaminant haematopoeitic cells, HS8
+ve
 may target early progenitor cells in 
the heterogeneous hMSC cultures. Finally, the proportion of active FGFR1 
appears to be a useful marker for an optimal hMSC phenotype. 






































The major aim of the thesis was to engineer a scalable heparan sulfate that 
was capable of binding to FGF-2 in such a way that it maintained the naiveté 
of human bone marrow-derived mesenchymal stem cells while at the same 
time greatly enhancing their expansion.  Consideration was given to certain 
key factors such as   simplicity, safety, scalability and efficacy. Based on this 
study, the following conclusions were formed: 
 
1. An HS sub-fraction (HS8+ve) was successfully produced using FGF-2 
peptide-affinity chromatography from commercially available 
unfractionated porcine intestinal mucosa HS in a manner that was 
simple, reproducible and readily scalable. 
2. HS8+ve mediates the activity of FGF-2 based on its increased FGF-2 
binding affinity and specific disaccharide composition. 
3. HS8+ve has little anticoagulant activity and thus may be used in 
regenerative settings where normal blood clotting is particularly 
beneficial. 
4. HS8+ve increases the efficiency of hMSCs isolation from bone marrow 
mononuclear cells by plastic adherence and increases their 
proliferation through a mechanism that may involve improving the 
stability of endogenous FGF-2, and fine-tuning the formation of an 
FGF-2-FGFR1 signaling cascade. These expanded hMSCs are 
consisting with higher CFU-F efficiencies and preserved or augmented 
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multilineage differentiation, immunophenotypic profiling and 
immunosuppressive characteristics.  
 
Overall, this thesis concludes that serially passaging hMSCs in 
standard culture conditions results in the expansion of a pool of multipotent 
cells, and that continual supplementation with the FGF-2 binding HS variant, 
HS8
+ve
, increases the total number of hMSCs whilst simultaneously preserving 
their immunomodulatory ability, clonegenicity and multipotentiality.  The 
same cannot be said for the potent mitogen FGF-2, a protein growth factor 
routinely used to grow and expand many types of stem and progenitor cells. 
Serial passaging with FGF-2 supplementation, whilst strongly mitogenic, 
resulted in a significant decrease in cell homogeneity (near loss of STRO-1 
expression) and a subsequent loss of osteogenic potential, highlighting their 
overall decrease in multipoteniality. 
 Because obtaining sufficient numbers of highly potent hMSCs from a 
bone marrow aspirate has always been a seen as the bottleneck to their 
therapeutic application. This study mainly focused on addressing this unmet 
medical need. The data in this thesis helps to advance MSCs manufacturing 
using a compound that acts to mediate the activity of endogenous growth 
factors like FGF-2 naturally present in the culture milieu.  
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5.2. Possible future research 
5.2.1. In vivo efficacy of HS8
+ve
 expanded hMSCs  
Robustly-expanded, but still plastic adherent hMSCs should have a 
major advantage for regenerative medicine. They should thus be trialled in 
preclinical animal models of ectopic bone formation, a relatively 





-expanded cells, could also be tested as 
previously described by our group (Rai et al., 2010). We could also use these 
expanded cells in mouse bone regeneration models (Zannettino et al., 2010) as 
well as the rat femoral defect model (Rai et al., 2010). To test their 
immunomodulatory properties in vivo, HS8
+ve
 expanded cells could be 
subjected to the xenogenic human NOD-SCID mice model of GvHD (Tisato 
et al., 2007; Toubai et al., 2009).  
 
 
5.2.2. Further fine-tuning of HS8
+ve
 variants, and eventual synthetic forms 
We also envisage a “second generation” HS8+ve variant, with an 
increased binding avidity for FGF-2. The delay in HS8
+ve 
variant elution in 
high salt buffer suggested that a mixture of binding HSs are present in the 
HS8
+ve
 variant fraction that could be sub-fractionated yet again. Hence, during 
affinity chromatography, if we use a gradual, step-wise NaCl series of washes, 
instead of the single 1.5 M NaCl wash, we could generate several sub-
fractions of HS8
+ve
. This would enable us to effectively remove the weaker 
binding HS8
+ve
 variants, and leave the stronger binding (more avid) HS bound 
to the peptide. As FGF-2 mediates its proliferation action on hMSCs via the 
FGFR1 receptor, and HS spans both species, we could use an FGFR1-HBD 
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peptide to further sub-fractionate a bifunctional HS fraction with affinity for 
both the FGF-2 and the FGFR1. As the HS becomes more homogenous, 
compositional analysis coupled with strict separation on the basis of chain 
length, should generate candidates that, when further broken down with 
heparanases and nitrous acid, could be sequenced. As organic synthesis 
methods improve, it can be envisaged that completely synthetic versions of 
HS8 could be generated. 
 
5.2.3. The 3-dimensional (3-D) culturing of hMSCs 
 The major drawback retarding the wider exploitation of hMSCs for 
cell-based therapies is the difficulty in generating sufficient cell numbers to 
meet the clinical demand. The use of stirred microcarrier (MC) culture has 
been suggested as another method for supplying large volumes of hMSCs for 
clinics (Chen et al., 2013; Goh et al., 2013; Rafiq et al., 2013; Santos et al., 
2011). Goh et al. have shown that a 12- to 16-fold enhancement in expansion 
of fetal MSCs can be effected by three-dimensional (3D) scaffold culturing as 
compared to the 4- to 6-fold expansion with traditional monolayer (MNL) 
cultures (Goh et al., 2013). Similar to these finding Rafiq et al. have shown 
that hMSCs cultured at the litre-scale on microcarriers in a stirred-tank of 5 l 
bioreactor had a 6-fold increase with traditional monolayer (MNL) cultures 
while cells retained their multipotentiality (Rafiq et al., 2013).  In addition, 
Santos et al. have shown hMSC expansion in a microcarrier-based culture 
system under xeno-free conditions (Santos et al., 2011). Therefore, it would be 
interesting to see the expansion of hMSCs in either xeno-free culture media or 
normal culture media supplemented with HS8
+ve
 in 3-D culture systems.  
 Confidential  249 
 
 
5.2.4. Synergistic effect of HS8
+ve
 and FGF-2 used on hMSCs proliferation 
I was able to reach the maximum fold-increase in hMSC proliferation 
with 16-times less FGF-2 (from 2.5 to 0.156 ng/ml) combined with 8-times 
less HS8
+ve
 (from 2.5 to 0.3125 µg/ml). In addition, HS8
+ve
 was also able to 
bind and increase the stability of FGF-2 under normal culture conditions. I 
believe it would therefore be worth observing cells expanded with the 
combination of HS8
+ve
 and FGF-2 in long-term proliferation studies, and 
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Figure A1: Binding capacity of FGF-2-HBD for 
3
H-heparin. FGF-2-HBD peptides 
Sequence ID No. 5 and 7 were spotted onto nitrocellulose membranes, air-dried and incubated 






Figure A2: Binding capacities of FGF-2-HBDs for heparin. Heparin was immobilized onto 
the GAG-binding 96-well plates (Iduron) by electrostatic interaction, which did not affect 
protein binding capability. The Sequence ID No. 5 and 7 FGF-2-HBD peptides had their 
binding ability for immobilized heparin assessed by dint of their biotinylated portion yielding 
a colourimetric reaction. 
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APPENDIX B: SUPPLEMENTARY INFORMATION FOR MATERIAL 
AND METHODS 
General chemicals and reagents 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Cat No. 34021, Thermo  
   Fisher Scientific Inc, IL, USA) 
Acetic acid (Cat. No.1.00063.2500, Merck Millipore, Darmstadt, Germany) 
Agarose powder (Cat. No. 10975-035, Invitrogen, Life Technologies  
 Corporation, CA, USA) 
Bio-Gel® P-10 Gel (Cat No. 150-4144, Biorad Laboratories, Hercules, USA) 
Bovine serum albumin (BSA) (Cat No. A7906, Sigma Aldrich, MO, USA) 
Crystal violet powder (Cat. No. C3886, Sigma Aldrich, MO, USA) 
Dimethyl sulfoxide (DMSO) (Cat.No. D2438 , Sigma Aldrich, MO, USA) 
Ethanol (Cat. No. 1.00983.2500, Merck Millipore, Darmstadt, Germany) 
ExtrAvidin® - Alkaline phosphatase (Cat No. E2636, Sigma Aldrich, MO,  
 USA) 
Fish gelatin powder (Cat. No. G7041, Sigma Aldrich, MO, USA) 
Heparan sulfate sodium salt from porcine intestinal mucosa (HSpm) (Cat No. 
 HO-03103, Celsus  Laboratories Inc, Ohio, USA) 
Heparin Sepharose beads (Cat. No. H6508, Sigma Aldrich, MO, USA) 
Heparin sodium salt from porcine intestinal mucosa (Cat. No. H3149, Sigma 
 Aldrich, MO, USA) 
HPLC grade water (Cat. No. 95304, Sigma Aldrich, MO, USA) 
Laemmli buffer (Cat. No. S3401, Sigma Aldrich, MO, USA) 
LumiGLO chemiluminescent substrate (Cat. No. 54-61-01, Kirkegaard & 
 Perry Laboratories, Gaithersburg, USA)) 
Methanol (Cat. No. 1.06009.2500, Merck Millipore, Darmstadt, Germany) 
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MilliQ water (MilliQ Integral water purification system, Merck Millipore, 
 Darmstadt, MO, USA) 
MOPS SDS running buffer (20 X) (Cat No. NP 0001-02, Invitrogen) 
Paraformaldehyde (Cat. No. P6148, Sigma Aldrich, MO, USA) 
Ponceau S staining solution (Cat. No. P7170, Sigma Aldrich, MO, USA) 
Precision Plus protein standards (Cat No. 161-0373, Biorad Laboratories, 
 Hercules, USA) 
SIGMAFAST
TM
 p-Nitrophenyl phosphate tablets (Cat. No. N2770, Sigma 
 Aldrich, MO, USA) 
Sodium acetate (NaAc) (Cat No. 71185, Sigma Aldrich, MO, USA) 
Sodium chloride (NaCl) (Cat No. 73575, Sigma Aldrich, MO, USA) 
Sodium dodecyl sulfate (SDS) powder (Cat. No. 1.13760.1000, Merck 
 Millipore, Darmstadt, Germany) 
Sodium hydroxide (NaOH) (Cat. No. S8045, Sigma Aldrich, MO, USA) 
Streptavidin-HRP (Cat No. 21324, Thermo Fisher Scientific Inc, IL, USA) 
Sulfuric acid (H2SO4) (Cat No. 87003 – 234, VWR, USA) 
Triton X100 (Cat No. 161-0407, Biorad Laboratories, Hercules, USA) 
Trizma
®
 base minimum 99.9 % (Cat No. T1503, Sigma Aldrich, MO, USA) 
Tween 20 (Cat. No. P1379, Sigma Aldrich, MO, USA) 
Ultima Gold scintillation cocktail (Cat. No. 6013321, Perkin Elmer,  
 Massachusetts, USA.) 
 
Other materials 
0.2 μM nitroceullose membrane (Cat No. 162-0112, Biorad Laboratories, 
 Hercules, USA) 
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Heparin (Cat No.25 5539 63, Chromogenix, USA) 
DNAse 1 (Cat No. 04716728001, Roche, USA) 
FGF2 quantikine assay (R& D Systems) (Cat No. DFB50, R & D Systems, 
 USA) 
Glycosaminoglycan 96-well binding plates (Cat No. H/G Plates, Iduron Ltd, 
 Manchester, UK) 
HiPrep 26/10 Desalting, 53 ml (Cat No. 17-5087-01, GE Healthcare,UK) 
HiTrap Streptavidin HP, 1 ml (Cat No. 17-5112-01, GE Healthcare,UK) 
LumiGLO Chemiluminescent substrate (Cat No. 54-61-00, KPL, USA) 
 Manchester, UK) 
NUPAGE
®
 4-12% Bis-Tris gel SDS-PAGE gel (Cat No. NP0335PK2, 
 Invitrogen, Life Technologies Corporation, CA, USA) 
SYPRO
®
 Orange Protein Gel Stain (5000X Concentrate in DMSO) (Cat No.S-
 6650, Invitrogen, USA) 









 Confidential  279 
 
Antibodies for inhibitory studies 
Human FGF basic antibody Antigen Affinity-purified Polyclonal Goat IgG
 (Cat No. AF-233-NA, R & D Systems, USA) 
IMBR1 (Ling et al, 2006) 
SU5402 (Cat No. 572631-500UG Calbiochem, Merck Millipore 
 
Proteins and antibodies for GAG-ELISA assay 
Anti-BMP2 (Cat No. BAM 3552, R & D Systems, USA) 
Anti-FGF-1 (Cat No. BAF232, R & D Systems, USA) 
Anti-FGF-2 (Cat No. BAM233, R & D Systems, USA) 
Anti-FGF-7 (Cat No. BAF251, R & D Systems, USA) 
Anti-PDGF-BB (Cat No. BAF220, R & D Systems, USA) 
Anti-VEGF (Cat No. BAF 293293 VE, R & D Systems, USA) 
BMP2 (Cat No. 355 BM, R & D Systems, USA) 
FGF-1 (Cat No. 231 BC, R & D Systems, USA) 
FGF-2 (Cat No. 233 FB, R & D Systems, USA) 
FGF-7 (Cat No. 251 KG, R & D Systems, USA) 
PDGF-BB (Cat No. 220 BB, R & D Systems, USA) 
VEGF (Cat No. 293 VE, R & D Systems, USA) 
 
Media, TCPS and solutions for cell culture 
0.25 % Trypsin-EDTA (Cat No. 25200, Invitrogen, Life Technologies 
 Corporation, CA, USA) 
24-well TCPS plates (Cat No. 142475, NUNC, Denmark) 
48-well TCPS plates (Cat No. 150687, NUNC, Denmark) 
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6-well TCPS plates (Cat No. 140675, NUNC, Denmark) 
96-well TCPS plates (Cat No. 167008, NUNC, Denmark) 
DMEM high glucose 4500 mg/l (Biopolis Shared Fascility, A*STAR, 
 Singapore) 
DMEM low glucose 1000 mg/l (Biopolis Shared Fascility, A*STAR, 
 Singapore) 
Fetal calf serum (FCS) (Cat No. AUD34653, HyClone, Thermo Scientific) 
L-glutamine (Cat No. 25030-081, Invitrogen, Life Technologies Corporation, 
 CA, USA) 
Penicillin-Streptomycin (Cat. No. 15140, Invitrogen, Life Technologies 
 Corporation, CA, USA) 
Phosphate buffered saline 1 X (1XPBS) (Biopolis Shared Fascility, A*STAR, 
 Singapore) 
TrypLETM express (Cat No.12604-021, Invitrogen, Life Technologies 
 Corporation, CA, USA) 
α-MEM (Biopolis Shared Fascility, A*STAR, Singapore) 
 
 
Preparation of media and solutions 
FACS blocking buffer  
PBS, 5% FCS, 1% BSA and 10% human serum (NHS) 
 
FACS staining buffer  
PBS, 2% FCS, 0.02% sodium azide (NaN3) 
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FACS Buffer for immunomodulation  
0.05% BSA, 2mM EDTA in PBS 
 
Low salt affinity chromatography buffer 
20 mM phosphate buffer, 150 mM NaCl, pH 7.2 
 
High salt affinity chromatography buffer 
20 mM phosphate buffer, 1.5 M NaCl, pH 7.2 
 
0.1 M MES buffer 
Weigh 1.952 g MES powder and dissolve in 100 ml MilliQ water. 
 
PBST 
30 ml 5 M NaCl, 66 ml 1.5 M Tris, 1ml Tween 20 and 990 ml MilliQ water 
 
1 x Transfer buffer 
For 1 L, add 24.22 g of Triza® base, 112.6 g glycine and top up with MilliQ 
water 
 
Standard assay buffer (SAB) 
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Flow cytometry Antibodies  
FGFR1 (IMBR1) (Ling et al, 2006) 
FITC Mouse Anti-human HLA-DR (Cat No. 555560, BD Diagnostics, USA)   
FITC Mouse IgG1k  Isotype control (Cat No. 555748, BD Diagnostics, USA) 
FITC Mouse IgG2bk  Isotype control (Cat No. 555742, BD Diagnostics, USA)   
Goat anti mouse IgM(µ) PE (Cat No. M31504, Invitrogen, USA) 
IgG1 PE (Cat No. 349043, R & D Systems , USA) 
Mouse IgM (Cat No. MGM00, Invitrogen, USA) 
PE Mouse Anti-human CD105 (Cat No. 550257, BD Diagnostics, USA) 
PE Mouse Anti-human CD14 (Cat No. 340683, BD Diagnostics, USA)   
PE Mouse Anti-human CD19 (Cat No. 555412, BD Diagnostics, USA)   
PE Mouse Anti-human CD34 (Cat No. 555822, BD Diagnostics, USA)   
PE Mouse Anti-human CD45 (Cat No. 555483, BD Diagnostics, USA)   
PE Mouse Anti-human CD49a (Cat No. 559596, BD Diagnostics, USA)   
PE Mouse Anti-human CD73 (Cat No. 550257, BD Diagnostics, USA)   
PE Mouse Anti-human CD90 (Cat No. 555596, BD Diagnostics, USA)   
PE Mouse Anti-human FGFR2 – PE (Cat No. FAB684P, R & D Systems , 
 USA) 
PE Mouse Anti-human FGFR3 – PE (Cat No. FAB766P, R & D Systems , 
 USA) 
PE Mouse Anti-human SSEA-4 (Cat No. 560128, BD Diagnostics, USA)   
PE Mouse IgG1 Isotype control Cat No. 349043, BD Diagnostics, USA) 
PE Mouse IgG1 k Isotype control (Cat No. 555749, BD Diagnostics, USA)   
PE Mouse IgG2bk Isotype control (Cat No. 555743, BD Diagnostics, USA)   
PE Mouse IgG3 k Isotype control (Cat No. 556659, BD Diagnostics, USA)   
PE rat Anti-human FGFR4 – PE (Cat No. FAB6852P, R & D Systems, USA) 
Rabbit IgG1 (Cat No. 02-6102, Invitrogen, USA) 
 Confidential  283 
 
Rabbit IgG1 AF (Cat No. A11008, Invitrogen, USA) 
Rat IgG2ak PE (Cat No. MAB006, R & D Systems, USA) 
STRO1 (From Stan Gronthos lab) 
 
Immunomodulation assays 
Diluent (Cat No. 00-5223-56, eBioscience , USA) 
FITC-conjugated Mouse anti-Human CD3 (Cat No. 555332, BD Pharmingen, 
 USA) 
FITC-conjugated Mouse IgG1 k Isotype (Cat No. 555748, BD Pharmingen, 
 USA) 
Fix Perm (Cat No. 00-5123-43, eBioscience , USA) 
Human cTNF R1/TNFRSF1A Quantikine ELISA Kit (Cat No. DRT100. R & 
 D Systems, USA) 
PE-conjugated Mouse anti-Human Ki-67 (Cat No. 51-36525X, BD 
 Pharmingen,  USA) 
PE-conjugated Mouse IgG1 Isotype (Cat No. 51-35405X, BD Pharmingen, 
 USA) 
Perm Buffer (Cat No. 00-8333-56, eBioscience , USA) 
 
Western blot antibodies 
phospho-FRS2a (Cat No. 3861, Cell Signaling, USA) 
actin (Cat No. MAB1501R, Millipore Chemicon, USA) 
HRP-conjugated goat anti-mouse Ig G (H+L) antibody (Cat No. 115-035-062, 
 Jackson Immunoresearch laboratories Inc, PA, USA) 
HRP-conjugated goat anti-rabbit Ig G (H+L) antibody (Cat No. 111-035-045, 
 Jackson Immunoresearch laboratories Inc, PA, USA) 
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 Restore* Western Blot Stripping Buffer (Cat No. 21509, Thermo Scientific, 
 USA) 
Ponceau S staining solution (Cat. No. P7170, Sigma Aldrich, MO, USA) 
LumiGLO chemiluminescent substrate (Cat. No. 54-61-01, Kirkegaard & 
 PerryLaboratories, Gaithersburg, USA) 
phospho-ERK1/2 (Cat No. 9106L, Cell Signaling, USA)  
total ERK1/2 (Cat No. 9102L, Cell Signaling, USA)        
Novex 4-12% Bis-Tris SDS PAGE gel, 10 well (Cat No. NP0335BOX, 
 Invitrogen, Life Technologies Corporation, CA, USA) 
 
Multilineage differentiation reagents 
3-isobutyl-1-methylxanthine (Cat No. 15879, Sigma Aldrich, USA) 
Alcian blue (Cat No. A5268, Sigma Aldrich, USA) 
Alezarin red (Cat No. A5533, Sigma Aldrich, USA) 
Dexamethasone (Cat No. D4902, Sigma Aldrich, USA) 
hMSC Chondro Bullet kit (Cat No.PT3003, Cambrex, Lonza, USA) 
Indomethacin (Cat No. 17378, Sigma Aldrich, USA) 
Insulin (Cat No. 16634, Sigma Aldrich, USA) 
L-ascorbate-2-phosphate (Cat No. A8960, Sigma Aldrich, USA) 
Oil-red-O (Cat No. O0625, Sigma Aldrich, USA) 
Silver nitrate (Cat No. S8157, Sigma Aldrich, USA) 
Sodium thio sulfate (Cat No. S7026, Sigma Aldrich, USA) 
TGF-β3 (Cat No. 243-B3, R & D Systems, USA) 
β-glycerol-phosphate (Cat No. G9422, Sigma Aldrich, USA) 
 
 
